checkAd

    GW Pharmaceuticals - Erfolg auf Cannabis-Basis - 500 Beiträge pro Seite

    eröffnet am 19.06.13 11:13:04 von
    neuester Beitrag 20.11.15 02:59:14 von
    Beiträge: 290
    ID: 1.183.057
    Aufrufe heute: 0
    Gesamt: 30.778
    Aktive User: 0

    ISIN: GB0030544687 · WKN: 693692
    8,6990
     
    EUR
    +0,36 %
    +0,0310 EUR
    Letzter Kurs 05.12.16 Tradegate

    Werte aus der Branche Pharmaindustrie

    WertpapierKursPerf. %
    1,3600+72,15
    4,2800+56,20
    0,7500+50,00
    1,5400+33,91
    0,7630+26,53
    WertpapierKursPerf. %
    5,0101-15,80
    3,8500-16,12
    7,5000-16,67
    1,8500-20,94
    3,6400-38,62

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 19.06.13 11:13:04
      Beitrag Nr. 1 ()
      GW Pharmaceuticals swings to net profit in first half

      http://finance.yahoo.com/news/gw-pharmaceuticals-plc-reports…
      Avatar
      schrieb am 19.06.13 11:42:30
      Beitrag Nr. 2 ()
      GW Pharmaceuticals: Giving New Meaning To 'High Potential'

      http://seekingalpha.com/article/1490392-gw-pharmaceuticals-g…
      1 Antwort
      Avatar
      schrieb am 19.06.13 11:47:00
      Beitrag Nr. 3 ()
      Antwort auf Beitrag Nr.: 44.876.369 von pickuru am 19.06.13 11:42:30Du hast dir eine super aktie ausgesucht die schon seit längerer zeit beobachte .

      Werde die tage was dazu schreiben aber jetzt geh ich erstmal schwimmen um mich abzukühlen :laugh:
      Avatar
      schrieb am 19.06.13 14:10:21
      Beitrag Nr. 4 ()




      Könnte nach Jahren des stetigen Kursrückgangs was werden. Die neuesten nachrichten sind recht hoffnungsvoll. Ganz wichtig, GW generiert Umsatz.

      Hier Interview
      http://www.forbes.com/sites/tomtaulli/2013/05/02/interview-w…


      -Sativex nun in 21 Ländern zugelassen (ex-US) zur Behandlung von Multiple Sklerose Spastik
      -Kostenerstattung in Italien Mai 2013 gewährt. Im September 2013 erwartete Markteinführung
      -Mehrere zusätzliche Starts in der Planung für die nächsten 12 Monate
      http://seekingalpha.com/article/1490392-gw-pharmaceuticals-g…


      Werde mir das mal noch genauer anschauen.

      Gruß binda
      Avatar
      schrieb am 19.06.13 14:45:41
      Beitrag Nr. 5 ()



      Cash and cash equivalents at 31 March 2013 of £27.9m ($42.3m) compared to £29.3m as at 30 September 2012. Additional £18.2m of net proceeds after expenses from initial public offering on NASDAQ received after period end.

      :rolleyes:



      http://ir.gwpharm.com/

      Trading Spotlight

      Anzeige
      Was die Börsencommunity nach Ostern auf keinen Fall verpassen willmehr zur Aktie »
      Avatar
      schrieb am 19.06.13 14:55:45
      Beitrag Nr. 6 ()
      Trust Me Dude, Here's How to Invest in Marijuana

      http://moneymorning.com/2013/06/04/trust-me-dude-heres-how-t…
      Avatar
      schrieb am 19.06.13 15:55:02
      Beitrag Nr. 7 ()
      Zitat von pickuru: Trust Me Dude, Here's How to Invest in Marijuana

      http://moneymorning.com/2013/06/04/trust-me-dude-heres-how-t…


      There is one company, GW Pharmaceuticals PLC (LSE:GWP), which is traded on the London Stock Exchange. GW engages in research, with little to no exposure to marijuana retail market. The company researches a range of cannabinoids (the psychoactive chemicals found in marijuana and elsewhere) and is developing a portfolio of cannabis-based medicines. The stock is traded in pound sterling, and has reached as high as £93 ($142) this year. It currently sits at just under £50 ($76). :confused:


      London Stock Exange
      19.06.13 13:26:55 Uhr
      46,75 GBp
      £ 0,467




      Nicht Pounds £ sondern Pence GBp (kleines p )

      Dann wäre der Kurs in frankfurt bei 50€

      Was war das für ein Clown? Autor: Greg Madison, Associate Editor, Money Morning

      Bevor man ( Greg Madison) sowas veröffentlicht sollte man es noch mal Korrektur lesen.
      :(
      Avatar
      schrieb am 19.06.13 16:07:02
      Beitrag Nr. 8 ()
      Bestimmt beim Schreiben nen zu tiefen Zug von der Tüte genommen. Oder das falsche Kraut??





      ;)
      Avatar
      schrieb am 21.06.13 11:43:31
      Beitrag Nr. 9 ()
      New Biotech Names With Excellent Prospects

      http://seekingalpha.com/article/1501432-new-biotech-names-wi…
      Avatar
      schrieb am 21.06.13 11:47:55
      Beitrag Nr. 10 ()
      GW Pharmaceuticals Cannabis Labs UK BBC Tour

      Avatar
      schrieb am 01.07.13 19:06:47
      Beitrag Nr. 11 ()
      Viele Infos und gut zu lesen. ( von Juni 2013 )

      http://files.shareholder.com/downloads/AMDA-1TW341/253847714…
      Avatar
      schrieb am 08.07.13 10:48:04
      Beitrag Nr. 12 ()
      http://www.stockmarketwire.com/article/4627938/GW-Pharmaceut…

      GW Pharmaceutical launches Sativex in Italy

      8 July 2013 | 07:33am
      StockMarketWire.com - GW Pharmaceuticals has noted an announcement from its partner Almirall that Sativex is now available in Italy as a prescription medicine for use in the treatment of moderate to severe spasticity in Multiple Sclerosis patients who have not responded adequately to other anti-spasticity medications.

      The launch follows receipt of full marketing authorisation for Sativex by the Italian health authorities in May.

      The medicine is reimbursed by the Italian authorities as a Class H (hospital dispensed) medicine. The reimbursed price of the medicine granted by the authorities in Italy is consistent with the reimbursed Sativex price in Spain.

      Chief executive Justin Gover said: "As one of the largest markets in Europe, the launch of Sativex in Italy is a key milestone in the commercialization of this important new medicine.

      "Italy represents yet another addition to the growing number of countries in Europe in which Sativex is now available to treat MS spasticity, a particularly debilitating symptom of MS that is not adequately treated with currently available medications.

      "With a total of 21 countries that have now approved Sativex for use in the treatment of MS spasticity, and a further nine countries in which regulatory submissions are ongoing, we look forward to a series of further commercial launches over the coming twelve months."



      Story provided by StockMarketWire.com
      - See more at: http://www.stockmarketwire.com/article/4627938/GW-Pharmaceut…
      Avatar
      schrieb am 08.07.13 10:49:40
      Beitrag Nr. 13 ()
      Avatar
      schrieb am 15.07.13 09:51:38
      Beitrag Nr. 14 ()
      http://www.finanznachrichten.de/nachrichten-2013-07/27395839…

      LONDON, July 15, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 August 2013 its financial results for the third quarter ending 30 June, 2013. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT).

      Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
      Avatar
      schrieb am 19.07.13 08:42:11
      Beitrag Nr. 15 ()
      Pot-Based Diabetes Drug Maker GW Sees Slowing of Illness

      http://www.bloomberg.com/news/2013-07-18/pot-based-diabetes-…
      Avatar
      schrieb am 25.07.13 00:17:33
      Beitrag Nr. 16 ()
      GW Pharmaceuticals (GWPH - Snapshot Report) recently submitted a marketing authorization application for Sativex in France as per the European Mutual Recognition Procedure (MRP). GW Pharma is looking to get Sativex approved for the treatment of spasticity due to multiple sclerosis (MS).

      Earlier this month, Sativex was launched in Italy.

      In May 2013, GW Pharma received full marketing authorization for Sativex in Italy. GW Pharma also successfully reimbursed Sativex in Italy as a Class H (hospital dispensed) medicine. The price reimbursed in Italy is comparable to the price in Spain.

      Following the launch, Sativex became the only drug in Italy containing cannabinoids, for the treatment of spasticity in MS.

      Sativex is approved in 21 countries for the treatment of MS spasticity so far. The company is also seeking regulatory submission for the drug in other countries. GW Pharma is also looking to launch the drug in 8 European countries, and also in Australia and New Zealand.

      We note that GW Pharma has a licencing agreement with Almirall S.A. for Sativex. As per the agreement, Almirall has the exclusive rights to market the drug in the European Union (excluding the UK), EU accession countries as well as Switzerland, Norway and Turkey. Almirall also has the rights to market the drug in Mexico. However, GW Pharma holds the rights to manufacture and supply Sativex to Almirall.

      GW Pharma also has an agreement with Novartis (NVS - Snapshot Report) to commercialize Sativex in Australia, New Zealand, Asia (excluding Japan, China and Hong Kong), the Middle East (excluding Israel/Palestine) and Africa. As per the agreement, Novartis holds exclusive commercialization rights to Sativex and will also act as marketing authorization holder of the drug while GW Pharma will be responsible for the manufacture and supply of the drug.

      GW Pharma is also conducting two phase III studies on the drug in the US for treating pain in cancer patients. The company expects top-line results from these studies by next year, after which it will file a New Drug Application (NDA) for the drug in the US.

      GW Pharma presently carries a Zacks Rank #3 (Hold). However, other pharma stocks such as Jazz Pharmaceuticals (JAZZ - Snapshot Report) and Sarepta Therapeutics, Inc. (SRPT - Snapshot Report) currently look better positioned with a Zacks Rank #1 (Strong Buy).

      http://www.zacks.com/stock/news/104681/GW-Pharma's-Sativex-F…
      Avatar
      schrieb am 29.07.13 17:05:23
      Beitrag Nr. 17 ()
      :eek: englischer Handelsplatz


      Eine Meinungen aus http://www.iii.co.uk/investment/detail?code=cotn:GWP.L&displ…

      I attribute this rise to investors waking up to the fact that GW is getting really close to their breakthrough. For the first time ever, GW is publicly reporting a quarterly result. We have seen half-year reporting for a couple of years Next Monday they begin reporting quarterly. I expect they will use the occasion to announce some big development.

      This company was selling for almost 20% of their go public price. In 2001 GW announced an ambitious plan to take Cannabis through the drug approval process. There have been some delays, but the company has succeeded. It has survived without diluting itself unnecessarily. The company is sitting on a lot of cash that it intends to use to pump its own pipeline. There is simply no reason for the price to be as low as it is other than market manipulation and meager efforts on the part of the company to toot its own horn. This is purposeful, and smart of them to lay low, but it clearly affects their stock price.

      The Almirall contract is up for renewal. This is on unique cannabinoids that GW has solid IP on. Almirall would not throw tens of millions into this pipeline if the early results were not spectacular. Expect a huge promise of milestone payments and other benefits to GW in this negotiation. If Almirall re-ups, it is a clear sign GW has made amazing process developing products that will meet widely held medical needs.
      Avatar
      schrieb am 29.07.13 17:06:20
      Beitrag Nr. 18 ()
      http://www.insuranceage.co.uk/insurance-age/news/2285333/his…

      Hiscox sees GWP rise to £1bn as profit and COR improve
      Avatar
      schrieb am 30.07.13 09:26:19
      Beitrag Nr. 19 ()
      Avatar
      schrieb am 30.07.13 12:35:24
      Beitrag Nr. 20 ()
      Zitat von binda: http://www.insuranceage.co.uk/insurance-age/news/2285333/his…

      Hiscox sees GWP rise to £1bn as profit and COR improve


      Korrektur, dies hat nichts mit GWP zu tun.

      Das GWP in der Überschrift bedeutet lediglich: "gross written premium"
      Avatar
      schrieb am 05.08.13 10:20:03
      Beitrag Nr. 21 ()
      FINANCIAL HIGHLIGHTS FOR THE THREE MONTHS ENDED 30 JUNE 2013

      Sativex product sales revenues of £0.5 million ($0.8 million) for the three months ended 30 June 2013, compared to £0.1million for the three months ended 30 June 2012, reflecting increased shipments of inventory to commercial partners

      Total revenue for the three months ended 30 June 2013 of £7.3 million ($11.0 million) compared to £14.5 million for the three months ended 30 June 2012, a period in which a £9.8 million milestone payment was received

      Loss after tax for the three months ended 30 June 2013 of £2.0 million ($3.1 million) compared to a profit of £7.9 million for the three months ended 30 June 2012, which primarily reflected the impact of the £9.8 million milestone payment received in the comparable period last year

      Cash and cash equivalents at 30 June 2013 of £43.6 million ($66.3 million) compared to £29.3 million as at 30 September 2012

      mehr:

      http://www.gwpharm.com/GW%20Pharmaceuticals%20plc%20Reports%…
      Avatar
      schrieb am 05.08.13 10:27:30
      Beitrag Nr. 22 ()
      http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Re…

      5 August 2013
      GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition

      London, UK, 5 August 2013: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces top-line results from a 12 month placebo-controlled study of Sativex in patients with spasticity due to Multiple Sclerosis (MS).

      The study results confirm the reassuring safety profile of Sativex and provide further evidence of long-term efficacy.

      The study was a 12 month multicentre, double-blind, randomised parallel group, placebo-controlled study in 121 patients with MS spasticity. The study was required as a post-approval commitment by the UK regulatory authority, the Medicines and Healthcare products Regulatory agency (MHRA), with the primary objective of evaluating whether Sativex may have long term adverse effects on cognitive function or mood. The primary endpoint was the change in cognitive function as assessed by the total Paced Auditory Serial Addition Test (PASAT) score from baseline to end of treatment. Mood was assessed by the Beck Depression Inventory-II.

      There was a slight improvement in the PASAT score from the beginning to the end of the study in both the Sativex and placebo groups, thus confirming that there is no evidence of long-term cognitive impairment in patients taking Sativex compared with those taking placebo. Similarly, the change in mood over the 12 month period was more or less identical in the Sativex and the placebo group, confirming no untoward effect on mood.

      The key efficacy secondary endpoints were the global impression of change scores as assessed by the patient, physician and carer. Each of these endpoints was highly significantly in favour of Sativex (p<0.0001, p=0.001 and p=0.004 respectively).

      Detailed data from this study is due to be presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on 2-5 October in Copenhagen, Denmark.

      Dr Stephen Wright, GW’s R&D Director, said, “We are pleased to report positive and wholly reassuring results from this 12 month placebo-controlled study in patients with MS spasticity. We have now shown that Sativex does not impair cognition either in short-term or in long-term use in well designed, randomised, placebo controlled clinical trials. These data not only confirm the good tolerability of Sativex in long-term use but also provide further evidence of efficacy consistent with that seen in previous shorter duration clinical trials.”
      Avatar
      schrieb am 08.08.13 08:24:46
      Beitrag Nr. 23 ()
      GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference

      London, UK, 8 August 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the 33rd Annual Canaccord Genuity Growth Conference on Wednesday, 14 August, 2013 at 2:00 p.m. ET. The conference will be held at the InterContinential Boston in Boston, MA.

      A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section at www.gwpharm.com.
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/pr…
      Avatar
      schrieb am 13.08.13 17:39:52
      Beitrag Nr. 24 ()
      http://www.finanznachrichten.de/nachrichten-2013-08/27702254…

      The ADR initiation follows GW Pharmaceuticals' US initial public offering (IPO), in which it raised c $30m from the sale of ADRs (each of which represents 12 ordinary shares) in May this year. Edison's comprehensive report examines the investment merits of GW Pharmaceuticals and derives a valuation of $18.90/ADR. It contends that this is a base case valuation as it principally values only GW Pharmaceuticals' lead product, Sativex, in its approved indications in Europe and lead development indication (cancer pain) in the US. It thus excludes any contribution from GW Pharmaceuticals' proprietary R&D activities, which are expected to be funded by the proceeds of the IPO. Edison highlights that its base case valuation would rise to $22.60/ADR on the successful development of Sativex for cancer pain in the US.
      Avatar
      schrieb am 13.08.13 17:46:20
      Beitrag Nr. 25 ()
      Kurs in USA (je 12 Aktien)

      Avatar
      schrieb am 14.08.13 09:14:45
      Beitrag Nr. 26 ()
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/in…

      London, UK; 14 August 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today that it has opened a Phase 3 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a pivotal efficacy and safety clinical program to evaluate Sativex® for the treatment of spasticity due to Multiple Sclerosis (MS). Sativex is currently approved in 22 countries outside the U.S. as a treatment for MS spasticity.

      The proposed U.S. Phase 3 program will be conducted under the agreement with GW's licensing partner for Sativex®, Otsuka Pharmaceutical Co. Ltd. Under the terms of GW's agreement with Otsuka, Otsuka is responsible for wholly funding the MS Phase 3 clinical program, as is the case with the current Phase 3 cancer pain program.

      As part of its MS spasticity IND application, GW requested feedback from the FDA on key features of the proposed single Phase 3 trial protocol. GW expects to work with the FDA over the coming months to incorporate FDA feedback and to finalize the protocol design, which may include a request for Special Protocol Assessment (SPA). GW expects the Phase 3 trial to commence in 2014.

      Cancer pain remains the initial target indication for Sativex in the U.S. and it is intended that MS spasticity would represent a future second indication for the U.S. market. GW and Otsuka are currently undertaking a Phase 3 clinical trials program for Sativex in cancer pain and results from two pivotal Phase 3 trials are expected in 2014.

      "With results from our U.S. Phase 3 program in cancer pain due next year, this new Phase 3 IND provides us with the opportunity to broaden the future U.S. market potential for Sativex to include MS spasticity. As such, this new IND represents an important extension of GW's and Otsuka's ambitions for Sativex in the U.S.," stated Justin Gover, Chief Executive Officer of GW. "We now look forward to working with the FDA to gain agreement on the required program to enable a future filing of an NDA for the MS indication."
      Avatar
      schrieb am 14.08.13 09:17:57
      Beitrag Nr. 27 ()
      In February 2007, GW and Otsuka entered into an exclusive license agreement to develop and market Sativex in the U.S. Under the terms of this agreement, the costs of pre-clinical and clinical required for U.S. approval are to be wholly funded by Otsuka.

      Keine weiteren Kosten für GW ;)
      GW hat cash at 30 June 2013 of £43.6 million ($66.3 million)laut letztem FB
      Avatar
      schrieb am 14.08.13 09:21:00
      Beitrag Nr. 28 ()
      The financial terms of this agreement include total milestone payments to GW of up to $273m as well as a long term commercial supply price and royalty. Otsuka will pay GW a signature fee of $18m. In addition, Otsuka will bear the costs of all US development activities for Sativex in the treatment of cancer pain, additional indications, and future formulations.

      http://www.gwpharm.com/Cannabinoid%20Alliance.aspx
      Avatar
      schrieb am 30.08.13 12:16:22
      Beitrag Nr. 29 ()
      Der Jahresbericht wird im Nov veröffentlicht.

      Die Prognose für 2013 war im GB von 2012:
      http://files.shareholder.com/downloads/AMDA-1TW341/260878248…

      Profitability
      In the last few years,significant milestone
      income receipts from Sativex agreements have
      led the Group reporting smallpre-taxprofits.
      Inline with market expectations, we are not
      expecting significant milestones receipts in 2013
      and this factor, together with our increasing
      R&D spend in the pipeline, leads us to expect to
      report a loss for the 2013 financial year. This is
      consistent with market expectations and is in
      accordance with our strategic plan to create
      long-termvalue from our pipeline of products by
      investing in R&D. It should be noted however
      that a loss in 2013 should enable the Group to
      claim an R&D tax credit for the year.

      Adam George
      FinanceDirector
      27November 2012
      Avatar
      schrieb am 04.09.13 16:26:26
      Beitrag Nr. 30 ()
      Bin gespannt, ob dieser Anstieg nachhaltig ist. Schade in D kaum gehandelt.




      Bin ich der Einzige, der investiert ist?
      Avatar
      schrieb am 06.09.13 10:25:59
      Beitrag Nr. 31 ()
      Fantastisch, wie der Kurs in letzter Zeit abgeht.

      Auf Tradegate:

      09:19:34 1,005 3000 Stk
      09:03:17 0,959 3000 Stk

      in London hoch auf

      86,00 GBp +7,00
      +8,86%
      42.537 Stk.
      2 Antworten
      Avatar
      schrieb am 06.09.13 12:52:19
      Beitrag Nr. 32 ()
      Avatar
      schrieb am 06.09.13 13:24:15
      Beitrag Nr. 33 ()
      Antwort auf Beitrag Nr.: 45.396.615 von binda am 06.09.13 10:25:59@binda

      Das liegt daran das die Aktie seit kurzer zeit an der Nasdaq handelbar ist und die Amis immer mehr GWPH entdecken . So in mitte 2014 kommen sehr wichtige Phase 3 daten , ich denke 100% sind noch locker drin bis dahin .

      1 Antwort
      Avatar
      schrieb am 06.09.13 13:35:44
      Beitrag Nr. 34 ()
      Antwort auf Beitrag Nr.: 45.397.983 von Biohero am 06.09.13 13:24:15Hi Biohero, also doch noch dabei..und ich dachte schon ich wäre der einzige der dieses Potenzial sieht.

      Die Pipeline/ Portfolio ist voll und aussichtsreich.
      Avatar
      schrieb am 06.09.13 15:41:51
      Beitrag Nr. 35 ()
      USA GWPRF

      Avatar
      schrieb am 06.09.13 16:11:19
      Beitrag Nr. 36 ()
      Ein Gap ist in USA entstanden. Gaps wollen in der Regel geschlossen werden. Denke, die Aktie ist überkauft. Für Neueinsteiger und zum Nachkauf wäre es nicht schlecht.



      ebenso in London


      Avatar
      schrieb am 09.09.13 15:00:38
      Beitrag Nr. 37 ()
      Halte nicht viel von seekingAlpha, stelle es trotzdem rein


      Stay Away From GW Pharmaceuticals
      http://seekingalpha.com/article/1680882-stay-away-from-gw-ph…
      Avatar
      schrieb am 17.09.13 10:49:02
      Beitrag Nr. 38 ()
      http://blog.pharmexec.com/2013/09/11/with-cannabis-science-t…

      With Cannabis, Science Trumps Culture, Says GW Pharma CEO
      By BEN COMER | Published: SEPTEMBER 11, 2013
      Already approved in 22 countries, GW Pharma’s Sativex product, if approved by FDA, would become the first prescription drug derived from raw cannabis to enter the US market.


      In the last several years, the US – a place where marijuana still has a decidedly bad reputation, and a prosecutorial history tinged with socioeconomic bias, if not outright racism – has changed its mind about the need to jail everyone caught holding a dime bag. Sixteen states have either decriminalized or legalized small amounts of cannabis for personal use, or made it legal for patients to consume the drug on doctor’s orders.


      sativexspray
      GW Pharmaceuticals' Sativex
      Medicinal marijuana, as a catchall term covering everything from physician-prescribed pot brownies for glaucoma patients, to anxiety-ridden graduate students self-medicating with bong hits, does not include Sativex, GW Pharmaceuticals’ product indicated for multiple sclerosis-related spasticity, and approved in 22 countries, according to Justin Gover, CEO at GW Pharmaceuticals. Gover doesn’t even like to use the word “marijuana;” he strongly prefers the scientifically precise “cannabis” when describing the company’s platform botanical. “When we look at the cannabis plant…it’s not a single entity. It’s the embodiment of a number of cannabanoids which have a distinct pharmacology.”

      To illustrate this distinction, take epilepsy, says Gover. “There are anti-convulsant properties within the cannabis plant, and there are pro-convulsant molecules. If you gave crude marijuana to an epilepsy patient, you risk providing a patient with unknown quantities of a part of a plant which could be good, or might be bad,” says Gover. “We’re able to identify which part of the plant, which molecules, may contribute to an anti-convulstant effect.” Gover says GW Pharma identifies and isolates individual components from the cannabis plant, via extraction, and applies “genuine science and scientific research to produce medicines specifically formulated to target different medical conditions.” Individual components extracted from the cannabis plant can stand alone, or be combined to target disease.

      In the US, Sativex – a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) – is currently undergoing phase III trials for cancer pain. Sativex is formulated as an oromucosal mouth spray, akin to OTC sprays like Chloraseptic or Binaca. Gover says smoking as a delivery mechanism isn’t consistent, and wouldn’t pass regulatory scrutiny, so the options were an oral capsule, an injection, an inhalation, or an oromucosal spray. Sativex was developed as a spray because that route avoids the liver; the active ingredients are absorbed through the lining of the mouth, and go straight into the blood stream, says Gover. The spray formulation also lets patients “fine tune” their dose, a key feature of the drug, since one patient may need five sprays over a day, and another may need six or seven to get the optimal, efficacious dose. Patients can feel the effects of the drug about 20 or 30 minutes after administration, Gover says.

      Since GW Pharma is dealing with a schedule 1 substance in the US, the company has worked with several government agencies, including the Drug Enforcement Agency (DEA) and the Office of National Drug Control Policy (ONDCP), the White House’s advisory group on drug policy. Gover says Sativex is a poster child for the future of developing cannabis-derived products. The drug is acknowledged on the White House’s website as an example of legitimate research into the therapeutic components of marijuana. As for the agency that will make the decision to approve, or not, Gover says “FDA expects us to conform to the standards of any medicine they approve, with regard to quality, safety and efficacy.”

      growingfacility
      GW Pharmaceuticals' in-house grow room
      FDA is also tasked with recommending a schedule for the product, whether they approve it or not. Sativex could be the first drug to bring cannabis out of schedule 1 exile, where it currently resides alongside heroin, LSD, peyote, and other substances with “no currently accepted medical use and a high potential for abuse,” according to the DEA classification. FDA has approved synthetic cannabinoid products – Marinol (dronabinol) and Cesamet (nabilone) – but hasn’t to date approved anything derived from the actual plant itself.

      After 15 years, Gover says GW Pharma has matured as a company, and its executives don’t have to go out and face intense skepticism any more about whether its products represent genuine scientific promise, and whether regulatory approval is possible. In the US, Otsuka has signed on as the company’s marketing partner. In the UK and Canada, Bayer is marketing Sativex, and Novartis has marketing rights in Australia, parts of Asia and the Middle East, and Africa. Gover says GW Pharma’s products face the same regulatory scrutiny as any other drug its big pharma partners might in-license. The company grows its own cannabis plants in the UK, to control quality and consistency, in “as clean an environment as you can get in the context of a plant-based drug being manufactured to pharmaceutical standards,” says Gover. “When we export, we’re exporting a finished product.”

      Phase III trials for Sativex in cancer pain will conclude next year, with an NDA to follow in early 2015, says Gover. But if the product does win FDA approval, it won’t be because of any national trends in the culture, adds Gover. “I actually think it’s in spite of that. The regulatory success of Sativex, and the standing we have with industry is entirely independent of public views about the good or bad of marijuana,” says Gover. “It’s all about looking at cannabinoids as an interesting new source of therapeutics.”

      Extra: the BBC took a trip to GW Pharma headquarters back in 2009, as part of a documentary titled “Cannabis: The Evil Weed.” Footage of the visit is available here.https://www.youtube.com/watch?v=Un5JSkNX5oQ
      Avatar
      schrieb am 18.09.13 08:51:46
      Beitrag Nr. 39 ()
      http://www.finanznachrichten.de/nachrichten-2013-09/28038982…

      18.09.2013 | 08:01

      PR Newswire · Mehr Nachrichten von PR Newswire
      GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy
      Avatar
      schrieb am 20.09.13 09:14:36
      Beitrag Nr. 40 ()
      Avatar
      schrieb am 20.09.13 11:18:24
      Beitrag Nr. 41 ()
      :lick:

      http://www.leafscience.com/2013/09/18/france-considers-legal…

      France Considers Legalizing Cannabis-Based Medicine

      IN WORLD — 18 SEP, 2013

      French health authorities are expected to make a decision on approving the sale of the cannabis-based pharmaceutical Sativex in the coming months.

      Dr. Nathalie Richard of the country’s National Security Agency of Medicines and Health Products (MSNA) says the decision to authorize medicines “containing cannabis or its derivatives” will be made “in the autumn,” reports Le Monde. If approved, Sativex could be sold in French pharmacies by as early as the end of 2014. Approval is also expected to open the doors for clinical research and other forms of cannabis medicine. Despite being hotly debated, the Ministry of Health maintains that approval of Sativex would not permit personal cultivation of medical marijuana. “Neither home growing of cannabis or handicrafts [cannabis-based products] are provided by the decree. ”Sativex is an oral spray manufactured by the UK-based GW Pharmaceuticals and contains natural cannabis extract in a controlled dosing formula. The two most recognized compounds in marijuana (THC and CBD) are present in an equal 1:1 ratio. So far, Sativex has been approved in over 20 countries worldwide, including Canada, the UK and various countries across Europe. The company is currently seeking approval from the FDA to be sold in the U.S.According to GW Pharmaceuticals’ website, Sativex has proven effective for the treatment of multiple sclerosis spasticity and is currently undergoing trials for the treatment of neuropathic and cancer-related pain.
      Professor Thibault Moreau, head of the neurology department of the University Hospital of Dijon, welcomes the authorization of Sativex – a medicine that he believes could help many patients with MS. “Its effectiveness is modest but significant effect on spasticity. It also appears to have beneficial effects on sleep.” The neurologist notes that Sativex and cannabis-based drugs also show promise in treating a variety of other disorders. “Their method of action is non-specific, it is likely that they are effective contractures of other causes during a spinal injury or after a stroke, for example,” Moreau says.
      Avatar
      schrieb am 23.09.13 14:30:22
      Beitrag Nr. 42 ()
      GW Pharmaceuticals Announces Agreement on Sativex® Pricing in Germany

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/ag…
      Avatar
      schrieb am 24.09.13 15:58:35
      Beitrag Nr. 43 ()
      GW Pharmaceuticals PLC Director/PDMR Shareholding
      24 September 2013
      GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company", "GW")
      NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/gr…
      Avatar
      schrieb am 02.10.13 15:13:47
      Beitrag Nr. 44 ()
      02.10.2013 | 14:11

      PR Newswire · Mehr Nachrichten von PR Newswire
      GW Pharmaceuticals Announces New Sativex Data at ECTRIMS

      http://www.finanznachrichten.de/nachrichten-2013-10/28180002…
      Avatar
      schrieb am 03.10.13 19:51:17
      Beitrag Nr. 45 ()
      in USA scheint Party zu sein
      (1 Aktiepaket = 12 original Aktien)
      Avatar
      schrieb am 04.10.13 10:01:30
      Beitrag Nr. 46 ()
      in London wurde gerade die 1Pfund-Marke überschritten.
      Avatar
      schrieb am 07.10.13 13:11:41
      Beitrag Nr. 47 ()
      London

      Avatar
      schrieb am 07.10.13 14:32:48
      Beitrag Nr. 48 ()
      GWPH GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital

      October 7, 2013

      GWPH GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital
      Lazard Capital raised its price target significantly for GW Pharmaceuticals to $65 citing the company's orphan program for epilepsy. The firm calls GW one of the most compelling opportunities its ever seen and keeps a Buy rating on the stock
      Avatar
      schrieb am 07.10.13 14:33:23
      Beitrag Nr. 49 ()
      Tradegate

      14:28:39 1,69 200
      09:16:55 1,307 1500
      08:45:10 1,286 430
      08:02:40 1,286 1300


      Geld
      1,681
      Brief
      1,735
      Zeit
      07.10.13 14:32:45
      Avatar
      schrieb am 07.10.13 14:51:53
      Beitrag Nr. 50 ()
      Zitat von Biohero: GWPH GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital

      October 7, 2013

      GWPH GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital
      Lazard Capital raised its price target significantly for GW Pharmaceuticals to $65 citing the company's orphan program for epilepsy. The firm calls GW one of the most compelling opportunities its ever seen and keeps a Buy rating on the stock



      65$ = 47,80€
      noch viiiiel Luft nach oben. ;)
      Avatar
      schrieb am 07.10.13 15:06:24
      Beitrag Nr. 51 ()
      Zitat von binda:
      Zitat von Biohero: GWPH GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital

      October 7, 2013

      GWPH GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital
      Lazard Capital raised its price target significantly for GW Pharmaceuticals to $65 citing the company's orphan program for epilepsy. The firm calls GW one of the most compelling opportunities its ever seen and keeps a Buy rating on the stock



      65$ = 47,80€
      noch viiiiel Luft nach oben. ;)


      Da sich das Ganze auf die GWPH `s bezieht, darf man nicht vergessen, dass:
      1 GWPH = 12 ordinery shares
      Avatar
      schrieb am 08.10.13 19:18:56
      Beitrag Nr. 52 ()
      Der Anstieg, in den letzten Tagen, war schon extrem. Nun kehrt etwas Ruhe ein.
      Mal schaun, wie weit es runter geht.
      An den Aussichten hat sich nichts geändert. Keine Bad-News.
      Avatar
      schrieb am 10.10.13 16:44:28
      Beitrag Nr. 53 ()
      MS-Patienti von mir bekommt Sativa

      ist sehr zufrieden
      Avatar
      schrieb am 11.10.13 13:44:01
      Beitrag Nr. 54 ()
      ist das hier eigentlich die gleiche Firma wie
      http://www.wallstreet-online.de/aktien/43701051

      hier mit 177 Mio Aktien, dort mit 15 mio ADrs?
      Und Hauptbörse London? Auch noch mal jede Menge Aktien ...


      Jedenfalls gewaltiger Kursanstieg bei allen drei
      Avatar
      schrieb am 16.10.13 11:24:26
      Beitrag Nr. 55 ()
      Zitat von dottore: ist das hier eigentlich die gleiche Firma wie
      http://www.wallstreet-online.de/aktien/43701051

      hier mit 177 Mio Aktien, dort mit 15 mio ADrs?
      Und Hauptbörse London? Auch noch mal jede Menge Aktien ..
      .


      Jedenfalls gewaltiger Kursanstieg bei allen drei



      Alles zusammen sind 177 Mio Aktien


      Number of Securities in Issue
      As of 30 September 2012, the total number of ordinary shares of 0.1p each in the capital of the company in issue was 133,055,154 with each share carrying the right to one vote.

      GW's Nasdaq listing added 44,136,000 ordinary shares of 0.1p each bringing the total number of securities in total as of 4 June 2013 to 177,506,354 with each share carrying the right to one vote.

      http://ir.gwpharm.com/issuedSecurities.cfm
      Avatar
      schrieb am 16.10.13 16:25:13
      Beitrag Nr. 56 ()
      Hallo,

      ich habe neulich 1000 Stk für 1,91€ gekauft. Leider sind sie jetzt etwas darunter aber das macht mir keine Angst den ich bin überzeugt das sie demnähst steigen werden.

      Die Frage ist folgende: Ich bin noch ziemlich neu an der Börse und ich habe gemerkt as es 2 Werte (Aktien) gibt. Ich habe schon versucht zu suchen warum, aber nichts gefunden.

      1. GW Pharmaceuticals (1,80€)
      2. GW Pharmaceuticals PLC Reg. Shares (27,56$ USD)

      Ich habe mich bei der Nr. 1 beteidigt. Ich denke schon das 1. und 2. die gleiche sind. Doch kann mir jemand die unterschiede erklären?

      Hoffe das es nicht eine zu naive Frage ist.

      Danke im Vorraus,

      J.A.
      Avatar
      schrieb am 21.10.13 08:53:39
      Beitrag Nr. 57 ()
      Zitat von JorgeCAltamirano: Hallo,

      ich habe neulich 1000 Stk für 1,91€ gekauft. Leider sind sie jetzt etwas darunter aber das macht mir keine Angst den ich bin überzeugt das sie demnähst steigen werden.

      Die Frage ist folgende: Ich bin noch ziemlich neu an der Börse und ich habe gemerkt as es 2 Werte (Aktien) gibt. Ich habe schon versucht zu suchen warum, aber nichts gefunden.

      1. GW Pharmaceuticals (1,80€)
      2. GW Pharmaceuticals PLC Reg. Shares (27,56$ USD)

      Ich habe mich bei der Nr. 1 beteidigt. Ich denke schon das 1. und 2. die gleiche sind. Doch kann mir jemand die unterschiede erklären?

      Hoffe das es nicht eine zu naive Frage ist.

      Danke im Vorraus,

      J.A.


      Guten morgen,
      die 2. sind ein Altienpaket. Das heißt: ein Paket = 12 Aktien. Deshalb ist der Kurs dort so hoch. Nur in USA handelbar. Durch dieses IPO damals, bekam GW neues Geld in die Kasse.



      News von heute: Vermarktung in Frankreich zugelassen.

      21.10.2013 | 08:01
      (2 Leser) Schrift ändern:
      (0 Bewertungen)

      PR Newswire · Mehr Nachrichten von PR Newswire
      GW Pharmaceuticals Announces Successful Closing of Mutual Recognition Procedure for Sativex in France


      LONDON, Oct. 21, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the successful closing of the European Mutual Recognition Procedure (MRP) in France for Sativex® oromucosal spray in the treatment of spasticity due to Multiple Sclerosis (MS) and a resulting recommendation for approval by the French authorities.

      The next step in the regulatory process is to work with the French National Agency of Medicine and Health Products Safety (ANSM) to finalize any country-specific requirements. Following completion of this next step, it is then expected that France will issue a national marketing authorisation. Launch timing in France is dependent on completion of subsequent national pricing and reimbursement procedures. Sativex will be commercialized in France by GW's European partner, Almirall S.A.

      "The successful completion of this regulatory process for Sativex in France maintains our positive regulatory track record for Sativex, which is already approved in 22 countries, and provides further endorsement of the important role Sativex can play in meeting a substantial unmet need of people with Multiple Sclerosis," stated Justin Gover, Chief Executive Officer of GW Pharmaceuticals. "We look forward to working with our partners, Almirall, towards the launch of Sativex in this important European country."

      Sativex is approved as a treatment for MS spasticity in 22 countries, including 17 countries in Europe. The medicine is currently available on prescription in the UK, Spain, Germany, Canada, Denmark, Norway, Israel, Austria, Poland, Sweden, Italy and Finland with launches currently in preparation for a further 8 European countries, as well as Australia, New Zealand and Kuwait.

      In the United States, GW announced in August 2013 that it had opened a Phase 3 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a pivotal efficacy and safety clinical program to evaluate Sativex® for the treatment of MS spasticity. GW expects the U.S. Phase 3 trial to commence in 2014.

      Sativex is also currently in Phase 3 clinical trials as a treatment for cancer pain. This represents the lead target indication for the product in the United States.
      http://www.finanznachrichten.de/nachrichten-2013-10/28344879…
      Avatar
      schrieb am 23.10.13 10:49:30
      Beitrag Nr. 58 ()
      Vielen Dank!!

      binda, was hälst du von GW, siehst du wircklich potential? Kursziel?

      LG
      Avatar
      schrieb am 24.10.13 01:18:02
      Beitrag Nr. 59 ()
      Zitat von JorgeCAltamirano: Vielen Dank!!

      binda, was hälst du von GW, siehst du wircklich potential? Kursziel?

      LG



      Ja, sehe ich.

      Hier einige Analysten- GWPH- Bewertungen:

      http://www.analystratings.net/stocks/NASDAQ/GWPH/?Registrati…

      Wie man sehen kann, haben Canaccord Genuity, das Kursziel angehoben, auf 39$.
      Da es sich um das Paket (12Aktien) handelt, läge der Kurs für die einzelne Aktie bei 3,25$. Das wären in Euro: aktuell 2,36


      Ob dies wirklich so eintrifft? Potenzial ist da. Immer mehr Zulassungen...weltweit.
      Avatar
      schrieb am 25.10.13 10:42:41
      Beitrag Nr. 60 ()
      Interessante Zusammenfassung mit Details zu Epidiolex ( GW- Produkt)
      vom 22.10.13
      http://www.beyondthc.com/comes-now-epidiolex-fda-approves-in…

      z.B.:
      To date FDA has approved intermediate-sized INDs sponsored by Orrin Devinsky, MD, at the NYU School of Medicine, and Roberta Cilio, MD, PhD, at UCSF —each set up to follow 25 patients using Epidiolex™ as a treatment for pediatric epilepsy— plus two individual INDs by Cilio. More INDs await FDA approval.
      Avatar
      schrieb am 26.10.13 20:30:13
      Beitrag Nr. 61 ()
      Vielen Dank!

      Hab mir das mit "Epidiolex" durchgelesen und klingt sehr interessant!

      Danke das du uns up to date hältst.

      Gruss.
      Avatar
      schrieb am 06.11.13 14:35:09
      Beitrag Nr. 62 ()
      :confused:Keine News??
      Avatar
      schrieb am 06.11.13 15:52:07
      Beitrag Nr. 63 ()
      Demnächst kommt der Jahres-Finanzbericht. Rechne jeden Tag damit.

      GW's financial year ends on 30 September.


      Und die pipeline ist voll.
      Da wird noch so einiges kommen ;)

      z.B. hier :


      Sativex is approved as a treatment for MS spasticity in 22 countries, including 17 countries in Europe. The medicine is currently available on prescription in the UK, Spain, Germany, Canada, Denmark, Norway, Israel, Austria, Poland, Sweden, Italy and Finland with launches currently in preparation for a further 8 European countries, as well as Australia, New Zealand and Kuwait.
      In addition, regulatory authorization has been received in Belgium, the Netherlands, Portugal, Czech Republic and Slovakia with launches expected from the end of 2013 onwards.

      und natürlich USA:

      In the United States, GW announced in August 2013 that it had opened a Phase 3 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a pivotal efficacy and safety clinical program to evaluate Sativex® for the treatment of MS spasticity. GW expects the U.S. Phase 3 trial to commence in 2014.

      Sativex is also currently in Phase 3 clinical trials as a treatment for cancer pain. This represents the lead target indication for the product in the United States.

      http://www.finanznachrichten.de/nachrichten-2013-10/28344879…

      Mir ist es lieber, die arbeiten an ihren Projekten, als das sie ständig blabla-news bringen würden.


      Was auch wichtig ist, ist dass Sativex MS von den deutschen, spanischen und einigen anderen Krankenkassen akzeptiert wird und somit die Kosten mittlerweile übernommen werden.
      acceptable reimbursement price for Sativex® in Germany, Europe's largest potential market for Sativex®. This agreement ensures that people suffering from Multiple Sclerosis spasticity in Germany will have long-term access to this important medicine," statedJustin Gover, GW's Chief Executive Officer.

      It is estimated that approximately 4,000 patients are currently being treated with Sativex in Germany.

      http://www.finanznachrichten.de/nachrichten-2013-09/28082726…
      http://www.gwpharm.com/Sativex%20granted%20reimbursement%20i…

      Ich rechne mit guten Zahlen im Abschlussbericht 2013. Mal schaun
      Avatar
      schrieb am 08.11.13 13:08:34
      Beitrag Nr. 64 ()
      Sieht erst mal nach einer Seitwärtsbewegung aus.



      Noch mal was zu den Zahlen für das gesamte Jahr 2013, aus dem letzten Jahresbericht ( 2012)
      http://files.shareholder.com/downloads/AMDA-1TW341/260878248…
      Inline with market expectations, we are not
      expecting significant milestones receipts in 2013
      and this factor, together with our increasing
      R&D spend in the pipeline, leads us to expect to
      report a loss for the 2013 financial year.


      Ende 2012 haben die einen Verlust für dieses Jahr in Aussicht gestellt, aus den oben genannten Gründen. Jedoch ist so einiges Positive passiert, glaube nicht, dass es so schlecht ausfällt.


      Natürlich alles nur meine Meinung.
      Avatar
      schrieb am 09.11.13 02:40:23
      Beitrag Nr. 65 ()
      FDA Approves Marijuana-Based Epilepsy Drug For Use On Kids In Clinical Trials
      By Matthew Mientka | Nov 5, 2013 02:30 PM EDT


      Cannibidiol May Provide Anti-Seizure Relief
      (Shutterstock) Researchers on both US coasts will soon enroll children in a study testing a marijuana-based epilepsy drug's ability to stop seizures.
      Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children.

      In San Francisco and New York City, the physician-led pediatric studies will assess the viability of a purified cannabidiol as an anti-seizure treatment among patients with various forms of epilepsy. Although both studies will enroll 25 patients initially, the U.S. Food and Drug Administration (FDA) may approve more as the studies progress.

      Drs. Roberta Cilio and Orrin Devinsky, of the University of California, San Francisco and New York University, respectively, will investigate the use of Epidiolex, a 98 percent purified cannabidiol drug manufactured by GW Pharmaceuticals, of the United Kingdom. Cilio will also conduct two individual studies of the drug.

      Geoffrey Guy, chairman of the pharmaceutical company, told reporters that the purified drug contains no tetrahydrocannabinol (THC), the psychotropic ingredient in marijuana causing the recreational high. “Our definition of pure is no THC,” Guy said, adding that clinical study would help provide “better understanding and experience in what cannabidiol does in these different children groups, what benefit we can see, and how the results can best be measured.”

      In the upcoming U.S. studies, Cilio and Devinsky will be provided with Epidiolex, the “latest pure” cannabidiol product, in two strengths — 25 mg/ml and 100 mg/ml.


      Aside from considerable anecdotal evidence suggesting marijuana’s efficacy in treating epilepsy, the company won regulatory approval with nearly five years of pre-clinical trial data — with more studies to come. “In the coming months, if the FDA is comfortable about how things are going, there will be a number of senior epileptologists in major university centers throughout the [United States], each treating a couple of dozen patients with various epilepsies,” Guy said.

      Thus, the regulator plans to take the drug on a case-by-case basis, leaving the marijuana-derivative unapproved for general clinical prescriptive use.

      Medical researchers believe cannabidiol provides therapeutic benefit by interacting with receptors in the brain and spinal cord. During the past couple of decades, investigators have discovered two different types of cannabinoid receptors in the brain, spinal cord, and peripheral tissues, including immune tissues. Scientists say the cannabinoid system interacts with many other neurotransmitter/neuromodulator systems for a reach that extends nearly throughout the body.

      Moreover, researchers say current knowledge of the cannabinoid system suggests the existence of other cannabinoid receptors yet to be discovered.

      Although the FDA continues to classify marijuana as a Schedule II controlled substance, with no recognized medical use, 20 U.S. states have approved the drug for medicinal purposes, including Alaska, California, Connecticut, Illinois, Maine, Massachusetts, and Washington.

      Lawmakers in another four states — Minnesota, New York, Ohio, and Pennsylvania — are considering proposals to approve medical marijuana, too.

      http://www.medicaldaily.com/fda-approves-marijuana-based-epi…
      Avatar
      schrieb am 09.11.13 19:07:31
      Beitrag Nr. 66 ()
      Sehr gut!

      Ja ich stimme dir zu das sie lieber arbeiten sollen anstatt news zu bringen..

      Vielen danke für die Infos. Habe sie mir alle durchgelesen und bin ziemlich positiv.

      Aber ich denk mal vor 2014 wird nichts grosses passieren. Mal gucken..
      Avatar
      schrieb am 11.11.13 11:13:13
      Beitrag Nr. 67 ()
      Weiterer Schritt erreicht:
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/ph…
      GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial
      for the Treatment of Glioblastoma Multiforme (GBM)
      -Study Features THC and CBD as the Primary Cannabinoids-

      This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivoi,ii via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

      "We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW's first clinical study of cannabinoids as a potential treatment to inhibit tumor growth," stated Dr. Stephen Wright, Director of Research and Development at GW. "We believe this clinical program demonstrates the flexibility and broad application of GW's cannabinoid platform to treat significant, unmet therapeutic needs."
      Avatar
      schrieb am 11.11.13 15:24:58
      Beitrag Nr. 68 ()
      Schon gelesen! :)
      Avatar
      schrieb am 12.11.13 08:33:39
      Beitrag Nr. 69 ()
      LONDON, Nov. 12,2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 19 November 2013 its fourth quarter and full year financial results for the period ending 30 September, 2013. GW will also host a conference call the same day at 1:00 p.m. GMT (8:00 a.m. EST).

      Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
      Avatar
      schrieb am 12.11.13 17:26:10
      Beitrag Nr. 70 ()
      Auch mitbekommen!

      Was denkst du, dass die Ergebnisse eher + oder - sein werden?
      Avatar
      schrieb am 12.11.13 19:21:05
      Beitrag Nr. 71 ()
      GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial
      for the Treatment of Glioblastoma Multiforme (GBM)

      -Study Features THC and CBD as the Primary Cannabinoids-

      London, UK; 11 November 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW”) a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM).

      Glioma describes any tumor that arises from the glial tissue of the brain. GBM is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 50% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare, or orphan, disease by the FDA and the European Medicines Agency, or EMA.

      This study follows several years of pre-clinical research conducted by GW in the field of glioma which has demonstrated that cannabinoids inhibit the viability of glioma cells both in vitro and in vivo(i),(ii) via apoptosis or programmed cell death, may also affect angiogenesis, and have demonstrated tumor growth-inhibiting action and an improvement in the therapeutic efficacy of temozolomide, a standard treatment for glioma. In addition, GW has shown tumor response to be positively associated with tissue levels of cannabinoids. GW has identified the putative mechanism of action for our cannabinoid product candidate, where autophagy and programmed cell death are stimulated via stimulation of the TRB3 pathway.

      “We are very excited about moving this compound into further human study and the prospects of cannabinoids as new anti-cancer treatments. This is GW’s first clinical study of cannabinoids as a potential treatment to inhibit tumor growth,” stated Dr. Stephen Wright, Director of Research and Development at GW. “We believe this clinical program demonstrates the flexibility and broad application of GW’s cannabinoid platform to treat significant, unmet therapeutic needs.”

      This study is a 20-patient, multicentre, two part study with an open-label phase to assess safety and tolerability of GW cannabinoids in combination with temozolomide, and a double blind, randomised, placebo-controlled phase with patients randomised to active or placebo, and with a primary outcome measure of 6 month progression free survival. The study objective is to assess the tolerability, safety and pharmacodynamics of a mixture of two principal cannabinoids, THC and CBD in a 1:1 allocation ratio, in combination with temozolomide in patients with recurrent GBM. Secondary endpoints include
      http://www.sec.gov/Archives/edgar/data/1351288/0001104659130…
      Avatar
      schrieb am 14.11.13 10:30:55
      Beitrag Nr. 72 ()
      :eek:
      Frankfurt heute morgen:

      08:03:59 2,45 800
      Avatar
      schrieb am 14.11.13 12:20:47
      Beitrag Nr. 73 ()
      Ja!!! Aufeinmal war mein depo so im Plus und hab mich gewundert warum! Bis ich merkte das es an gw lag, doch jetzt sind sie wieder bei 2,09 :(
      Avatar
      schrieb am 15.11.13 09:18:57
      Beitrag Nr. 74 ()
      :)

      GW Pharmaceuticals
      Update on Epidiolex in Childhood Epilepsy
      RNS Number : 1079T
      GW Pharmaceuticals PLC
      15 November 2013

      

      GW Pharmaceuticals Provides Update on Orphan Program in Childhood Epilepsy for Epidiolex®

      - Orphan Drug Designation Granted for Epidiolex in Dravet syndrome by the FDA -

      - Seven Expanded Access INDs granted by FDA to U.S. physicians to treat with Epidiolex 125 children suffering from intractable epilepsy syndromes -

      London, UK; 15 November 2013: GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex®, our product candidate that contains plant-derived Cannabidiol (CBD) as its active ingredient, for use in treating children with Dravet syndrome, a rare and severe form of infantile-onset, genetic, drug-resistant epilepsy syndrome. Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant. Following receipt of this orphan designation, GW anticipates holding a pre-IND meeting with the FDA in the near future to discuss a development plan for Epidiolex in Dravet syndrome.

      Dravet syndrome is a rare pediatric epilepsy syndrome with a distinctive but complex electroclinical presentation. Onset of Dravet syndrome occurs during the first year of life with clonic and tonic-clonic seizures in previously healthy and developmentally normal infants. Prognosis is poor and patients typically develop intellectual disability and life-long ongoing seizures. There are approximately 5,440 patients with Dravet in the United States and an estimated 6,710 Dravet patients in Europe. These figures may be an underestimate as this syndrome is reportedly underdiagnosed.

      In addition to GW's clinical development program for Epidiolex in Dravet syndrome, which is expected to commence in 2014, GW has also made arrangements to enable independent U.S. pediatric epilepsy specialists to treat high need pediatric epilepsy cases with Epidiolex immediately. To date in 2013, a total of seven "expanded access" INDs have been granted by the FDA to U.S. clinicians to allow treatment with Epidiolex of approximately 125 children with epilepsy. These children suffer from Dravet syndrome, Lennox-Gastaut syndrome, and other pediatric epilepsy syndromes. GW is aware of further interest from additional U.S. and ex-U.S. physicians to host similar INDs for Epidiolex. GW expects data generated under these INDs to provide useful observational data during 2014 on the effect of Epidiolex in the treatment of a range of pediatric epilepsy syndromes.

      "I, together with many colleagues in the U.S. who specialize in the treatment of childhood epilepsy, very much welcome the opportunity to investigate Epidiolex in the treatment of Dravet syndrome. The FDA's timely approval of the orphan drug designation for Epidiolex in Dravet syndrome is a key milestone that comes after many years of reported clinical cases that suggest encouraging evidence of efficacy for CBD in this intractable condition," stated Dr. Orrin Devinsky, Professor of Neurology, Neurosurgery and Psychiatry in New York City. "With GW now making plans to advance Epidiolex through an FDA development program, we have the prospect for the first time of fully understanding the science of CBD in epilepsy with a view to making an appropriately tested and approved prescription medicine available in the future for children who suffer from this debilitating disease."

      "GW is proud to be at the forefront of this important new program to treat children with Dravet Syndrome and potentially other forms of intractable childhood epilepsy. For families in these circumstances, their lives are significantly impacted by constant and often times very severe seizures in children where all options to control these seizures have been exhausted," stated Dr. Stephen Wright, GW's R&D Director. "GW intends to advance a full clinical development program for Epidiolex in Dravet syndrome as quickly as possible, whilst at the same time helping families in the short term through supporting physician-led INDs to treat intractable cases. Through its efforts, GW aims to provide the necessary evidence to confirm the promise of CBD in epilepsy and ultimately enabling children to have access to an FDA-approved prescription CBD medicine."

      "This orphan program for Epidiolex in childhood epilepsy is an important corporate strategic priority for GW. Following receipt of today's orphan designation, GW now intends to commence discussions with the FDA regarding the U.S. regulatory pathway for Epidiolex," stated Justin Gover, GW's Chief Executive Officer. "GW intends to pursue this development in-house and retains full commercial rights to Epidiolex."

      About Orphan Drug Designation

      Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition - generally a disease or condition that affects fewer than 200,000 individuals in the U.S. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication.
      Avatar
      schrieb am 16.11.13 17:49:47
      Beitrag Nr. 75 ()
      Überlege gerade ob der Einstieg lohnt. Wo würde man denn nun am besten kaufen (London, Nasdaq, Stuttgart, ...?)
      Avatar
      schrieb am 16.11.13 23:04:17
      Beitrag Nr. 76 ()
      Zitat von me_2: Überlege gerade ob der Einstieg lohnt. Wo würde man denn nun am besten kaufen (London, Nasdaq, Stuttgart, ...?)


      In Deutschland ist das Handelsvolumen noch recht gering, deshalb wäre die Heimatbörse, UK, besser. Jedoch steigt die Infopolitik von GW immer mehr und somit ihr Bekanntheitsgrad.

      Es gibt wieder eine neue Analystenbewertung ( für die ADS`s):

      http://www.i3investor.com/servlets/fdnews/165775.jsp
      Equities researchers at Cowen and Company boosted their price target on shares of GW Pharmaceuticals Plc – American Depositary Shares (NASDAQ:GWPH) from $33.00 to $40.00 in a research report issued on Friday, Stock Ratings News reports. Cowen and Company’s target price points to a potential upside of 12.14% from the stock’s previous close.

      Other equities research analysts have also recently issued reports about the stock. Analysts at Canaccord Genuity raised their price target on shares of GW Pharmaceuticals Plc – American Depositary Shares from $26.00 to $39.00 in a research note to investors on Monday, October 21st. They now have a “buy” rating on the stock. Finally, analysts at Lazard Capital Markets raised their price target on shares of GW Pharmaceuticals Plc – American Depositary Shares from $22.00 to $65.00 in a research note to investors on Monday, October 7th. They now have a “buy” rating on the stock. Four analysts have rated the stock with a buy rating, GW Pharmaceuticals Plc – American Depositary Shares has an average rating of “Buy” and a consensus price target of $36.60.
      Avatar
      schrieb am 18.11.13 12:33:38
      Beitrag Nr. 77 ()
      Ich bin in Frankfurt ziemlich zufrieden.. Letztens waren sie sogar bei 2,45€

      Binda: Morgen kommen die Zahlen, hast du eine Meinung?
      Avatar
      schrieb am 18.11.13 12:55:55
      Beitrag Nr. 78 ()
      Zitat von JorgeCAltamirano: Ich bin in Frankfurt ziemlich zufrieden.. Letztens waren sie sogar bei 2,45€

      Binda: Morgen kommen die Zahlen, hast du eine Meinung?


      In den ersten 6 Monaten hatten die recht positive Zahlen gemeldet:
      FINANCIAL HIGHLIGHTS

      · Total revenue for the six months ended 31 March 2013 of £12.9m ($19.6m) compared to £11.1m in H1 2012

      · Net profit after tax for the six months ended 31 March 2013 of £0.1m ($0.2m) compared to a loss of £3.2m in H1 2012

      · Cash and cash equivalents at 31 March 2013 of £27.9m ($42.3m) compared to £29.3m as at 30 September 2012. Additional £18.2m of net proceeds after expenses from initial public offering on NASDAQ received after period end.

      Dann der Q3 Bericht :

      FINANCIAL HIGHLIGHTS FOR THE THREE MONTHS ENDED 30 JUNE 2013

      · Sativex product sales revenues of £0.5 million ($0.8 million) for the three months ended 30 June 2013, compared to £0.1 million for the three months ended 30 June 2012, reflecting increased shipments of inventory to commercial partners

      · Total revenue for the three months ended 30 June 2013 of £7.3 million ($11.0 million) compared to £14.5 million for the three months ended 30 June 2012, a period in which a £9.8 million milestone payment was received

      · Loss after tax for the three months ended 30 June 2013 of £2.0 million ($3.1 million) compared to a profit of £7.9 million for the three months ended 30 June 2012, which primarily reflected the impact of the £9.8 million milestone payment received in the comparable period last year

      · Cash and cash equivalents at 30 June 2013 of £43.6 million ($66.3 million) compared to £29.3 million as at 30 September 2012



      Durch den US Börsengang konnten die ihre Cashposition schön ausbauen.( schönes Polster)

      Ich rechne mit guten Jahreszahlen, obwohl es, wie angekündigt, wohl keine Milestone- Zahlungen in 2013 gab.
      Avatar
      schrieb am 18.11.13 13:01:26
      Beitrag Nr. 79 ()
      Hier wird es von GW noch mal erklärt, warum Revenue für 2013 geringer ausfallen könnte:

      5 August 2013 | 08:01am
      StockMarketWire.com - GW Pharmaceuticals reports an after-tax loss of £2.0m for the three months to the end of June compared with a profit of £7.9m for the third quarter last year.

      The group said this primarily reflected the impact of the £9.8 million milestone payment received in the comparable period last year.

      The group had cash and cash equivalents of £43.6m of at the end of June compared with £29.3m at the end of September 2012.

      Chief executive Justin Gover said: "Following our successful Nasdaq listing in May, GW has established an important new US shareholder base and further enhanced its robust financial position.

      "GW continues to make good progress with the US phase 3 development of Sativex as a treatment for cancer pain, and is also now advancing plans for the US development of Sativex as a treatment for MS spasticity.

      "In addition, the recent launch of Sativex in Italy and new regulatory application in France are expected to support further commercial progress in Europe, and provide important validation for Sativex and GW's position as a world leader in cannabinoid science.

      "As we move forward in the second half of 2013, we expect a significant amount of clinical activity to occur with respect to our cannabinoid pipeline candidates."
      - See more at: http://www.stockmarketwire.com/article/4644908/GW-Pharmaceut…
      Avatar
      schrieb am 18.11.13 20:40:43
      Beitrag Nr. 80 ()
      London, UK, 18 November 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Thursday, 21 November, 2013 at 8:00 a.m. GMT. The conference will be held at the Waldorf Hilton Aldwych, London.

      A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/gw…
      Avatar
      schrieb am 18.11.13 20:58:47
      Beitrag Nr. 81 ()
      Meist sickert vor den Zahlen etwas durch und der Kurs bewegt sich auffällig in eine Richtung.

      Hier ist nichts dergleichen geschehen. Seitwärts seit ca 10 Tagen.

      Bin gespannt auf morgen früh 8 Uhr.

      Avatar
      schrieb am 19.11.13 10:03:11
      Beitrag Nr. 82 ()
      19 November 2013 | 08:37am
      StockMarketWire.com - GW Pharmaceuticals posts a net loss after tax of £4.5m for the year to the end of September compared to a profit after tax of £2.5m in 2012.

      Total revenue for 2013 of £27.3m compared to £33.1m last time. 2012 included a £9.8m milestone receipt compared to £0.3m milestone income this time.

      Chief executive Justin Gover said: "This was a transformative year for GW with the successful completion of an IPO on NASDAQ, progress with two Phase 3 programs for Sativex in the United States, and the emergence of a new exciting orphan development program in childhood epilepsy.

      "We believe that the Company is poised to meet a number of significant clinical, regulatory and commercial milestones for GW investors. These include Phase 3 data from our US-focused pivotal Sativex trials, further Sativex commercial launches and sales growth, progress of the new orphan epilepsy program in the US, and further advancement of several other cannabinoid pipeline candidates."
      - See more at: http://www.stockmarketwire.com/article/4708707/GW-Pharmaceut…
      Avatar
      schrieb am 19.11.13 10:24:44
      Beitrag Nr. 83 ()
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/fi…

      Lese ich die Zahlen richtig, dann wurde in 2013 ein totaler Umsatz von 27,3mio Pfund erreicht, worin eine Meilensteinzahlung von nur 0,3 mio enthalten sind. Ohne diese "Sonderzahlungen" wurden also 27 mio Umsatz erreicht.

      In 2012 Umsatz von 33,1 mio Pfund, jedoch sind eine M-Zahlung von 9,8 mio enthalten. Ohne diese "nur" 23,3 mio.

      Somit eine "versteckte" Steigerung des Umsatz in 2013. ;)

      Ebenso beim Verlust: in 2012 ein Plus durch die Meilensteinzahlungen. Zieht man diese aber ab, wäre für 2012 ein Verlust von 7,7 mio errechenbar. Nun, in 2013 " nur" 4,5 mio ( 0,3 mio M-Zahlung = 4,8 mio)

      Und ein fettes Cash ;)


      Ich finde die Zahlen gut. Die Aussichten sind besonders gut.

      Der Kurs geht erst mal runter. Mal schaun, wie es sich weiter entwickelt.

      Ich bin seit 0,72 € drin und somit sehr gelassen.

      Gruß binda
      Avatar
      schrieb am 19.11.13 10:32:21
      Beitrag Nr. 84 ()
      Aussichten u. Überblick:

      2013 HIGHLIGHTS:

      -Initial public offering on the NASDAQ Global Market completed in May 2013 raising total net proceeds before expenses of $30.7m (£19.8m)

      -Two U.S.-targeted Sativex® Phase 3 pivotal programs advanced in 2013
      Cancer Pain: two pivotal Sativex Phase 3 trials in recruitment

      -First Phase 3 top-line results expected in H2 2014

      -Data intended to lead to a New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA)

      -Multiple Sclerosis (MS): Phase 3 Investigational New Drug (IND) application opened with the FDA for Sativex in the treatment of MS spasticity
      Special Protocol Assessment (SPA) to be requested prior to anticipated start of Phase 3 trial in 2014

      -All Sativex Phase 3 clinical trials targeted at FDA approval are fully funded by U.S. partner, Otsuka

      -Sativex U.S. patent position further strengthened through two additional U.S. Notices of Allowance

      -Sativex now approved in 22 countries (ex-U.S) as a treatment for MS spasticity

      -In-market sales by partners increased by 25%

      +Commercial launch in Italy in July 2013
      +Germany pricing agreement reached in September 2013
      +Recommendation for approval in France in October 2013
      +On-going commercial launches in planning over next 12 months
      +New Sativex data presented at ECTRIMS in October 2013
      +Expansion of epilepsy research program through commencement of a new orphan pediatric epilepsy program for Epidiolex® (purified extract of Cannabidiol, or CBD)

      -FDA orphan drug designation granted by FDA for Epidiolex in Dravet syndrome
      +Seven physician-led INDs granted by FDA to treat 125 pediatric epilepsy patients in the U.S. with Epidiolex
      +Epidiolex pediatric epilepsy clinical trials in planning for 2014
      +Additional epilepsy pipeline candidate, GWP42006 (Cannabidivarin or CBDV), commenced Phase 1 trial in September 2013

      -Significant clinical activity for GW's other cannabinoid pipeline product candidates, including:
      Positive preliminary data reported from a Phase 2a exploratory clinical trial of the novel cannabinoid medicine GWP42004 in type-2 diabetes with a Phase 2 dose ranging trial expected to commence in early 2014
      Phase 2 trial of GWP42003 for the treatment of ulcerative colitis on-going with data expected in the first half of 2014
      Phase 2 trial of GWP42003 for the treatment of schizophrenia expected to commence in the first half of 2014
      Phase 1b/2a trial of THC:CBD for the treatment of glioma commenced in November 2013
      Avatar
      schrieb am 19.11.13 10:55:07
      Beitrag Nr. 85 ()


      Last Price
      167.72
      10.28 down (5.775%)
      Avatar
      schrieb am 19.11.13 11:59:41
      Beitrag Nr. 86 ()
      Puh, heftig. Tief war bei 1,60. Es sind zwei Gaps entstanden. Das untere wird gerade geschlossen:



      Im 6 Monat-Chart sieht es weniger schlimm aus. ;)

      Avatar
      schrieb am 19.11.13 15:08:10
      Beitrag Nr. 87 ()
      Präsentation vom 19.11.2013

      PDF View Presentation 1.6 MB

      http://ir.gwpharm.com/common/download/download.cfm?companyid…
      Avatar
      schrieb am 25.11.13 17:38:29
      Beitrag Nr. 88 ()
      danke fuer die info! :)

      ich habe gw auch seit sie bei 0,65 waren angefangen zu beobachten doch zu lange gewartet... :/
      Avatar
      schrieb am 27.11.13 08:19:14
      Beitrag Nr. 89 ()
      Zulassung in der Schweiz

      http://www.finanznachrichten.de/nachrichten-2013-11/28733724…
      27.11.2013 | 08:01

      PR Newswire · Mehr Nachrichten von PR Newswire
      GW Pharmaceuticals plc Announces Sativex Regulatory Approval in Switzerland


      LONDON, Nov.27, 2013 /PRNewswire/ --GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has received regulatory approval for its prescription medicine Sativex® in Switzerland. A full marketing authorization has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications. Launch timing is dependent on completion of pricing and reimbursement procedures. Sativex will be commercialized in Switzerland by GW's European partner, Almirall S.A.

      "This approval in Switzerland marks yet another regulatory success for Sativex, which is now approved in a total of 23 countries," stated Justin Gover, Chief Executive Officer of GW. "We now look forward to working with our partners, Almirall, towards this launch so as to enable MS patients in Switzerland to benefit from this important new treatment."

      Sativex is approved for use in the treatment of MS spasticity in 23 countries, including 17 countries in Europe. The medicine is currently available on prescription in the UK, Spain, Germany, Canada, Denmark, Norway, Israel, Austria, Poland, Sweden, Italy and Finland with launches currently in preparation for a further 8 European countries, as well as Australia, New Zealand and Kuwait.
      Avatar
      schrieb am 27.11.13 09:57:05
      Beitrag Nr. 90 ()
      Avatar
      schrieb am 27.11.13 11:12:21
      Beitrag Nr. 91 ()
      die Kursprognose (für ADR) wird ein weiteres Mal angehoben:

      GW Pharma rises on Piper call
      GW Pharmaceuticals (GWPH) rallies 11% AH.Piper's Josh Schimmer is reportedly out with a $73 price target, representing upside of 108% from where the stock closed in regular trading.


      http://www.iii.co.uk/investment/detail?code=cotn%3AGWP.L&dis…


      Ganz schön hoch gegriffen.:rolleyes:

      das wären umgerechnet für jede GWP ca 6,08 Pfund = 7,28 Euro

      Naja, es wird in der Prognose kein Zeitraum genannt. Somit alles möglich. ;)
      Avatar
      schrieb am 27.11.13 14:41:01
      Beitrag Nr. 92 ()
      vorbörslich in usa im plus

      nasdaq gwph


      und auch london nicht übel

      Avatar
      schrieb am 27.11.13 21:37:41
      Beitrag Nr. 93 ()
      na 7E ist auch mal was.. ich finde schon das man bei GW sicher ist.. nicht wie bei Paion oder Epi und Evo.. an den bin ich auch.. doch hier merkt man schon das der Kurs echt ziemlich langsam steigt... fast garnichts.. aber das ist mal fuer Long ganz gut.. und ich finde GW ist auch noch nicht bekannt wie andre Unternehmen wo sich die ganze Zocker befinden. 2014 wird spannend.
      Avatar
      schrieb am 29.11.13 15:01:35
      Beitrag Nr. 94 ()
      NEW YORK, NY -- (Marketwired) -- 11/29/13 -- A new FDA approval has created a buzz inside biotechs involved with medical marijuana research. When Nuvilex, Inc. (OTCQB: NVLX) announced the formation of its new medical marijuana subsidiary, Medical Marijuana Sciences, Inc., the company's CEO, Dr. Robert Ryan, said then that its research would focus initially on cannabidiol (CBD), one of the compounds found in Cannabis, as the basis for developing treatments for serious and deadly forms of cancer. Well, this month the U.S. Food and Drug Administration (FDA) apparently agreed that CBD is the way to go and they've approved clinical trials using the compound.





      This landmark approval involves the use of a cannabis-based drug and its effects on epilepsy, and could very well change the face of the industry. According to the FDA, the treatment, Epidiolex, made by GW Pharmaceuticals based out of the U.K., is 98 percent purified cannabidiol.



      While Nuvilex was well aware of the apparent benefits of cannabidiol, it wasn't until CNN's chief medical correspondent, Dr. Sanjay Gupta, released his documentary, "Weed," that the compound seemed to gain real momentum as the key to the drug's success. Nuvilex's plan is use its expertise, current research and its success in the biotechnology sector to make it among the leaders in the medical marijuana industry, and the FDA's approval of these clinical trials could ramp up research industry wide.



      In the announcement, the FDA said, there are around 60 known chemicals contained in cannabis called cannabinoids. Tetrahydrocannabinol (THC) is the main component responsible for the psychoactive nature of most varieties of cannabis. CBD, however, is the second most abundant cannabinoid in the cannabis and provides medicinal benefits without the "high."



      These trials could very well open the floodgates to more FDA approvals using CBD as the basis for developing treatments for a number of different ailments. The benefit to Nuvilex is that their research into those difficult to treat cancers may have just gotten the green light.
      1 Antwort
      Avatar
      schrieb am 29.11.13 16:59:32
      Beitrag Nr. 95 ()
      Antwort auf Beitrag Nr.: 45.948.080 von JorgeCAltamirano am 29.11.13 15:01:35Danke fürs Reinstellen.
      Die Chancen auf eine US-Zulassungen werden immer größer. ;)
      Avatar
      schrieb am 29.11.13 17:04:14
      Beitrag Nr. 96 ()
      Ausübung von Mitarbeiter-aktien-optionen

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/bl…
      Porton Down, UK, 29 November 2013: GW Pharmaceuticals (AIM: GWP) hereby provides notification that application has today been made to the London Stock Exchange for admission to trading on AIM of three blocks of new ordinary shares of 0.1p each.

      These new ordinary shares will be issued from time to time pursuant to the exercise of employee share options under the GW Pharmaceuticals share options schemes, as follows:

      800,000 new ordinary shares for issue by the GW Pharmaceuticals Unapproved Share Option Scheme 2001.

      200,000 new ordinary shares for issue by the GW Pharmaceuticals Approved Share Option Scheme 2001

      300,000 new ordinary shares for issue by the GW Pharmaceuticals Long Term Incentive plan 2008.

      On exercise the shares will be issued as fully paid and will rank pari passu in all respects with the Company's existing ordinary shares.

      Admission is expected to be effective on 5 Dec
      Avatar
      schrieb am 30.11.13 22:44:35
      Beitrag Nr. 97 ()
      Brain Tumors and Cannabinoids: GW Pharmaceutical Sparks Up Cannabis Based Drug Trail
      Posted November 13th, 2013 by Monterey Bud & filed under marijuana cannabinoids, marijuana research, Studies


      Das Video ist interessant:

      http://www.marijuana.com/news/2013/11/brain-tumors-and-canna…
      Avatar
      schrieb am 01.12.13 16:14:16
      Beitrag Nr. 98 ()
      Danke für die Info sowie das Video, sehr interessant!! :)

      Würdest du mir empfehlen noch einige Stk. zu kaufen?
      Avatar
      schrieb am 02.12.13 09:28:43
      Beitrag Nr. 99 ()
      Zitat von JorgeCAltamirano: Danke für die Info sowie das Video, sehr interessant!! :)

      Würdest du mir empfehlen noch einige Stk. zu kaufen?



      Hi Jorge.., grundsätzlich mache ich keine Kauf-oder Verkaufsempfehlungen.

      Nur eins, ich bin immer mehr davon überzeugt, dass die FDA positiv entscheiden wird.

      Nicht zu vergessen: Steigende Umsätze in den anderen 23 Ländern ( neu Schweiz)-In-market sales by partners increased by 25%


      Alles auf den vorherigen Seiten,mit Quellen, nach zu lesen.

      Gruß binda
      Avatar
      schrieb am 02.12.13 10:15:00
      Beitrag Nr. 100 ()
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/pr…

      GW Pharmaceuticals to Present at the Piper Jaffray 25th Annual Health Care Conference

      London, UK, 2 December 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Piper Jaffray 25th Annual Health Care Conference on Wednesday, 4 December, 2013 at 8:30 a.m. ET. The conference will be held at the New York Palace Hotel in New York City.

      A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
      Avatar
      schrieb am 02.12.13 10:28:37
      Beitrag Nr. 101 ()
      Zwar vom 11.Nov,aber trotzdem interessant:
      http://seekingalpha.com/article/1829142-gw-pharma-capitalizi…

      Hier ein kleiner Auszug aus dem Text:

      World Class Marketing Partners

      The company has already received $113mm in upfront fees and milestones and has the potential to earn another $325mm in milestones. The most important partner is Japanese company Otsuka, which pays for all U.S. development costs. Novartis is its partner in the Mid-East, Africa, Asia and Australasia. Bayer, its partner in the UK and Canada, has the least favorable deal, characterized as "mid 30s-40%." Almirall is the partner in Europe and Mexico. Finally, Neopharm is its partner in Israel. None of the agreements would preclude acquisition of GWPH.
      Avatar
      schrieb am 03.12.13 23:04:39
      Beitrag Nr. 102 ()
      Der kurzfristige Aufwärtstrend ist nach unten gebrochen. Schade. Der Langfristige ist jedoch intakt.




      Bei ca 153 gibt es ein Gap, vielleicht muß dieses erst noch geschlossen werden?

      Avatar
      schrieb am 04.12.13 10:41:19
      Beitrag Nr. 103 ()
      Hmm.... Oh man :(

      Schade aber naja bei solche Papiere muss man einfach Long bleiben.
      Avatar
      schrieb am 04.12.13 11:14:34
      Beitrag Nr. 104 ()
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/pr…

      Vielleicht hört man heute Interessantes von der Piper Jaffray 25th Annual Health Care Conference on Wednesday, 4 December, 2013 at 8:30 a.m. ET

      ;)
      1 Antwort
      Avatar
      schrieb am 04.12.13 16:28:41
      Beitrag Nr. 105 ()
      Antwort auf Beitrag Nr.: 45.975.552 von binda am 04.12.13 11:14:34Live conference
      http://www.media-server.com/m/p/kmnky9sw
      Avatar
      schrieb am 05.12.13 10:31:03
      Beitrag Nr. 106 ()
      Alles was die ganze Monaten langsam Aufstieg ist wieder wo es mal war..

      Obwohl gute Nachrichten es gab, verstehe nicht warum alles wieder innerhalb 1 Woche nach unten ging.

      Binda, hast du eine Idee warum? Ich hoffe es geht nicht tiefer den ich bin leicht im Minus :/

      Gruß.
      2 Antworten
      Avatar
      schrieb am 05.12.13 11:02:16
      Beitrag Nr. 107 ()
      Antwort auf Beitrag Nr.: 45.984.122 von JorgeCAltamirano am 05.12.13 10:31:03GW hat in nur 3 Monaten eine Verdreifachung hinter sich. Für mich sieht es eher nach einer ganz normalen Konsolidierung aus.
      Im Bereich Forschung und Entwicklung gibt es keine negativen Nachrichten, im Gegenteil.

      Würde mich nicht wundern, wenn in Kürze ein weiteres Land hinzu kommt:

      Sativex is approved for use in the treatment of MS spasticity in 23 countries, including 17 countries in Europe. The medicine is currently available on prescription in the UK, Spain, Germany, Canada, Denmark, Norway, Israel, Austria, Poland, Sweden, Italy and Finland with launches currently in preparation for a further 8 European countries, as well as Australia, New Zealand and Kuwait.http://www.finanznachrichten.de/nachrichten-2013-11/28733724…

      Und nicht zu vergessen, auch aus dieser Ecke könnten bald Nachrichten kommen.:

      -All Sativex Phase 3 clinical trials targeted at FDA approval are fully funded by U.S. partner, Otsuka
      1 Antwort
      Avatar
      schrieb am 05.12.13 14:39:59
      Beitrag Nr. 108 ()
      Antwort auf Beitrag Nr.: 45.984.408 von binda am 05.12.13 11:02:16Ja, mit den 3 Monaten hast du recht. Ich habe mich vorhin auf dem Punkt wo ich eingestiegen bin bezogen (1,93). Aber wenn man es vor 3 Monaten betrachtet wo es auf 0,60 war dann natürlich. :)

      Naja jetzt wieder 1,98. Solange wir nicht wieder unter 1,50 sind mache ich mir keine grosse Gedanken.

      Ich möchte zu einem Online Broker wechseln, hast du mal einen Vorschlag für mich? ich habe mir Lynx angeguckt aber ich komme mit der Software nicht klar. Überlege grade nach Cortal zu wechseln...

      Dir ein schönes Wochenende. :)
      Avatar
      schrieb am 09.12.13 11:07:13
      Beitrag Nr. 109 ()
      Das Gap wurde heute komplett geschlossen. Sollte jetzt wieder hoch gehen.

      Avatar
      schrieb am 10.12.13 17:28:47
      Beitrag Nr. 110 ()
      Bei den Kursen braucht man echt starke Nerven, oder man steigt aus.
      Noch ist der Long-up-trend nicht gebrochen. Ich denke die 147p ist eine wichtige Marke. Wird diese gerissen...
      Sollte ein Chartfreak unter den Lesern sein, fände ich es gut, wenn er sich äußern würde.

      Wen`s interessiert, ich bin noch drin.




      Edison Investment Research hat wieder was veröffentlicht:

      http://www.finanznachrichten.de/nachrichten-2013-12/28854624…
      PR Newswire · Mehr Nachrichten von PR Newswire
      Edison highlights the potential of GW Pharmaceuticals' cannabinoid pipeline and furthers its US healthcare presence
      LONDON, Dec. 10,2013 /PRNewswire/ --Edison's ADR outlook note, Orphan opportunities, highlights that 2014 could be transformative for GW ......

      Wer ist Edison?

      About Edison Investment Research

      This continued ADR coverage on GW Pharmaceuticals is part of a programme of research coverage on pharmaceutical companies exposed to global market opportunities. Edison provides detailed research on more than 150 pharmaceutical and healthcare companies in Europe, North America, Australia and New Zealand. Its team of over 100 analysts and investment professionals works with leading companies, fund managers and investment banks worldwide to support its capital markets activity. It provides services to more than 400 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. All reports Edison publishes are available to download free of charge from its website www.edisongroup.com.

      Edison is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do'sid=181584). Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

      @ JorgeCAltamirano
      Hi, ich bin bei comdirect. Die sind aber nicht so prickelnd, wenn man an ausländischen Börsen ordern will. Geht fast nur telefonisch.
      Avatar
      schrieb am 11.12.13 10:47:11
      Beitrag Nr. 111 ()
      :) GW sichert sich ab. Sehr gut.

      Ein Patent, das die Verwendung von Cannabinoiden zur Behandlung von Gliomen abdeckt. Das erteilte Patent aus dieser Anwendung wird eine Ausschließlichkeitsfrist bis Juni 2029 erbringen.

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/u-…

      London, UK, 11 December 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

      Glioma describes any tumor that arises from the glial tissue of the brain. Glioblastoma, or GBM, is a particularly aggressive tumor that forms from abnormal growth of glial tissue. According to the New England Journal of Medicine, GBM accounts for approximately 46% of the 22,500 new cases of brain cancer diagnosed in the United States each year. Treatment options are limited and expected survival is a little over one year. GBM is considered a rare disease by the FDA and the European Medicines Agency, or EMA.

      The subject patent specifically covers a method for treating glioma in a human using a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) wherein the cannabinoids are in a ratio of from 1:1 to 1:20 (THC:CBD) with the intent to reduce cell viability, inhibit cell growth or reduce tumor volume. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent from this application will provide an exclusivity period until June 2029.

      "This Notice of Allowance follows the recent launch of our first human trials in glioma and several years of pre-clinical research in the field," stated Justin Gover, GW's Chief Executive Officer. "The treatment of Glioma is part of our exciting new orphan drug program which includes a number of therapeutic targets and demonstrates the flexibility of GW's proprietary cannabinoid platform in treating a broad range of disease types."

      GW's intellectual property portfolio includes multiple patent families with issued and/or pending claims directed to plants, plant extracts, extraction technology, pharmaceutical formulations, drug delivery and the therapeutic uses of cannabinoids, as well as plant variety rights, know-how and trade secrets.
      Avatar
      schrieb am 20.12.13 18:11:24
      Beitrag Nr. 112 ()
      Neue ADR`s sollen an der US Börse platziert werden. Wann und zu welchem Wert ist noch unklar. Außerdem muß dem Antrag, auf der GM am 6.Jan, noch von den Aktionären zugestimmt werden

      Das könnte den Kurs kurzzeitig etwas nach Süden schicken.


      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/no…

      London, UK, 20 December 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform, announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") for a proposed public offering of American Depositary Shares ("ADSs") on the NASDAQ Global Market ("Nasdaq"). The number of shares to be offered and the price range for the offering have not yet been determined.

      The Directors believe the proposed offering would allow the Group to progress the development of Epidiolex as well as advance other epilepsy research programmes whilst retaining commercial rights to any products that may evolve from such programmes.

      The proposed offering is subject to GW shareholder approval at a General Meeting which is expected to take place on 6 January, 2014. Although the final timing has yet to be determined, GW is aiming to complete the ADS offering in January 2014.


      "This proposed fundraising is intended to enable GW to carry out the clinical development of Epidiolex as well as advance other epilepsy research programmes whilst allowing GW to retain full commercial rights to the product."
      Avatar
      schrieb am 20.12.13 18:14:48
      Beitrag Nr. 113 ()
      Bei den Amis scheint es, nach einem kleinen Abrutscher, normal weiterzugehen.

      Avatar
      schrieb am 20.12.13 18:18:17
      Beitrag Nr. 114 ()
      Aus dem hotcopperboard, auf die Frage, ob der Kurs nun runter geht, kommt diese Meinung:

      Not necessarily. I am puzzled as to why they would suddenly need to raise cash for further expansion given that they raised some money earlier in the year, are fully funded and have a lot of money in the bank, funding from other pharma companies e.g. Otsuka and steadily increasing sales of Sativex and now epidiolex. Which leads me to believe that either (or both) the clinical trials are going very well or they need to increase production either of which is actually very good news. So the issue of more shares might not actually be negative. They will have to set out their reasons for doing this so I would say, watch this space, I am sure all will become clear over the next few weeks.
      Avatar
      schrieb am 30.12.13 22:44:22
      Beitrag Nr. 115 ()
      :eek: heute über 6% plus bei den Amis. Neues AllTimeHigh




      OBTAINING EPIDIOLEX™ IN THE U.S.
      http://www.dravetfoundation.org/dravet-syndrome/consider-dra…
      Avatar
      schrieb am 31.12.13 09:04:40
      Beitrag Nr. 116 ()
      In den USA wird heute gehandelt, ob der Kurs hält? :rolleyes:

      Guten Rutsch





      binda
      Avatar
      schrieb am 31.12.13 11:52:53
      Beitrag Nr. 117 ()
      London
      Avatar
      schrieb am 02.01.14 08:40:01
      Beitrag Nr. 118 ()
      Avatar
      schrieb am 06.01.14 13:50:03
      Beitrag Nr. 119 ()
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/re…


      GW Pharmaceuticals plc

      Results of General Meeting

      Porton Down, UK, 6 January 2014: GW Pharmaceuticals plc (AIM: GWP, NASDAQ: GWPH or the "Company") hereby provides notification that, at the General Meeting of Company held earlier today, all the resolutions set out in the Notice of General Meeting sent to shareholders on 20 December 2013 were duly passed without amendment.

      Today's General Meeting follows the announcement by the Company on 20 December 2013 of a proposed Public Offering on the Nasdaq Global Market of American Depositary Shares. The resolutions passed at today's General Meeting were required to be approved by shareholders in order to enable the Company to progress with these proposals.

      Details of the proxy votes received in relation to each of the resolutions (which are more particularly described in the Notice of General Meeting) are as follows:


      For
      Against
      Total votes
      % of votes cast
      in favour
      Resolution 1
      68,253,635
      1,540,838
      69,794,473
      97.8%
      Resolution 2
      66,435,061
      3,359,412
      69,794,473
      95.2%

      Proxy forms which gave the Chairman and other Directors discretion have been included in the "For" total.

      Resolution 1 required a simple majority of votes cast whilst Resolution 2 required the approval of not less than 75% of shareholder votes cast.

      As at 10.00 a.m. on 4 January 2014, the total number of ordinary shares of £0.001 each eligible to be voted at the General Meeting was 177,988,687.

      Dr Geoffrey Guy, Chairman, said, "We are pleased that, for each of the resolutions proposed and passed at the shareholders meeting today, over 95% of the proxy votes cast by our shareholders were in favour. Having achieved the support of our shareholders we will now be able to progress to the next phase of the proposed U.S. public offering."

      For further information, please contact:

      Enquiries:

      GW Pharmaceuticals plc

      Justin Gover, CEO
      +44 1980 557000
      Stephen Schultz, VP Investor Relations
      + 1 401 500 6570

      FTI Consulting (Media enquiries)

      +44 20 7831 3113
      Ben Atwell / Simon Conway / John Dineen


      Trout Group, LLC (US investor relations)

      + 1 646 378 2900
      Jonathan Fassberg / Seth Lewis / Danielle Spangler


      Peel Hunt LLP
      +44 207 418 8900
      James Steel


      Notes to Editors

      About GW Pharmaceuticals plc
      Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 24 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet syndrome, a severe infantile-onset, genetic, drug-resistant epilepsy syndrome. Our product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type‑2 diabetes, and schizophrenia.



      This information is provided by RNS
      The company news service from the London Stock Exchange

      END
      Avatar
      schrieb am 07.01.14 13:40:35
      Beitrag Nr. 120 ()
      http://ir.gwpharm.com/common/download/sec.cfm?companyid=AMDA…

      PROSPECTUS (Subject to Completion)
      Issued January 6, 2014
      2,000,000 American Depositary Shares / Representing 24,000,000 Ordinary Shares

      Proposed
      Maximum
      Offering Price
      Per ADS
      $ 39.70
      Avatar
      schrieb am 09.01.14 08:38:20
      Beitrag Nr. 121 ()
      LONDON, Jan. 8, 2014 /PRNewswire/ --GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the pricing of its follow-on offering of American Depositary Shares, or ADSs, on the NASDAQ Global Market. GW will issue 2,441,110 ADSs on the NASDAQ Global Market at a price of $36.00 per ADS raising gross proceeds of $87.9 million (before deducting underwriting discount, commissions and offering expenses). GW has also granted the underwriters a 30-day option to purchase up to an additional 366,165 ADSs at the offering price. Closing of the offering is expected to occur on January 14, 2014.

      http://www.finanznachrichten.de/nachrichten-2014-01/29072933…



      1 ADS zu 36$ = 1,83 Pfund für 1 normale GWP = 2,205€

      Bis zum closing könnte 36$ nun die Kursrichtung sein.
      Avatar
      schrieb am 09.01.14 08:52:59
      Beitrag Nr. 122 ()
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/ra…


      The follow-on offering price represents a premium of 10.1% to the closing middle market price for an ADS of $32.70 on 19 December 2013, the day immediately prior to announcement of the proposed follow-on offering, and a discount of 5.4% to the closing middle market price for an ADS of $38.06 on 8 January 2014.

      "We are announcing today that GW has successfully completed an oversubscribed offering raising $87.9 million. This offering enables GW to carry out the clinical development of our childhood epilepsy orphan development programme centred on our product candidate Epidiolex®. We believe that Epidiolex has the potential to meet significant unmet needs in the treatment of orphan childhood epilepsy syndromes such as Dravet syndrome and Lennox-Gastaut syndrome. With the new funds raised, and GW retaining global commercial rights for the epilepsy programmes, we believe that GW has enhanced its potential to deliver value to investors and patients," stated Justin Gover, Chief Executive Officer of GW.

      Each ADS represents 12 ordinary shares of 0.1p each ("Ordinary Shares") in the capital of the Company. Application is being made for the 2,441,110 new ADSs, representing 29,293,320 new Ordinary Shares, to be issued at closing to be admitted to trading on the AIM market. It is expected that these new Ordinary Shares will be admitted to the AIM market on or around 15 January 2014.

      As part of the offering, M&G, which is a related party for the purpose of the AIM Rules by virtue of being a "substantial shareholder", has agreed to purchase 200,000 ADSs in the offering, representing 1.2 percent of the Company's issued share capital on the closing of the offering. As at 7 January 2014 (being the last practicable date prior to the release of this press release), M&G held 26,241,389 Ordinary Shares representing 14.7 percent of the existing Ordinary Shares. Immediately upon the closing of the offering, M&G is expected to hold 28,641,389 Ordinary Shares, together representing 13.8 per cent of the enlarged share capital immediately following the closing of the offering. The Directors consider, having consulted with the Company's nominated adviser, Peel Hunt that the participation by M&G in the offering is fair and reasonable in so far as the Company's shareholders are concerned.


      oversubscribed offering :eek: überzeichnetes Angebot
      Avatar
      schrieb am 09.01.14 16:07:15
      Beitrag Nr. 123 ()
      in U.S. sind wir auf grad 42 (US)$ hochgeschnellt. Is ja super, aber ich verstehe die (Um-)Rechnung nicht...
      Avatar
      schrieb am 09.01.14 16:55:46
      Beitrag Nr. 124 ()
      Zitat von me_2: in U.S. sind wir auf grad 42 (US)$ hochgeschnellt. Is ja super, aber ich verstehe die (Um-)Rechnung nicht...


      Meine Umrechnung?

      Each ADS represents 12 ordinary shares
      GW will issue 2,441,110 ADSs on the NASDAQ Global Market at a price of $36.00 per ADS. representing 29,293,320 new Ordinary Shares

      Die Aktien, die an der USBörse neu angeboten wurden sind ein Aktienpaket (ADR)

      ADR`s wurden zu 36 US Dollar angeboten

      1 ADR- Aktie sind 12 ordinary shares

      36 US$ : 12 = 3 US$ pro ordinary share

      3 US$ = 1,83 Pfund(183p) oder 2,208 Euro


      Warum der Kurs so abging? Vielleicht, weil GWP von einer Überzeichnung spricht. Ergo sehr hohes Interesse.

      Auf jeden Fall sehr schön, von mir aus kann es so weiter gehen.;)

      USA London
      1 Antwort
      Avatar
      schrieb am 10.01.14 01:27:11
      Beitrag Nr. 125 ()
      Latest update : 2014-01-09
      France’s health ministry announced Thursday it had approved the use of Sativex, a cannabinoid mouth spray, to treat patients suffering from multiple sclerosis (MS). The drug is the first marijuana-based medicine to be made available in the country.

      http://www.france24.com/en/20140109-france-approves-first-ca…
      Avatar
      schrieb am 10.01.14 11:16:45
      Beitrag Nr. 126 ()
      Neues Gap

      Avatar
      schrieb am 10.01.14 15:39:02
      Beitrag Nr. 127 ()
      Antwort auf Beitrag Nr.: 46.193.671 von binda am 09.01.14 16:55:46Hi, war nur etwas verwirrt wg. der Währungen. Ich hab in Sttg. gekauft (auch doof), beobachte aber Nasdaq. Deine Rechnung passt schon.
      Nur der Sprung auf 47$ kam mir etwas übertrieben vor, aber kommt ja auch schon wieder zurück. Gibt es eigtl. Kursziele zu GWPH? Ich finde recht wenig Info und Coverage.
      Avatar
      schrieb am 10.01.14 16:22:59
      Beitrag Nr. 128 ()
      Zitat von me_2: Gibt es eigtl. Kursziele zu GWPH? Ich finde recht wenig Info und Coverage.


      Z.B.
      Edison's revised DCF valuation is $715m, or $48.30 per ADR, following the inclusion of R&D pipeline programmes. Positive data from physician-led studies of Epidiolex (mid-2014 onwards) would see the DCF rise to $818m or $55.30/ADR. Positive Sativex Phase III data in cancer pain (late 2014) would see the DCF rise further to $867m or $58.60/ADRhttp://www.finanznachrichten.de/nachrichten-2013-12/28854624…

      oder hier

      Piper's Josh Schimmer is reportedly out with a $73 price targethttp://www.iii.co.uk/investment/detail?code=cotn%3AGWP.L&dis…


      oder

      Lazard Capital Markets raised their price target on shares of GW Pharmaceuticals Plc – American Depositary Shares from $22.00 to $65.00 http://www.i3investor.com/servlets/fdnews/165775.jsp


      Diese Kursziele gelten für die ADR´s. Geteilt durch 12 und gewandelt in Pfund, kann man sich die Kursziele für die Odinary Shares errechnen.

      Ob es für die ADR´s wirklich 65 Dollar werden?
      Avatar
      schrieb am 13.01.14 16:05:30
      Beitrag Nr. 129 ()
      Haha bald 3€ das ist doch schÖÖÖÖÖÖn :D
      Avatar
      schrieb am 13.01.14 18:23:01
      Beitrag Nr. 130 ()
      Avatar
      schrieb am 14.01.14 08:34:30
      Beitrag Nr. 131 ()
      Ipsen and GW Pharmaceuticals plc
      Enter Into Agreement for Ipsen to Promote and Distribute Sativex® in Latin America



      London (UK) and Paris (France), 14 January 2014 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical company, and GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announce that they have entered into an exclusive agreement for Ipsen to promote and distribute Sativex®1, a sublingual cannabis extract spray intended for the treatment of spasticity due to multiple sclerosis (MS) in Latin America (excluding Mexico and the Islands of the Caribbean). GW will be responsible for commercial product supply to Ipsen.

      Sativex® is already approved in 24 countries (principally in Europe) as a treatment of spasticity due to multiple sclerosis. GW Pharmaceuticals and Ipsen aim to start regulatory filings in selected countries in Latin America during 2014 for the MS spasticity indication. The rights granted to Ipsen cover spasticity due to MS and also cover the future cancer pain indication. Financial terms include an upfront payment to GW Pharmaceuticals, regulatory and commercial milestone payments, and a long term supply price.

      Justin Gover, Chief Executive Officer of GW, stated: "We are pleased to have expanded our commercial distribution agreements for Sativex® to include Latin America. Ipsen is an ideal partner with both a strong presence in the region as well as international expertise in the two relevant therapeutic areas of neurology and oncology. We look forward to working with Ipsen to achieve successful approvals and launches of Sativex® across Latin America."

      Christophe Jean, Executive Vice-President, Strategy and Business Development, Ipsen stated: "Ipsen is delighted to enter into partnership with GW for Latin America, as Sativex® is a good complement to our neurology franchise portfolio in this region. Sativex® will bring added value to patients with spasticity due to multiple sclerosis. Furthermore, this partnership is fully aligned with our neurology franchise strategy focused on helping patients suffering from debilitating neurologic diseases, in particular spasticity."

      About Ipsen in Latin America
      Ipsen has a direct presence in Brazil and Mexico and presence via various partners in other countries such as Colombia, Argentina, Venezuela, Chile and Peru. In Brazil, in the therapeutic area of neurology, Ipsen has consolidated its leadership position with Dysport® in the public market and grown its market share in the private segment.

      1 The product will be distributed under either Sativex® or any substitute trademark, if needed

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/ag…
      Avatar
      schrieb am 14.01.14 08:38:01
      Beitrag Nr. 132 ()
      Financial terms include an upfront payment to GW Pharmaceuticals, regulatory and commercial milestone payments, and a long term supply price.

      Die finanziellen Bedingungen sind eine Vorauszahlung an GW Pharmaceuticals , regulatorische und kommerzielle Meilensteinzahlungen und ein langfristiger Versorgungspreis .

      ;)
      Avatar
      schrieb am 14.01.14 11:07:09
      Beitrag Nr. 133 ()
      Strategisch sehr guter Zeitpunkt. Uruguay( LateinAmerika) hat vor Wochen Marihuana freigegeben:
      Uruguay legalisiert als erstes Land weltweit Marihuana

      In Uruguay wurde kürzlich ein Gesetz verabschiedet, das weltweit für ein Umdenken in der Drogenpolitik der Länder sorgen könnte. Als erster Staat der Welt wird Uruguay die Produktion, den Handel und den Konsum von Marihuana in einem bestimmten Rahmen und unter staatlicher Kontrolle legalisieren. Damit soll dem organisierten Verbrechen der Markt entzogen und eine Tendenz zum Konsum von härteren Drogen verhindert werden. Die Entscheidung war im Senat mit 16 zu 13 Stimmen denkbar knapp, wird aber vom linksgerichteten Präsidenten des Landes, José Mujica, begrüßt. Dieser wünscht sich, dass der kontrollierte Anbau und Verkauf schon im kommenden Jahr beginnen kann. Bis Mitte April hat die nationale Drogenkontrollbehörde nun Zeit, alle Bestimmungen, die den Anbau bis zum finalen Konsum regeln, festzulegen.



      Denke, dass dies einer Zulassung von Sativex sehr entgegenkommt.
      Außerdem Sativex Vorteil: kein Rauschzustand, keine Schädigung der Atmungsorgane da kein Inhalieren, schnelle unkomplizierte Anwendung etc )

      Und in den US-Staaten tut sich auch was:

      So erlaubt Colorado, als erster US-Staat überhaupt, Marihuana selbst für rein privaten Genuss. Und nun zieht auch New York nach, wiewohl noch halbherzig: Am Mittwoch will der demokratische Gouverneur Andrew Cuomo, bisher ein Legalisierungsgegner, eine beschränkte Freigabe verkünden - freilich nur bei schweren Krankheiten wie Krebs.

      Damit ist Cannabis schon in fast der Hälfte der USA in der einen oder anderen Form legal: Mit New York erhöht sich die Zahl der Staaten, die Marihuana zumindest teilweise zulassen, auf 21 (siehe Karte). Déjà-vu: Wie einst die Alkoholprohibition wird auch die gesetzliche Verteufelung von Cannabis zu einem Relikt amerikanischer Sittengeschichte.
      http://www.spiegel.de/panorama/justiz/marihuana-in-usa-immer…
      Avatar
      schrieb am 14.01.14 13:49:36
      Beitrag Nr. 134 ()
      Avatar
      schrieb am 14.01.14 17:54:34
      Beitrag Nr. 135 ()
      GW Pharmaceuticals plc Announces the Closing of its U.S. Follow-on Offering of American Depositary Shares (ADSs) on the Nasdaq Global Market and Full Exercise of Underwriters' Option to Purchase Additional ADSs


      Offering raises $101.1 million



      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/cl…
      Avatar
      schrieb am 16.01.14 16:31:14
      Beitrag Nr. 136 ()
      http://247wallst.com/healthcare-business/2014/01/16/piper-ja…

      GW Pharmaceuticals PLC (NASDAQ: GWPH) recently entered an agreement with Ipsen, a French pharmaceutical company to promote and distribute Sativex, its controversial cannabis spray, in Latin America (excluding Mexico and the Caribbean islands). Sativex is used to treat spasticity in multiple sclerosis patients, and has been approved in 24 countries, primarily across Europe. The company also announced the pending use patent on Epidolex could extend exclusivity of the potential migraine drug until 2032. This is another cannabis related extract. The Piper Jaffray price target for the stock is $73. The Thomson/First Call target is set at $54.50. The stock closed Wednesday at $51.
      Avatar
      schrieb am 23.01.14 11:49:10
      Beitrag Nr. 137 ()
      Bin gespannt, ob das Gap bei ca 213 cent noch geschlossen wird. Das Vorherige, Ende Nov, wurde auch geschlossen. :rolleyes:

      1 Antwort
      Avatar
      schrieb am 23.01.14 13:18:06
      Beitrag Nr. 138 ()
      Antwort auf Beitrag Nr.: 46.285.697 von binda am 23.01.14 11:49:10ganz sicher, Gaps werden immer geschlossen.
      Avatar
      schrieb am 23.01.14 16:17:18
      Beitrag Nr. 139 ()
      mal schauen, wohin die reise geht !
      Avatar
      schrieb am 29.01.14 08:37:12
      Beitrag Nr. 140 ()
      GW Pharmaceuticals to Report Q1 2014 Financial Results and Host Conference Call on 5 February, 2014

      London, UK, 29 January 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 February, 2014 its first quarter financial results for the period ending 31 December, 2013. GW will also host a conference call the same day at 1:00 p.m. GMT (8:00 a.m. EST).

      Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/no…
      Avatar
      schrieb am 30.01.14 11:29:34
      Beitrag Nr. 141 ()
      Das mit dem Gap kann ich mir wohl abschminken. Bei Gapclose hätte ich gerne noch mal günstig nachgelegt.
      Anscheinend erwarten die Anleger gute Q1 Ergebnisse

      Avatar
      schrieb am 03.02.14 19:45:41
      Beitrag Nr. 142 ()
      nette Auflistung der GWP Patente, und bald kommt dieses noch hinzu: U.S. Application Serial Number 12/996,124, a patent which covers the use of cannabinoids for treating glioma.

      http://www.faqs.org/patents/assignee/gw-pharma-limited/
      Avatar
      schrieb am 03.02.14 20:20:44
      Beitrag Nr. 143 ()
      Avatar
      schrieb am 04.02.14 16:24:01
      Beitrag Nr. 144 ()
      So wie der Kurs in USA für die ADRs abgeht, müßte man meinen, dass einige schon mehr wissen und die Zahlen morgen verdammt gut sind.
      Auch in London, nach einem schleppenden Start, springt der Kurs an

      :rolleyes::)
      Avatar
      schrieb am 05.02.14 08:50:00
      Beitrag Nr. 145 ()
      Avatar
      schrieb am 05.02.14 09:34:51
      Beitrag Nr. 146 ()
      GW Pharmaceuticals operating losses rise

      5 February 2014 | 07:55am
      StockMarketWire.com - GW Pharmaceuticals posts a net loss after tax of £2.8m for the three months to the end of December compared to a profit of £2.1m a year ago.

      Total revenue rose to £7.5m - up from £5.2m in the corresponding period in 2012 - but operating losses rose to £3.5m from £2.4m.

      Cash and cash equivalents stood at £35.3m at the end of December compared to £38.1m at 30 September. Since the period end, this cash position has been further enhanced by receipt of the net proceeds after expenses from the follow-on offering of ADSs on the NASDAQ Global Market of $94.0m (£57.1m) in January.

      Chief executive Justin Gover said: "Our successful US follow-on offering in early January raised $101m and reflects excitement regarding GW's childhood epilepsy programme.

      "We believe that our lead epilepsy product candidate, Epidiolex, has the potential to meet significant unmet needs in the treatment of orphan childhood epilepsy syndromes such as Dravet syndrome and Lennox-Gastaut syndrome.

      "With the new funds raised, we have the financial strength to accelerate this development programme whilst retaining global commercial rights.

      "In addition to our orphan epilepsy programme, as we move through 2014, we expect a significant amount of milestones, including Phase 3 cancer pain data for Sativex as well as important clinical progress across our robust pipeline of cannabinoid product candidates."







      Story provided by StockMarketWire.com
      - See more at: http://www.stockmarketwire.com/article/4751158/GW-Pharmaceut…
      Avatar
      schrieb am 05.02.14 11:46:13
      Beitrag Nr. 147 ()
      http://sharecast.com/news/gw-pharmaceuticals-operating-losse…

      - Q1 losses widen while revenues improve
      - Expect Sativex revenues to return to growth in 2014
      - Robust pipeline of cannabinoid products

      AIM-listed pharmaceutical company GW Pharmaceuticals said losses for the first quarter of 2014 widened as revenue improved.

      The biopharmaceutical firm, known for its multiple sclerosis treatment Sativex, said pre-tax losses widened to $3.5m for the three months to December 31st compared to a loss of $2.4m a year earlier.

      Total revenue for the period rose to £7.5m compared to £5.2m before.

      Chief Executive Officer Justin Gover said: "In addition to our orphan epilepsy programme, as we move through 2014, we expect a significant amount of milestones, including Phase 3 cancer pain data for Sativex as well as important clinical progress across our robust pipeline of cannabinoid product candidates."

      The group, which last year received regulatory approval in Switzerland for its treatment of spasticity due to multiple sclerosis, said it continues to expect Sativex revenues to return to growth in 2014. Sativex is approved for use in 25 countries.

      Furthermore, it said upon the first patient being randomised into the planned US Phase 3 MS spasticity trials, it expects to receive a $5m milestone payment from pharmaceutical company Otsuka.

      Cash and cash equivalents as at December 31st of £35.3m compared to £38.1m as at September 30th.
      Avatar
      schrieb am 05.02.14 12:54:51
      Beitrag Nr. 148 ()
      Avatar
      schrieb am 06.02.14 17:15:17
      Beitrag Nr. 149 ()
      GW Pharmaceuticals Plc (GWPH) F1Q14 Earnings Call February 5, 2014 8:00 AM ET

      Operator

      Greetings and welcome to the GW Pharmaceuticals’ First Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions). As a reminder, this conference is being recorded.

      I would now like to turn the conference over to your host, Steve Schultz, Vice President of Investor Relations. Thank you, sir. You may now begin.

      http://seekingalpha.com/article/1997351-gw-pharmaceuticals-c…
      Avatar
      schrieb am 07.02.14 22:46:43
      Beitrag Nr. 150 ()
      Neue Kursziele für die ADRs


      GW Pharmaceuticals price target raised to $97 from $77 at Piper Jaffray
      Piper Jaffray raised its price target for GW Pharmaceuticals shares to $97 citing increased confidence in the company's Epidiolex drug. Piper keeps an Overweight rating on the stock.
      http://www.theflyonthewall.com/permalinks/entry.php/GWPHid19…


      GW Pharmaceuticals price target raised to $80 from $40 at Cowen
      Cowen raised GW Pharmaceuticals price target to $80 based on promising Epidiolex expectations.
      http://www.theflyonthewall.com/permalinks/entry.php/GWPHid19…
      Avatar
      schrieb am 08.02.14 16:49:20
      Beitrag Nr. 151 ()
      In a report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals plc (NASDAQ: GWPH [FREE Stock Trend Analysis]) and raised the price target from $77.00 to $97.00.

      Schimmer mentioned new checks with specialists who were convinced that CBD has “meaningful utility” for seizure patients. The analyst commented that CBD and THC have been reported to benefit individuals with migraine headaches and autism.

      The analyst wrote that after reviewing Dravet studies, the “finding is consistent with what we have heard from specialists, suggesting the Epidiolex Phase III studies may be overpowered, and thereby substantially improving the probability that the 'views from the field' represent a true drug effect.”

      GW Pharmaceuticals closed at $57.71 on Thursday. Shares have traded as high as $64.73, up 12.16% on Friday. This has been the biggest intraday gain since January 9.

      http://www.benzinga.com/analyst-ratings/analyst-color/14/02/…
      Avatar
      schrieb am 10.02.14 19:19:21
      Beitrag Nr. 152 ()
      GW Pharmaceuticals to Present at the Leerink Global Healthcare Conference

      London, UK, 10 February 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Dr. Stephen Wright, GW's Director of Research and Development, is scheduled to present at the Leerink Global Healthcare Conference on Wednesday, 12 February, 2014 at 3:30 p.m. ET. The conference will be held at the Waldorf Astoria Hotel in New York City.

      A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/pr…
      Avatar
      schrieb am 11.02.14 16:13:39
      Beitrag Nr. 153 ()
      Avatar
      schrieb am 11.02.14 16:36:24
      Beitrag Nr. 154 ()
      Die Legalisierung von Marijuhana in einigen Ländern ist nicht gegen GWP, im Gegenteil, die können beide Seiten bedienen.
      Avatar
      schrieb am 18.02.14 11:51:08
      Beitrag Nr. 155 ()
      Aktuell abwärts. Konsolidierungsphase?



      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/bl…
      Avatar
      schrieb am 20.02.14 16:48:14
      Beitrag Nr. 156 ()
      Vielleicht doch das Gap- Close?

      Derweil schießt ein Autor(Pseudonym:Infitalis) von seekingalpha massiv gegen GWP

      GW Pharmaceuticals: High As A Kite And Too Close To The Sun
      Feb. 20, 2014 10:04 AM ET | About: GWPH
      Disclosure: I am short GWPH I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

      http://seekingalpha.com/article/2034243-gw-pharmaceuticals-h…
      Avatar
      schrieb am 28.02.14 00:27:03
      Beitrag Nr. 157 ()
      :eek:
      Da machen die in usa einen SK im All Time High



      Das Gap- close kann ich wohl vergessen.
      Avatar
      schrieb am 28.02.14 19:34:33
      Beitrag Nr. 158 ()
      GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome
      GW PHARMACEUTICALS PLC (NASDAQ:GWPH)
      Intraday Stock Chart
      Today : Freitag 28 Februar 2014

      GW Pharmaceuticals plc (AIM:GWP) (Nasdaq:GWPH) ("GW") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Epidiolex®, GW's product candidate that contains plant-derived Cannabidiol (CBD) as its active ingredient, for use in treating children with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant.
      In November 2013, GW announced that the FDA had granted orphan drug designation for Epidiolex in the treatment of Dravet syndrome. Following the successful follow-on offering completed in January 2014, GW intends to advance a full clinical development program for Epidiolex for the treatment of both LGS and Dravet syndromes. Working with leading pediatric epilepsy specialists in the United States, GW expects to commence an initial Phase 2 clinical trial for Epidiolex in the second half of 2014. This trial, if successful, is expected to lead to Phase 3 pivotal trial programs in both Dravet syndrome and LGS intended to support New Drug Applications with the FDA.

      LGS is a severe form of childhood-onset epilepsy. Seizure types, which vary among patients, include tonic (stiffening of the body, upward deviation of the eyes, dilation of the pupils, and altered respiratory patterns), atonic (brief loss of muscle tone and consciousness, causing abrupt falls), atypical absence (staring spells), and myoclonic (sudden muscle jerks). Most children with LGS experience some degree of impaired intellectual functioning or information processing, along with developmental delays, and behavioral disturbances. LGS can be caused by brain malformations, perinatal asphyxia, severe head injury, central nervous system infection and inherited degenerative or metabolic conditions. It is estimated that there are approximately 14,000-18,500 patients with LGS in the United States and 23,000-31,000 patients with LGS in Europe.

      "This orphan designation for Epidiolex, GW's purified CBD medicine, in Lennox-Gastaut syndrome follows on from the recent FDA grant of orphan designation in Dravet syndrome. We are now in active discussions with the FDA regarding the US regulatory pathway for Epidiolex and believe that this medicine has the potential to meet the significant unmet need of children suffering with severe seizures where all options to control those seizures have been exhausted," stated Justin Gover, GW's Chief Executive Officer. "GW is responding to this need with the goal of providing an FDA-approved prescription CBD medicine that physicians have confidence in prescribing and parents can trust for quality, consistency and access."

      About Orphan Drug Designation

      Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition – generally a disease or condition that affects fewer than 200,000 individuals in the U.S. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the U.S. for that product, for that indication.

      http://de.advfn.com/p.php?pid=nmona&article=61265583
      Avatar
      schrieb am 02.03.14 11:07:05
      Beitrag Nr. 159 ()
      Cannabis-Aktien: Rauch im Depot
      Legales Marihuana wird zum Riesenmarkt. Was auch bei Schweizer Banken einfährt.

      Seit Jahresbeginn erlauben Colorado und Washington, D.C., Erwerb und Konsum von Marihuana; 20 Staaten legalisierten es bereits für medizinische Zwecke. Die Hoffnung, dass weitere Staaten nachziehen, ­beflügelt die Kurse von Aktien aus diesem Umfeld, die «Marihuana Stocks». Schweizer Banken sind am Rush beteiligt. Gehäuft halten sie Aktien der britischen GW Pharmaceuticals, die cannabinoide Medikamente zur Behandlung von Epilepsie oder spastischen Lähmungen bei MS-Patienten entwickelt. Bei der UBS lagern gemäss Bloomberg GW-Papiere im Wert von 3,5 Millionen Franken, die CS berauscht sich an einem Posten von 400 000 Franken.

      legales Marihuana-Geschäft

      In kleinerer Mischung sind die Bank Coop (130 000) und die Genfer Privatbank Mirabaud (90 000 Franken) aktiv. Die Geldhäuser tun sich schwer mit Äusserungen zu den Beständen und einer Marktmeinung. Gute Geschäfte waren damit auf jeden Fall zu machen; die GW-Papiere notierten Mitte 2013 noch bei weniger als 50 Pence und erlebten kürzlich ein High bei 3.30 Pfund. Eine Fortsetzung des Höhenflugs scheint möglich. Gemäss Schätzungen werden in den USA heute jährlich drei Milliarden Dollar im legalen Marihuana-Geschäft umgesetzt; in den nächsten Jahren könnten es 45 Milliarden werden.

      http://www.bilanz.ch/unternehmen/cannabis-aktien-rauch-im-de…
      Avatar
      schrieb am 02.03.14 11:09:05
      Beitrag Nr. 160 ()
      schaut mal hier im Board auf die Aktie


      HOP-On
      Avatar
      schrieb am 02.03.14 11:50:00
      Beitrag Nr. 161 ()
      entschuldigung falscher Text:

      Schaut hier im Board auf HOP-ON:COM über Tochterfirma wird ein Pflaster auf den Markt gebracht zudem dem hat hop-on mit Microsoft einen Deal für Hop-on Einweghandy

      diese Woche Investorenkonferenz
      Avatar
      schrieb am 05.03.14 15:35:45
      Beitrag Nr. 162 ()
      und jetzt wieder zu GWP bzw. GWPH

      Avatar
      schrieb am 07.03.14 14:18:15
      Beitrag Nr. 163 ()
      Cannabis Madness: Dr. Sanjay Gupta Reports," at 10 p.m. ET on Tuesday march11. Also, Dr. Gupta will be answering your questions on Reddit at noon ET Tuesday.
      http://edition.cnn.com/2014/03/05/health/gupta-medical-marij…
      Avatar
      schrieb am 08.03.14 14:01:16
      Beitrag Nr. 164 ()
      Avatar
      schrieb am 11.03.14 12:45:48
      Beitrag Nr. 165 ()
      London
      Avatar
      schrieb am 11.03.14 16:04:51
      Beitrag Nr. 166 ()
      102,883,226 Reasons Why Marijuana Bull Market May be Understated; The Marijuana Index Discusses Survey Feedback
      http://de.advfn.com/p.php?pid=nmona&article=61400643
      Avatar
      schrieb am 11.03.14 16:16:39
      Beitrag Nr. 167 ()
      In der heutigen Hauptversammlung wurde über diese Punkte abgestimmt:

      Avatar
      schrieb am 11.03.14 16:20:19
      Beitrag Nr. 168 ()
      Ergebnis der Abstimmung:

      London, UK, 11 March 2014: GW Pharmaceuticals plc (AIM: GWP, NASDAQ: GWPH or the "Company") hereby provides notification that, at the Annual General Meeting of the Company held earlier today, all the resolutions set out in the Notice of Meeting sent to shareholders were duly proposed and passed.

      Details of the proxy votes received in relation to each of the resolutions (which are more particularly described in the Notice of General Meeting) are as follows:




      Proxy forms which gave the Chairman and other Directors discretion have been included in the "For" total.

      About GW Pharmaceuticals plc
      Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 25 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex which has received Orphan Drug Designation from the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, severe, drug-resistant epilepsy syndromes. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type‑2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

      For further information, please contact:

      Enquiries:

      GW Pharmaceuticals plc

      Justin Gover, CEO
      +44 1980 557000
      Stephen Schultz, VP Investor Relations
      + 1 401 500 6570


      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/an…
      Avatar
      schrieb am 11.03.14 16:33:22
      Beitrag Nr. 169 ()
      GW Pharmaceuticals PLC- Coverage Initiated at Bank of America (GWPH)
      March 11th, 2014 - 0 comments - Filed Under - by Stacy Sanders
      Share on StockTwits
      GW Pharmaceuticals PLC- logoAnalysts at Bank of America began coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research report issued to clients and investors on Tuesday, AnalystRatingsNetwork reports. The firm set a “buy” rating on the stock.

      Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) opened at 77.28 on Tuesday. GW Pharmaceuticals PLC- has a one year low of $8.46 and a one year high of $78.42. The stock has a 50-day moving average of $60.14 and a 200-day moving average of $36.58. The company’s market cap is $1.145 billion.

      GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings results on Tuesday, February 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.32. The company had revenue of $7.49 million for the quarter, compared to the consensus estimate of $11.54 million. The company’s revenue for the quarter was up 44.6% on a year-over-year basis. Analysts expect that GW Pharmaceuticals PLC- will post $-1.53 EPS for the current fiscal year.

      Several other analysts have also recently commented on the stock. Analysts at Piper Jaffray reiterated an “overweight” rating on shares of GW Pharmaceuticals PLC- in a research note on Friday, February 7th. Analysts at Leerink Swann initiated coverage on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, February 4th. They set an “outperform” rating on the stock. Seven equities research analysts have rated the stock with a buy rating, GW Pharmaceuticals PLC- currently has a consensus rating of “Buy” and a consensus target price of $37.00.

      GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions.
      Avatar
      schrieb am 11.03.14 16:50:51
      Beitrag Nr. 170 ()
      Avatar
      schrieb am 11.03.14 17:29:23
      Beitrag Nr. 171 ()
      Hier eine Meinung, von jemandem der auf der Hauptversammlung war:

      http://www.discussthemarket.com/gwp-stream
      bobby0228
      16:02
      AGM Just got back from the meeting all I can say is the whole board are so upbeat about GWP prospects that I would not consider selling any shares until after the end of 2014, I do not think they really know how high this could go but there will be a lot very good news over the next eight months hold on to you hats.GL AllBob
      Avatar
      schrieb am 11.03.14 17:42:03
      Beitrag Nr. 172 ()
      Ein weiteres Gap ist entstanden.

      Eigentlich heißt es, dass Gaps grundsätzlich geschlossen werden. Doch das Gap bei 40 ist auch noch offen.

      Avatar
      schrieb am 11.03.14 18:04:40
      Beitrag Nr. 173 ()
      Avatar
      schrieb am 12.03.14 18:27:41
      Beitrag Nr. 174 ()
      Bilderbuch Gap-Close !!

      Und jetzt im Plus :)
      Avatar
      schrieb am 17.03.14 09:36:26
      Beitrag Nr. 175 ()
      GW Pharmaceuticals update on pipeline

      17 March 2014 | 08:01am
      http://www.stockmarketwire.com/article/4773711/GW-Pharmaceut…
      Avatar
      schrieb am 21.03.14 11:53:34
      Beitrag Nr. 176 ()
      TUE MAR 18, 2014 Big Pharma Blocking Feds From Legalizing Marijuana?

      http://www.hightimes.com/read/big-pharma-blocking-feds-legal…
      Avatar
      schrieb am 21.03.14 12:08:09
      Beitrag Nr. 177 ()
      The world’s most valuable cannabis business is growing in a sleepy corner of England
      By John McDuling @jmcduling March 20, 2014
      Avatar
      schrieb am 21.03.14 17:56:32
      Beitrag Nr. 178 ()
      Ich hoffe, es kommt so langsam eine Bodenbildung.
      Avatar
      schrieb am 24.03.14 18:33:09
      Beitrag Nr. 179 ()
      Zitat von binda: The world’s most valuable cannabis business is growing in a sleepy corner of England
      By John McDuling @jmcduling March 20, 2014



      Ups, Link fehlt ja.


      http://qz.com/189561/the-worlds-most-valuable-cannabis-busin…
      Avatar
      schrieb am 24.03.14 18:40:32
      Beitrag Nr. 180 ()
      Das Gab in London bei 310,00 p wurde heute geschlossen.




      und in den USA arbeitet man sich gerade vom Tief bei ca 59 $ wieder nach oben

      Avatar
      schrieb am 25.03.14 10:53:41
      Beitrag Nr. 181 ()
      http://finance.yahoo.com/news/shocking-prediction-next-dot-c…
      StreetAuthority Network
      2 hours ago

      ...The legal marijuana market could grow bigger than alcohol, especially because of its medicinal qualities, of which spirits have none. Its long-term success, however, is contingent on getting the blessings of the federal government, which for now is "looking the other way." (Take a look at what Street Authority's Austin Hatley wrote about marijuana's two legal codes in this article we featured a couple of weeks ago.)

      Indeed it looks as though the marijuana industry is closer to getting the green light. With the growth this market is already seeing -- along with the astronomical potential it has if the trend continues -- there's money to be made.

      In fact, this trend bears some resemblance to the dot-com era. For better or worse, we're talking about a new born industry with an immensely popular product. The combination of public and government acceptance (at least of the medical marijuana industry), along with proven business executives moving into the space, could be the catalysts that drive what could amount to a new gold rush in coming years.

      If you like the idea of investing in the marijuana market, stick to companies that file with the SEC, because there are plenty that don't and go unregulated. Right now, the investable space in this industry is not that broad -- only a handful of companies trade on the market. With that said, here are a couple of companies showing early promise:

      GW Pharmaceuticals (GWPRF)

      GW Pharma is based in the UK and is developing cannabinoid medications, primarily for multiple sclerosis and cancer. The company has assembled a large in-house team with extensive experience in developing cannabinoids -- medicines containing controlled substances -- as well as plant-based prescription pharmaceutical products.

      Its lead product, Sativex is now approved or recommended for approval in 25 countries, such as Norway, Israel, and Austria. Sales of the drug grew 36% in 2013 primarily due to use in Germany and Italy.

      [More from InvestingAnswers.com: This Could Be The Best Place In The World To Invest Right Now]
      The drug treats symptoms in patients with severe spasms from multiple sclerosis that have not responded adequately to other medication. GW has now entered into five separate licensing agreements for Sativex with Bayer HealthCare in the UK and Canada; Almirall in Europe and Mexico; Otsuka Pharmaceutical Co. Ltd. in the United States; Novartis in the Middle East, Africa, and Asia; and Neopharm in Israel.

      More recently, GW received Orphan Drug Designation from the FDA for Epdiolex for the treatment of Dravet Syndrome, and has applied for the same for the drug's treatment of Lennox-Gastaut Syndrome. Each of these syndromes represents rare, severe infantile-onset drug-resistant epilepsy conditions, with an estimated prevalence in the U.S. of 5,000 to 6,000 children for Dravet and approximately 14,000 to 18,000 for Lennox-Gastaut. GW will now move forward into Phase 2 and Phase 3 trials for both drugs.

      Although revenue grew in 2013, the company expects a profit loss in 2014. That said, GW showed $58.4 million in cash to close out last year. The company has one of the largest market caps in the industry at $1.06 billion. It trades at $5.34 and is up 79% over three months and 584% in a year.
      Avatar
      schrieb am 25.03.14 11:02:41
      Beitrag Nr. 182 ()
      GWP und PHOT

      Risks to Consider: Both of these stocks have experienced huge one-year gains and are susceptible to equally large losses. If you want to take the risk and invest in this arena, do so in small doses, not exceeding a total of 5% of your portfolio.

      Action to Take --> With the tailwinds beginning to increase for the marijuana industry, a small investment could turn into windfall returns, especially if states continue to legalize the drug and investors pile in to take advantage. When that happens, you might want to have a stake in this sector.
      Avatar
      schrieb am 27.03.14 18:52:24
      Beitrag Nr. 183 ()
      So langsam muß das aufhören. Hoffe die Unterstützung bei 58 hält.

      Avatar
      schrieb am 01.04.14 13:08:27
      Beitrag Nr. 184 ()
      NTRR Readies New Asset for Distribution Network
      By Business Wire, April 01, 2014, 05:00:00 AM EDT

      TAMPA, Fla.--(BUSINESS WIRE)-- Neutra Corp. (OTCBB:NTRR) announced today that representatives from its wholly owned subsidiary, Diamond Anvil Designs, will attend the world's top cannabis industry show this month to secure distributions for the company's revolutionary new vapor pens.

      The Big Industry Show is a business-to-business trade show for the rapidly expanding cannabis industry. The two-day event, held April 16-17, brings together manufacturers, distributors and wholesalers looking to sell their products to an army of buyers representing retailers, tobacconists, specialty shops, convenience stores, glass galleries, wholesalers, distributors, manufacturers and others serving the growing number of North American cannabis patients and suppliers.

      ...By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to enjoy unprecedented growth in 2014 alongside Cannabis Science, Inc. (OTCBB:CBIS), GW Pharmaceuticals, plc (NASDAQ:GWPH) and CannaBusiness Group, Inc. (OTCBB:CBGI), delivering technological advancements in the cultivation and processing of cannabis in approved markets.
      Avatar
      schrieb am 01.04.14 13:18:53
      Beitrag Nr. 185 ()
      http://www.bigindustryshow.com

      Day 4-5
 US CANNABIS CUP 2014
      The 26th-annual HIGH TIMES Cannabis Cup is coming! The two-day cannabis expo will feature cultivation seminars and activism sessions with HIGH TIMES editors, leaders of the marijuana movement, and major cannabis celebrities.
      Avatar
      schrieb am 02.04.14 19:58:24
      Beitrag Nr. 186 ()
      Hi Binda

      Kannst du mir sagen warum es in letzter Zeit immer weiter nach unten geht, obwohl da meiner Meinung nach gute Nachrichten gekommen sind ?
      Avatar
      schrieb am 02.04.14 19:59:33
      Beitrag Nr. 187 ()
      Avatar
      schrieb am 03.04.14 08:28:26
      Beitrag Nr. 188 ()
      Zitat von GuidoAW: Ach hier der Link

      http://www.marketwatch.com/story/courtagen-to-provide-geneti…

      http://www.marketwatch.com/story/courtagen-to-provide-geneti…


      Guten Morgen Guido,

      meine Antwort auf deine Frage, warum der Kurs da ist wo er jetzt ist, ist die, dass der wahnsinns Hype auf Marijuhana-Aktien sich etwas beruhigt. Jeder wollte zu Beginn dabei sein. Möglichst früh und zu niedrigen Kursen. Obwohl es keine negativen News zu GWP gibt und für die Zukunft hohe Einnahmen erwartet werden, haben etliche Früheinsteiger Kasse gemacht. Es gibt kaum ein MJ- Unternehmen, welches davon in den letzten Tagen nicht betroffen war/ist. Ich denke, mit weiteren guten Nachrichten, Zahlen, positiven Testergebnissen und weiteren Ländern, welche medical marijuhana legalisieren( die Aussichten sind gut), wird der Kurs wieder anziehen.

      GWP ist eins der wenigen gelisteten und durch die SEC regulierten Unternehmen. Neben Epidiolex hat GWP noch mehr Kandidaten in der Pipline:
      GWP42006 (CBDV) for epilepsy
      GWP42004 for Type 2 diabetes
      GWP42003 for schizophrenia
      Sativex in Phase 3 clinical development for cancer pain. Initial topline Phase 3 data expected towards the end of 2014
      Sativex in Phase 3 clinical development for MS spasticity. US Phase 3 trial expected to commence in second half of 2014
      GWP42003 extract in Phase 2 clinical development for ulcerative colitis. Phase 2 data expected mid-2014
      GWP42002:GWP42003 in Phase 1b/2a clinical development for recurrent glioblastoma multiforme

      Die (legale) Marijuhana-Industrie steht noch gaaaanz am Anfang und lernt gerade laufen. Das macht es so spannend. Ein Milliarden-Markt.

      ;)

      Gruß binda

      http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Upd…
      Avatar
      schrieb am 03.04.14 10:21:49
      Beitrag Nr. 189 ()
      MONEY FOUND, CALIFORNIA TO LEGALIZE MARIJUANA IN 2014
      Marijuana Control, Legalization and Revenue Act Secures Money to Make 2014 a Reality
      http://www.einnews.com/pr_news/198002186/money-found-califor…
      Avatar
      schrieb am 03.04.14 10:53:07
      Beitrag Nr. 190 ()
      Danke Binda für deine Antwort und die wirklich gute Darstellung aus deiner sicht. Dann heist es jetzt wohl Gedult haben und abwarten wie sich alles weiter entwickelt. Hoffen wir mal bald auf gute News :-)
      Avatar
      schrieb am 04.04.14 00:32:13
      Beitrag Nr. 191 ()
      Avatar
      schrieb am 04.04.14 23:51:20
      Beitrag Nr. 192 ()
      Das sieht richtig beschi..en aus. Nächste Unterstützung liegt bei 50. Heute hat sie gehalten...

      Avatar
      schrieb am 11.04.14 16:32:20
      Beitrag Nr. 193 ()
      Unglaublich....das Gemetzel geht weiter
      Avatar
      schrieb am 14.04.14 12:40:01
      Beitrag Nr. 194 ()
      Zitat von GuidoAW: Unglaublich....das Gemetzel geht weiter


      Leider.

      Auch vorbörslich (USA) sieht es bescheiden aus. Zwar geringes Volumen bis jetzt, jedoch der Downtrend scheint intakt.


      Avatar
      schrieb am 14.04.14 14:47:33
      Beitrag Nr. 195 ()
      Rechtsprofessor aus Bochum will Cannabis-Konsum legalisieren

      http://www.derwesten.de/politik/rechtsprofessor-aus-bochum-w…
      Avatar
      schrieb am 14.04.14 21:09:15
      Beitrag Nr. 196 ()
      Hi Binda

      Farge an dich ...macht es nach deiner Meinung Sinn hier investiert zu bleiben. Und wo ist die nachste Unterstützung? Ich bin hier ziemlich zu höchtkursen rein und es sieht bestimmt wie bei vielen Tiefrot in meinem Depot aus.
      Avatar
      schrieb am 14.04.14 23:01:27
      Beitrag Nr. 197 ()
      Zitat von GuidoAW: Hi Binda

      Farge an dich ...macht es nach deiner Meinung Sinn hier investiert zu bleiben. Und wo ist die nachste Unterstützung? Ich bin hier ziemlich zu höchtkursen rein und es sieht bestimmt wie bei vielen Tiefrot in meinem Depot aus.



      Zur Zeit wird im Marijuanaindex mächtig geschüttelt. Fast 90% Verlust in den letzten Wochen.
      http://marijuanaindex.org/



      GW Pharma ist für mich eines der wirklich ernst zu nehmenden Unternehmen, welches in diesem Index gelistet ist.

      Ob es Sinn macht dabei zu bleiben...., ich kann nur sagen, dass ich, nach meinem Kauf zu 0,72€, auch immer mal wieder was verkauft habe. Das letzte Mal zu 3,50€.
      Der Rest bleibt stehen, da ich GW für die Zukunft einiges zutraue.
      Argumente u. Fakten sind hier im Thread nach zu lesen.

      Ich kann und ich möchte hier keine Kauf-oder Verkauf bzw. Halte-Empfehlung geben. Es wäre schade, wenn ich mich irre und andere mir gefolgt wären.

      Da in USA wieder im Minus geschlossen wurde, gehe ich davon aus, dass der Kurs auch in London weiter fällt, so lange es keine News von GW gibt( z.B. Zulassung von Sativex in weiteren Länder,...)

      Die nächste Unterstützung? Bisher hat keine Unterstützung gehalten. Die nächste kleine liegt bei ca 40$ und eine etwas größere so um die 35$.

      Sicher ist, dass ich noch dabei bin. Nicht mehr so stark, aber noch dabei.

      Lieben Gruß binda
      Avatar
      schrieb am 15.04.14 08:09:05
      Beitrag Nr. 198 ()
      hi binda

      danke für deine antwort. nein ich wollte auch keine halte oder verkaufsempfehlung, nur deine einschätzung zur momentanen GW lage. ich bin zu 3,87 rein und hatte jetzt das pech das der gesamte bio bereich abschmiert. ich halte einige gute bio aktien, wie epi, paion usw, die leider alle durch verschieden faktoren gelitten haben. bei den oben genanten zwei heist es momentan auch abwarten wie die weitere entwickelung ist.(hoffe positiv) bei gw bin ich mir da nicht sicher weil ich mich zwar über das unternehmen informiert habe aber das potenzial nicht so recht einschätzen kann. und da du hier schon länger dabei bist wollte ich mir mal rat holen.
      gruß guidoaw
      Avatar
      schrieb am 15.04.14 09:28:17
      Beitrag Nr. 199 ()
      Aus dieser Ecke erwarte ich in nächster Zeit Meldungen:

      GW received Orphan Drug Designation from the FDA for Epdiolex for the treatment of Dravet Syndrome, and has applied for the same for the drug's treatment of Lennox-Gastaut Syndrome.

      Sativex is now approved or recommended for approval in 25 countries,

      Pipline:
      GWP42006 (CBDV) for epilepsy
      GWP42004 for Type 2 diabetes
      GWP42003 for schizophrenia
      Sativex in Phase 3 clinical development for cancer pain. Initial topline Phase 3 data expected towards the end of 2014
      Sativex in Phase 3 clinical development for MS spasticity. US Phase 3 trial expected to commence in second half of 2014
      GWP42003 extract in Phase 2 clinical development for ulcerative colitis. Phase 2 data expected mid-2014
      GWP42002:GWP42003 in Phase 1b/2a clinical development for recurrent glioblastoma multiforme

      Aber auch dies darf man nicht außer Acht lassen ( könnte den Kurs noch drücken) :

      Although revenue grew in 2013, the company expects a profit loss in 2014.
      Avatar
      schrieb am 17.04.14 11:11:48
      Beitrag Nr. 200 ()
      Mein lieber Mann, wieder bei 2,60€.
      Avatar
      schrieb am 22.04.14 16:21:36
      Beitrag Nr. 201 ()
      endlich wird hier mal wieder Boden gutgemacht, z. Zt. plus 37 % in NY.
      Avatar
      schrieb am 22.04.14 18:33:22
      Beitrag Nr. 202 ()
      Why GW Pharmaceuticals (GWPH) Stock Is Soaring Today
      BY Tony Owusu| 04/22/14 - 11:18 AM EDT

      NEW YORK (TheStreet) -- GW Pharmaceuticals (GWPH_) stock is soaring, up 31.1% to $60.37 in trading on Tuesday.

      The increase follows coverage initiation on the cannabis prescription drug company's stock with an "overweight" rating by analysts at Morgan Stanley (MS_). The firm set a $103 price target on the company's shares.
      Avatar
      schrieb am 22.04.14 22:29:32
      Beitrag Nr. 203 ()
      Es ist in den USA ein fettes Gap entstanden, jedoch mit hohem Handelsvolumen. Somit muß es nicht umbedingt geschlossen werden. Wir werden sehen, was passiert.



      Bei seekingalpha wurden noch mal alle Punkte, die für GW sprechen erwähnt:

      Morgan Stanley bullish on GW Pharmaceuticals
      Apr 22 2014, 08:09 ET
      Shares of cannabinoid biopharmaceutical firm GW Pharmaceuticals (GWPH) are up 7% premarket to $49.50 on modest volume after Morgan Stanley initiates coverage with an Overweight rating and $103 PT.Bank of America has a PT of $93, Piper Jaffray has $97 and Leerik Swann $79.

      The company's lead products are GWP42006 for epilepsy, GWP42004 for Type 2 diabetes and GWP42003 for schizophrenia.

      GWP42006's active ingredient is the non-psychoactive cannabinoid cannabidivarin extracted from the cannabis plant. A Phase 2 clinical trial should start later this year.

      GWP42004's active ingredient is the non-psychoactive plant-derived tetrahydrocannabivarin. A Phase 2b clinical trial is expected to start in H2 2015 to compare its glycemic control efficacy versus placebo as an add-on therapy to metformin.

      GWP42003's active ingredient is purified cannabidiol. A Phase 2a is underway to assess its efficacy as a first-line therapy. The study will be completed in H2 2015.

      The firm also has another Epilepsy drug, Epidiolex, in development. It's active ingredient is plant-derived cannabidiol. The FDA designated it an Orphan Drug for the treatment of Dravet Syndrome and Lennox-Gastaut Syndrome.
      Avatar
      schrieb am 23.04.14 09:51:36
      Beitrag Nr. 204 ()
      Cramer: This 'cannabis' stock will quickly double

      Jim Cramer strongly endorsed an analyst's bullish call on GW Pharma (GWPH) in his "Stop Trading" segment on CNBC's "Squawk on the Street" today.

      The UK-based company is working on prescription medicines based on cannabis to treat a number of medical conditions.

      Its stock soared as much as 43 percent to $65.97 after Morgan Stanley started coverage of the stock with an "overweight" rating and a price target of $103.

      Cramer called Morgan's recommendation "timely" and "bold," predicting the stock will quickly reach the target.

      "It's not a medical marijuana stock. They have a novel platform. It is an epilepsy company."

      Cramer warned investors to stay away from other marijuana-related penny stocks. "Forget it! If you like cannabis, and I'm not necessarily speaking about 'liking' cannabis, it's GW Pharma."

      http://www.cnbc.com/id/101603415
      Avatar
      schrieb am 28.04.14 10:46:49
      Beitrag Nr. 205 ()
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/sa…


      GW Pharmaceuticals Announces that Sativex Receives Fast Track Designation from FDA
      in Cancer Pain

      London, UK; 28 April 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Sativex® for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication.

      FDA's Fast Track program facilitates the development of drugs intended to treat serious or life‑threatening conditions and that have the potential to address unmet medical needs. A drug program with Fast Track status is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval.

      "The award of Fast Track designation for Sativex represents important recognition by the FDA of the potential of this medicine to address significant unmet needs in the treatment of cancer pain," stated Justin Gover, GW's Chief Executive Officer. "Sativex is the only non-opioid treatment currently in Phase 3 development for patients who do not respond to, or experience negative side effects with opioid medications. We are fully committed to delivering the first FDA-approved cannabinoid medicine for these patients who currently have nowhere else to turn."

      GW is developing Sativex in the United States in collaboration with Otsuka Pharmaceutical Co. Ltd.
      Avatar
      schrieb am 28.04.14 10:52:27
      Beitrag Nr. 206 ()
      A drug that receives Fast Track designation is eligible for some or all of the following:
      -More frequent meetings with FDA to discuss the drug’s development plan and ensure collection of appropriate data needed to support drug approval
      -More frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers
      Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met
      -Rolling Review, which means that a drug company can submit completed sections of its Biological License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the application is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA.

      http://www.fda.gov/forconsumers/byaudience/forpatientadvocat…
      Avatar
      schrieb am 29.04.14 23:43:16
      Beitrag Nr. 207 ()
      GW Pharmaceuticals to Report Q2 2014 and Half Year Financial Results
      and Host Conference Call on 7 May, 2014

      London, UK, 29 April 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 May, 2014 its second quarter and half year financial results for the period ending 31 March, 2014. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT).

      Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
      Avatar
      schrieb am 06.05.14 13:32:02
      Beitrag Nr. 208 ()
      GW Pharmaceuticals Appoints Dr. Kenneth Sommerville as VP, Clinical Science
      GW PHARMACEUTICALS PLC (NASDAQ:GWPH)
      Intraday Stock Chart
      Today : Dienstag 6 Mai 2014

      Click Here for more GW PHARMACEUTICALS PLC Charts.
      GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appointment of Kenneth Sommerville MD to the newly created position of VP, Clinical Science, based in the United States.
      Dr. Sommerville will play an important role in the clinical development, medical affairs, and regulatory activities related to the Company's epilepsy programs including the ongoing development of Epidiolex®, GW's product candidate for Dravet and Lennox-Gastaut syndromes. He will also support the late stages of the completion of the investigational plan for Sativex® in cancer pain.

      "We are delighted to announce this important appointment and welcome Ken's extensive industry experience and therapeutic expertise in support of our rapidly evolving programs in the United States," stated Justin Gover, GW's Chief Executive Officer. "We have received significant interest from physicians and parents regarding Epidiolex for childhood epilepsy and with the GW-sponsored pivotal trials expected to commence in the second half of this year, Ken will play a leading role in the clinical development of this important product in the U.S. His expertise and depth of knowledge in product development and regulatory matters will serve GW well as we seek to advance Epidiolex through clinical trials and, if successful, obtain FDA approval as rapidly as possible."

      Dr. Sommerville is a board-certified neurologist and joins GW with a significant record of achievement including twenty-three years of experience in the pharmaceutical industry. He has had senior roles at UCB/Schwarz Pharma where he led clinical and regulatory programs in epilepsy and other neurological product development initiatives including NDA submissions to FDA and EMEA for multiple compounds. Most recently, Dr. Sommerville served as Vice President of Clinical Sciences at Pfizer, Inc. where he was Global Clinical Lead for opioids and led a team of physicians and scientists in the development of abuse-deterrent opioids. He also has led teams in multiple medical and scientific areas including, but not limited to, indications of complex partial seizures, basic and rapid infusion of an intravenous anti-convulsant, painful diabetic neuropathy, migraine prophylaxis, Parkinson's disease, bipolar disorder, personality disorders, and schizophrenia. Dr. Sommerville has made major contributions to over twenty NDA submissions for both the FDA and EMEA and is recognized as an authority in drug development, especially anti-epileptic drugs, pain, and abuse-deterrent opioids.

      "This is an exciting time to be joining GW, with a number of important products currently under development for patients in the United States including Sativex and Epidiolex. Specifically, I believe that Epidiolex has the potential to become an important new therapeutic option for children suffering with intractable epilepsy, an area of significant unmet need," said Dr. Sommerville. "I look forward to working with the GW team to develop new treatments from their proprietary cannabinoid platform."

      Dr. Sommerville earned a M.D. degree from Jefferson Medical College in Philadelphia, Pennsylvania and is an Adjunct Assistant Professor of Medicine at the Duke University Medical Center in Durham, North Carolina. Dr. Sommerville was in the private practice of neurology for 11 years prior to entering the pharmaceutical industry.
      Avatar
      schrieb am 07.05.14 08:23:44
      Beitrag Nr. 209 ()
      London, UK, 7 May 2014: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the second quarter and half year ended 31 March 2014.

      RECENT OPERATIONAL HIGHLIGHTS

      · Follow-on offering of American Depositary Shares ("ADSs") on the NASDAQ Global Market closed in January 2014 raising total net proceeds after expenses of approximately $94.1 million (£56.8 million)

      · Advancement of Epidiolex® childhood epilepsy program:
      o Investigational New Drug Application (IND) authorized by the U.S. Food and Drug Administration (FDA) for Epidiolex® (Cannabidiol or CBD) in the treatment of Dravet Syndrome (announced separately today). Phase 2/3 trial on track to commence H2 2014
      o Orphan Drug Designation granted by the FDA for Epidiolex to treat Lennox-Gastaut syndrome (Orphan Drug Designation also granted in November 2013 for Dravet Syndrome)
      o Number of children suffering from intractable epilepsy syndromes authorized for treatment with Epidiolex by FDA under Expanded Access Treatment INDs increased to approximately 300 from 125 in January
      o Approximately 60 children now receiving treatment with Epidiolex in the U.S.
      o Treatment data on initial cohort of patients on track to be released mid-2014
      o Two U.S. state governments have publicly expressed interest in collaborating with GW on separate state-based clinical trials in epilepsy
      o Appointment of Dr. Kenneth Sommerville as Vice President Clinical Science

      · Advancement of Cannabidivarin (CBDV) epilepsy program:
      o Additional epilepsy pipeline candidate GWP42006 (CBDV), Phase 1 trial completed indicating CBDV was well tolerated with no treatment-related adverse events
      o Phase 2 IND expected to be submitted to FDA in H2 2014

      · Sativex® program developments:
      o Sativex received Fast Track designation by FDA for treatment of chronic cancer pain in patients with advanced cancer who have failed to respond adequately to optimized opioid therapy
      o Initial top-line Phase 3 cancer pain data on track for release towards the end of 2014. Data intended to lead to a New Drug Application (NDA) filing with the FDA in the U.S.
      o Special Protocol Assessment (SPA) ongoing with the FDA for proposed Sativex Phase 3 trial in the treatment of Multiple Sclerosis (MS) spasticity
      o Sativex now approved in 25 countries and available for use in 12 countries. In-market sales volumes sold by GW's commercial partners for the six months ended 31 March 2014 increased by 40% over the prior period

      · Significant additional on-going clinical trial activity for cannabinoid pipeline product candidates
      o Phase 2a trial of GWP42003 for the treatment of ulcerative colitis ongoing - data expected H2 2014
      o Phase 2b 12-week randomized, double blind, placebo controlled trial of GWP42004 in type-2 diabetes commenced in March 2014 with expected completion in H2 2015
      o Phase 2a trial of GWP42003 for the treatment of schizophrenia commenced in March 2014 with expected completion in H2 2015
      o Phase 1b/2a trial of GWP42002:GWP42003 in the treatment of glioma is ongoing with safety data on an initial cohort due this year

      FINANCIAL HIGHLIGHTS
      · Revenue for the six months ended 31 March 2014 of £15.0 million ($25.0 million) compared to £12.9 million in H1 2013

      · Loss for the six months ended 31 March 2014 of £8.0 million ($13.3 million) compared to a profit of £0.1 million in H1 2013

      · Cash and cash equivalents at 31 March 2014 of £95.6 million ($159.4 million) compared to £38.1 million as at 30 September 2013.

      "I am pleased to report another busy period for GW, during which we completed a successful follow-on offering on NASDAQ and made significant progress on a number of our development programs, in particular our Epidiolex childhood epilepsy program. In the last quarter, both the number of Epidiolex treatment programs authorized by the FDA, and the number of children receiving Epidiolex, has significantly expanded. In addition, we are very pleased to announce today that the FDA has agreed to allow the start of GW-sponsored placebo-controlled trials for the treatment of Dravet syndrome and we look forward to commencing this program as rapidly as possible," stated Justin Gover, GW's Chief Executive Officer. "We are also progressing towards the conclusion of our U.S. Phase 3 cancer pain trials for Sativex as well as advancing Phase 2 trials of several other pipeline candidates. We look forward to reporting on a number of key events during the second half of 2014."

      Conference Call and Webcast Information
      GW Pharmaceuticals will host a conference call and webcast to discuss the 2014 second quarter and half year financial results today at 8:00 a.m. ET / 1:00 p.m. BST. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada), or 0800-756-3429 (toll free from the UK) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company's website at http://www.gwpharm.com. A replay of the call will also be available through the GW website shortly after the call and will remain available for 30 days. Replay Numbers: (toll free):1-877-660-6853, (international):1-201-612-7415. For both dial-in numbers please use conference ID #13581697.
      Avatar
      schrieb am 07.05.14 12:35:13
      Beitrag Nr. 210 ()
      GW Pharmaceuticals (GWPH) Posts Q1 Loss of 4c/Share; Epidiolex IND Now Open for Phase 2/3


      GW Pharmaceuticals plc (NASDAQ: GWPH) reported Q1 EPS of ($0.04), $0.44 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $12.55 million versus the consensus estimate of $12.48 million.

      GW Pharma also announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for Epidiolex in the treatment of Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW expects to commence a Phase 2/3 clinical trial in the second half of 2014.

      Epidiolex has already received orphan drug designation from the FDA for the treatment of Dravet syndrome.

      "The acceptance of this IND by the FDA is a significant milestone for Epidiolex and for children with Dravet syndrome for whom existing anti-epileptic medicines often do not provide adequate relief," stated Justin Gover, GW's Chief Executive Officer. "This journey began with requests from the U.S. epilepsy physician and patient community to utilize Epidiolex and has now led to GW embarking on its own formal development program with a view to seeking market authorization from the FDA as rapidly as possible. We are committed to providing a prescription cannabidiol (CBD) medicine for children with Dravet syndrome who have exhausted all other therapeutic options."

      The Phase 2/3 trial is a two-part randomized double-blind, placebo-controlled parallel group dose escalation, safety, tolerability, pharmacokinetic and efficacy trial of single and multiple doses of Epidiolex to treat Dravet syndrome in children who are being treated with other anti-epileptic drugs. Part one comprises the pharmacokinetic and dose-finding elements of the trial in a total of 30 patients over a 3 week treatment period. Part two is a placebo-controlled safety and efficacy evaluation of Epidiolex over a 3 month treatment period in a total of 80 patients. All patients who participate in the study will be eligible to receive Epidiolex under a long term open label extension protocol.

      GW anticipates commencing an additional Phase 3 trial in Dravet syndrome in the first quarter of 2015 in parallel with part two of the first Phase 2/3 trial.

      In addition to Dravet syndrome, GW plans to conduct a clinical development program for Epidiolex in the treatment of Lennox-Gastaut syndrome (LGS). Following receipt earlier in 2014 of orphan drug designation by the FDA in LGS, GW expects to hold a pre-IND meeting with the FDA for Epidiolex in the treatment of LGS in mid-2014, and aims to conduct two Phase 3 trials in LGS during 2015.

      http://www.streetinsider.com/Corporate+News/GW+Pharmaceutica…
      Avatar
      schrieb am 07.05.14 12:40:57
      Beitrag Nr. 211 ()
      Avatar
      schrieb am 07.05.14 13:59:10
      Beitrag Nr. 212 ()
      http://www.sec.gov/Archives/edgar/data/1351288/0001104659140…

      Upcoming GW conference participation

      GW expects to participate in the upcoming Bank of America Merrill Lynch Health Care conference in Las Vegas, 13-14 May 2014.


      Results of Operations:

      Comparison of the six months ended 31 March 2014 and 31 March 2013:

      Revenue

      Total revenue for the six months to 31 March 2014 was £15.0 million, compared to £12.9 million for the six months ended 31 March 2013. This net increase reflects:

      · £1.5 million increase in Sativex product sales revenues to £2.1 million for the six months ended 31 March 2014 compared to £0.6 million for the six months ended 31 March 2013.
      · £0.5 million increase in research and development fees to £12.2 million for the six months ended 31 March 2014 from £11.7 million for the six months ended 31 March 2013.

      The increase in Sativex product sales for the six months ended 31 March 2014 compared to the six months ended 31 March 2014 was primarily related to a 51% increase in volume of Sativex inventory shipped to GW’s commercial partners. This increase was driven by increased shipments to Germany compared to the prior period, and strong sales in Italy following the territory’s launch in the second half of the year ended 30 September 2013.

      Sativex product sales revenue in the six months ended 31 March 2013 was negatively impacted by the German National Association of Statutory Health Insurance Funds decision to impose a price reduction on Sativex sales in Germany effective for sales from 1 July 2012. Consequently, an additional £0.7 million rebate provision was recognised in the six months ended 31 March 2013, of which £0.6 million related to sales recognised in the year ended 30 September 2012.

      Sativex in-market sales volumes sold by GW’s commercial partners for the six months ended 31 March 2014 were 40% higher than the six months ended 31 March 2013.

      Research and development fees charged to Otsuka for the six months to 31 March 2014 were £12.2 million, compared to £11.7 million for the six months ended 31 March 2013. The increased research and development fees reflect increased research and development expenditure which has been passed onto Otsuka, further details of which are given in the expenditure section below.

      License, collaboration and technical access fees for the six months ended 31 March 2014 were £0.7 million, compared to £0.6 million recognised in the six months ended 31 March 2013.


      GW-funded research and development expenditure for the six months ended 31 March 2014 was £8.8 million, an increase of £5.4 million from £3.4 million for the six months ended 31 March 2013. The increase was principally linked to:

      · £1.8 million increase in staff and employee-related expenses relating to increased headcount and operations for GW-funded activities.
      · £1.0 million movement on provision for payroll taxes on unrealized staff share option gains and share-based payment charges.
      · £1.5 million increase in epilepsy and other GW-funded clinical program costs — reflecting the recent successful completion of the CBDV Phase 1 study plus the costs of providing regulatory support and Epidiolex under FDA-approved expanded access INDs.
      · £0.4 million increase in growing costs driven by growing of an increased volume of raw materials for the Epidiolex program.
      · £0.4 million increase in preclinical activities.
      · £0.3 million increase in patent and intellectual property costs.
      Avatar
      schrieb am 07.05.14 14:03:24
      Beitrag Nr. 213 ()
      Guidance

      GW now expects strong double digit Sativex sales revenue growth in 2014, driven by growth of in-market sales volumes by commercial partners. The MS Phase 3 trial milestone of $5 million from Otsuka, which we had previously guided as receivable towards the end of our 2014 financial year, is now expected early in our 2015 financial year.

      Having successfully raised funds to enable us to prosecute our Epidiolex and other pipeline programs we expect that GW-funded R&D will continue to increase in the second half of this year. We expect a core operating cash outflow for 2014, including capital expenditure, of approximately £24 million ($40 million). This would result in a year end closing cash position of £75-80 million ($125-133 million).


      Going concern

      At 31 March 2014 the Group had cash and cash equivalents of £95.6 million. The Group is also generating revenues from Sativex sales, milestone payments and research and development fees receivable from pharmaceutical licensing partners. The Directors have reviewed the working capital and research and development funding requirements of the Group for the next twelve months and consider that the cash and cash equivalents, recurring revenues together with the strong development partner relationships that are in place mean that the Group is well placed to manage its business risks successfully.

      The Directors are satisfied that the Group has sufficient resources to continue in operation for the foreseeable future, a period of not less than 12 months from the date of this report. Accordingly, they continue to adopt the going concern basis in preparing the financial information for the six months ended 31 March 2014.
      Avatar
      schrieb am 07.05.14 14:06:27
      Beitrag Nr. 214 ()
      12. Subsequent events

      On May 5, 2014, GW entered into an amendment to a Sativex distribution and license agreement with Novartis Pharma AG dated as of April 8, 2011. As disclosed in the prospectus filed with the SEC in January 2014, GW and Novartis have agreed that Novartis will not be expected to make a decision about launching Sativex in its territory until final data for the two Phase 3 cancer pain clinical trials are available. A contract amendment has therefore now been signed with Novartis to this effect.

      AMENDMENT
      to the DISTRIBUTION AND LICENSE AGREEMENT
      between Novartis Pharma AG and GW Pharma Ltd. :
      http://www.sec.gov/Archives/edgar/data/1351288/0001104659140…
      Avatar
      schrieb am 13.05.14 11:05:04
      Beitrag Nr. 215 ()
      Bin auch dabei!
      Avatar
      schrieb am 02.06.14 11:12:02
      Beitrag Nr. 216 ()
      hier tut sich endlich mal wieder was:

      GW Pharmaceutical's announcement regarding MOU with State of Georgia

      Atlanta, Georgia, and London, UK 27 May 2014: A State of Georgia initiative making it possible to treat children with epilepsy with cannabidiol is moving forward. The state, GW Pharmaceuticals (NASDAQ: GWPH), and Georgia Regents University Augusta (GRU), announced today that they have entered into a Memorandum of Understanding to study GW's investigational cannabidiol (CBD) product Epidiolex® in the treatment of children with medication-resistant epilepsies.

      Georgia Governor Nathan Deal announced in April his support for clinical research that would investigate the use of CBD, a non-psychoactive component of the cannabis plant, and develop rigorous data that will inform and expand the scientific community's understanding of potential treatments for difficult-to-treat forms of childhood epilepsies. Deal's commitment to this research has led to this plan to form collaboration between GRU and GW Pharmaceuticals. It is expected that details of the collaboration will be finalized in the coming months in order for research to commence later this year.

      quelle: http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=850649
      Avatar
      schrieb am 06.06.14 08:48:14
      Beitrag Nr. 217 ()
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/ep…

      GW Pharmaceuticals Announces Epidiolex® Receives Fast Track Designation from FDA for the Treatment of Dravet Syndrome

      London, UK; 6 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to GW's investigational cannabidiol (CBD) product, Epidiolex®, in the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy.

      FDA's Fast Track program facilitates the development and review of drugs intended to treat serious conditions and fill an unmet medical need. A drug development program with Fast Track designation is afforded greater access to the FDA for the purpose of expediting the drug's development, review and potential approval to get important new drugs to the patient earlier.

      "GW is focused on advancing theEpidiolex development program as rapidly as possible with the aim of addressing the significant unmet need in children suffering from Dravet syndrome. The granting of Fast Track designation, in addition to Epidiolex having already received orphan drug designation from the FDA, represents significant additional support toward this objective," stated Justin Gover, GW's Chief Executive Officer. "With GW having already opened an Investigational New Drug (IND) for Epidiolex, we are on track to commence a Phase 2/3 clinical trial in Dravet syndrome in the second half of this year."

      In addition to Dravet syndrome, GW plans to conduct a clinical development program for Epidiolex in the treatment of Lennox-Gastaut syndrome (LGS). Following receipt earlier in 2014 of orphan drug designation by the FDA in LGS, GW expects to hold a pre-IND meeting with the FDA for Epidiolex in the treatment of LGS in mid-2014, and expects to conduct two Phase 3 trials in LGS during 2015.

      About Dravet syndrome

      Dravet syndrome, also known as Severe Myoclonic Epilepsy of Infancy (SMEI), is a rare and catastrophic form of epilepsy for which there is currently no cure. Seizures begin in the first year of life in an otherwise typically developing infant. Initial seizures are most often prolonged events (status epilepticus) and, in the second year of life, other seizure types emerge. All seizure types are remarkably resistant to medical therapy and the prognosis for Dravet syndrome is poor. Individuals with Dravet syndrome face a higher incidence of SUDEP (sudden unexplained death in epilepsy) and have associated co-morbid conditions, which also need to be properly managed. Children with Dravet syndrome do not outgrow this condition and it affects every aspect of their daily lives.
      Avatar
      schrieb am 17.06.14 13:07:51
      Beitrag Nr. 218 ()
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/ep…

      GW Pharmaceuticals Announces Physician Reports of Epidiolex® Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy from Physician-Led Expanded Access Treatment Program

      Data show promising signals of efficacy and safety
      Conference Call Today at 8:30 a.m. ET, 1:30 p.m. (UK)

      London, UK; 17 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol (CBD) product candidate, Epidiolex®, for a period of 12 weeks. The treatment-resistant patients suffer from a range of epilepsies in which current anti-epileptic drugs have been unsuccessful in adequately controlling seizures, and included such severe forms of epilepsy as Dravet syndrome and Lennox-Gastaut syndrome. Uncontrolled data from two hospital sites in the United States that were generated under expanded access Investigational New Drug applications (INDs) authorized by the Food and Drug Administration (FDA) were made available to the Company.

      "We are pleased to report preliminary data on Epidiolex which provides promising signals of efficacy in children with treatment-resistant epilepsy, including patients with Dravet syndrome. It is noteworthy that, of the patients who have responded to Epidiolex, a high proportion show a reduction in seizure frequency of greater than 50% and a portion of these patients were reported to be seizure-free at the end of 12 weeks of treatment," stated Justin Gover, GW's Chief Executive Officer. "We believe that these signals of efficacy, together with the side effect profile observed to date, support GW's decision to advance Epidiolex into a formal development program and we look forward to commencing a Phase 2/3 clinical trial of Epidiolex in Dravet syndrome in the second half of 2014."

      "There remains an enormous unmet need in a range of pediatric and adult treatment-resistant epilepsy syndromes, which affect approximately 750,000 Americans. Some of the greatest needs are in children with severe epilepsy syndromes such as Dravet and Lennox-Gastaut, where frequent seizures often persist despite high doses of multiple anti-epileptic drugs," stated Orrin Devinsky MD, Professor of Neurology, Neurosurgery, and Psychiatry at NYU School of Medicine, and Director, NYU Comprehensive Epilepsy Center. "The initial open-label study with Epidiolex has provided encouraging results. Some children have had marked reductions in their seizures and overall, the medication has been well tolerated."
      Avatar
      schrieb am 17.06.14 13:09:48
      Beitrag Nr. 219 ()
      Avatar
      schrieb am 17.06.14 13:14:59
      Beitrag Nr. 220 ()
      GW Development Program

      GW is developing Epidiolex in the treatment of Dravet syndrome, for which the Company has received both orphan drug designation and Fast Track designation from the FDA. A company-sponsored IND is open with the FDA and a Phase 2/3 trial is expected to commence in the second half of 2014. GW anticipates commencing an additional Phase 3 trial in Dravet syndrome in the first quarter of 2015. In addition to Dravet syndrome, GW plans to conduct a clinical development program for Epidiolex in the treatment of Lennox-Gastaut syndrome (LGS). Following receipt earlier in 2014 of orphan drug designation by the FDA, GW expects to hold a pre-IND meeting with the FDA for Epidiolex in the treatment of LGS in mid-2014, and expects to conduct two Phase 3 trials in LGS during 2015.
      Avatar
      schrieb am 17.06.14 13:17:37
      Beitrag Nr. 221 ()
      Avatar
      schrieb am 17.06.14 13:18:44
      Beitrag Nr. 222 ()
      in USA vorbörslich

      Avatar
      schrieb am 17.06.14 23:02:47
      Beitrag Nr. 223 ()
      GW Pharmaceuticals Announces Proposed Public Offering of ADSs
      GW PHARMACEUTICALS PLC (NASDAQ:GWPH)
      Intraday Stock Chart
      Today : Dienstag 17 Juni 2014


      GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that it and certain of its shareholders intend to sell, subject to market and other conditions, 1.7 million American Depositary Shares ("ADSs") representing ordinary shares of GW on the NASDAQ Global Market in an underwritten U.S. public offering. GW will grant the underwriters a 30-day option to purchase up to an additional 255,000 ADSs at the offering price. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The price for the offering has not yet been determined.
      Morgan Stanley, BofA Merrill Lynch and Cowen and Company are acting as joint book-running managers for the offering. Piper Jaffray is acting as lead manager.

      The ADSs described above are being offered by GW and the selling shareholders pursuant to a shelf registration statement filed by GW with the Securities and Exchange Commission ("SEC") that became automatically effective on May 7, 2014. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Morgan Stanley, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; BofA Merrill Lynch, 222 Broadway, New York, NY 10038, attention: Prospectus Department, email: dg.prospectus_requests@baml.com; or from Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department; or from Piper Jaffray, Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402.

      This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

      There will be no offer of ADSs to the public in the UK. This press release is not directed to, or intended for distribution or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

      The distribution of this press release into jurisdictions other than the UK may be restricted by law. Persons into whose possession this announcement come should inform themselves about and observe any such restrictions.
      http://de.advfn.com/p.php?pid=nmona&article=62601620

      Forschung bzw klinische Studien kosten Geld :rolleyes:
      Avatar
      schrieb am 18.06.14 09:26:15
      Beitrag Nr. 224 ()
      wow, da hat doch GW glatt ihr Allzeithoch rausgenommen..charttechnisch ist noch massig platz nach oben jetzt oberhalb des ATH..ziele erstmal ca. 110$ (also nasdaq) Wo bekommt ihr denn infos über cannaktien her? Gibt es da gute seiten? das thema interessiert mich sehr, ich finde aber nicht wirklich was deutschsprachiges :( danke für infos
      1 Antwort
      Avatar
      schrieb am 18.06.14 09:58:21
      Beitrag Nr. 225 ()
      Antwort auf Beitrag Nr.: 47.167.916 von cannatrader am 18.06.14 09:26:15Im netz habe ich eine deutschsprachige Analyse zu GW Pharma gefunden:

      GW Pharmaceuticals ein klarer Kaufkandidat nach reiner Charttechnik

      30.05.2014 15:26

      So langsam krisallisieren sich wenige Substanztitel heraus, hier ist mein persönlicher Favorit:GW Pharmaceuticals PLC





      Der Chart spricht für einen baldigen Ausbruch. Wahnsinnsperformance..seit Anfang des Jahres von 5$ auf 85$ gerannt..Das Flaggschiff der Branche GW Pharmaceuticals wurde im Zuge der SEC-Aussetzungen anderer Marihuana-Aktien abgestraft -konnte sich aber im wieder mit einem massiven Volumenanstieg kräftig erholen, v.a. Dank einer Kaufempfehlung von Morgan Stanley und Kommentaren von Jim Cramer auf CNBC. (Siehe http://marijuanaindex.org/2014/04/marij )
      Der massive Anstieg aufgrund dieser Meldung wird momentan auf hohem nioveau konsolidiert, es entsteht eine klassische Bullen-Flagge mit neuem Allzeithoch als Ziel. Die Konsolidierung wird zwar von abnehmenden Volumen begleitet, das ist aber nach solch einer Volumenspitze vollkommen normal. Der Markt sammelt sich. 65€ sollten von nun an nicht mehr unterschritten werden. Ein Durchbruch der Flaggenoberkante aktiviert das Kursziel, solange im Anschluss GW nicht mehr unter den roten Abwärtstrend fällt.
      Quelle:http://www.marihuana-aktien.de/news/gw-pharmaceuticals-ein-k…
      Avatar
      schrieb am 18.06.14 11:25:59
      Beitrag Nr. 226 ()
      In London gehts nach dieser Meldung erst mal runter.

      LONDON (Alliance News) - GW Pharmaceuticals PLC Wednesday announced plans to sell 1.7 million American depositary shares representing GW ordinary shares, in a public offering on the NASDAQ.


      The price of the offering has not yet been decided. GW and some of its shareholders intend to sell the ADSs in an underwritten offering. It also will grant the underwriters a 30-day option to purchase up to an additional 255,000 ADSs at the offer price, which has not yet been set.

      Morgan Stanley, Bank of America Merill Lynch and Cowen and Co will act as joint book-running managers for the offering. Piper Jaffray is acting as lead manager.

      Shares in GW Pharmaceuticals were trading down 6.2% at 402.25 pence Wednesday morning.

      By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
      http://www.lse.co.uk/AllNews.asp?code=wq5leyoy
      Avatar
      schrieb am 18.06.14 11:27:51
      Beitrag Nr. 227 ()
      Avatar
      schrieb am 19.06.14 09:55:21
      Beitrag Nr. 228 ()
      Ausgabepreis: 86,83 $ sehr schön, kein größerer Abschlag.

      GW Pharmaceuticals plc Announces Pricing of U.S. Public Offering of ADSs Totalling Approximately $148 Million on NASDAQ Global Market

      NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

      London, UK, 19 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company and certain of its shareholders of 1,700,000 American Depositary Shares ("ADSs") representing 20,400,000 ordinary shares of GW, at a price to the public of $86.83 per ADS on the NASDAQ Global Market. The ADSs being sold in the offering consist of 1,200,000 ADSs being sold by the Company and 500,000 ADSs being sold by the selling shareholders, raising gross proceeds to the Company of approximately $104.2 million (before deducting underwriting discount, commissions and offering expenses). GW will not receive any proceeds from the sale of ADSs by the selling shareholders in this offering. GW has granted the underwriters a 30-day option to purchase up to an additional 255,000 ADSs at the public offering price less the underwriting discount. Closing of the offering is expected to occur on June 25, 2014.

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/pr…
      Avatar
      schrieb am 20.06.14 10:55:03
      Beitrag Nr. 229 ()
      Avatar
      schrieb am 20.06.14 11:39:12
      Beitrag Nr. 230 ()
      neben marijuanaindex.org habe ich diesen hier noch gefunden
      Avatar
      schrieb am 20.06.14 11:59:14
      Beitrag Nr. 231 ()
      Avatar
      schrieb am 20.06.14 12:07:55
      Beitrag Nr. 232 ()

      und die einzelnen komponenten..
      Quellenangabe: www.marihuana-aktien.de
      Avatar
      schrieb am 23.06.14 11:34:13
      Beitrag Nr. 233 ()
      Cannabis Index +26,01% - Erneut sehr feste Woche dank GW Pharmaceuticals PLc

      http://www.marihuana-aktien.de/news/cannabis-index-feste-woc…
      Avatar
      schrieb am 23.06.14 11:36:36
      Beitrag Nr. 234 ()
      Avatar
      schrieb am 23.06.14 12:54:52
      Beitrag Nr. 235 ()
      Danke für die Charts.

      binda
      Avatar
      schrieb am 24.06.14 10:35:42
      Beitrag Nr. 236 ()
      GW Pharmaceuticals plc Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs

      NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

      London, UK, 24 June 2014: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the full exercise by the underwriters of their option to purchase from the Company 255,000 additional ADSs representing 3,060,000 ordinary shares of GW at a price of $86.83 per ADS. The exercise of the underwriters' option is further to the underwritten public offering by the Company and certain of its shareholders of 1,700,000 American Depositary Shares ("ADSs") representing 20,400,000 ordinary shares of GW, announced on 19 June 2014. The exercise of the option brings the total ADSs to be sold by GW to 1,455,000 and brings to $126.3 million the gross proceeds to the Company raised in the public offering (before deducting underwriting discount, commissions and offering expenses). Closing of the offering is expected to occur on 25 June 2014.

      Morgan Stanley, BofA Merrill Lynch and Cowen and Company, are acting as joint book-running managers for the offering. Piper Jaffray is acting as lead manager.

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/ex…
      Avatar
      schrieb am 24.06.14 11:00:22
      Beitrag Nr. 237 ()
      GW Pharmaceuticals - Korrektur einplanen!


      23.06.2014 23:01
      GW dürfte nun anfällig für Rücksetzer sein – rein charttechnisch wohlgemerkt!. Nachdem das Flaggenziel wunderbar abgearbeitet wurde, dürfte die Aktie eine kleine Korrektur starten. Die Mindestkorrektur nach Fibonacchi wäre das 38er Retracement (obere blaue Elipse), das sich momentan seit der jüngsten Aufwärtsbewegung (Flaggentrigger) in etwa mit dem alten Allzeithoch deckt, das ebenfalls unterstützend wirken sollte. Selbst Rücksetzer in den maximalen Korrekturbereich bis zum 61,8er Fibo (2. Blaue Elipse), das sich wiederum mit dem Flaggentrigger deckt, sollten für den laufenden dynamischen Aufschwung kein Hindernis darstellen, sondern wäre allemal gesund um weiter Kraft für höhere Kurse zu tanken.

      weiterlesen: hier gehts zum vollständigen Artikel:
      http://www.marihuana-aktien.de/news/gw-pharmaceuticals-korre…

      Avatar
      schrieb am 27.06.14 15:45:53
      Beitrag Nr. 238 ()
      :eek:
      Avatar
      schrieb am 30.06.14 15:14:57
      Beitrag Nr. 239 ()
      Avatar
      schrieb am 30.06.14 21:50:40
      Beitrag Nr. 240 ()
      http://www.fool.com/investing/general/2014/06/30/why-gw-phar…
      Why GW Pharmaceuticals PLC Stock Surged
      By Sean Williams | More Articles
      June 30, 2014 | Comments (0)

      Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

      What: Shares of GW Pharmaceuticals (NASDAQ: GWPH ) , a specialty pharmaceutical company focused on discovering and utilizing cannabinoid-based therapies to enact desired biologic effects, surged as much as 14% after receiving positive commentary and a big price hike from an analyst at Piper Jaffray.

      So what: According to Piper Jaffray analyst Dr. Joshua Schimmer, GW's investigational epilepsy drug epidiolex, which is currently targeting Dravet syndrome, a rare type of epilepsy that affects children and young adults, appears to be on the right path to being a success. Describing epidiolex as having the right combination of safety and effectiveness, Schimmer boosted his company's price target on GW to $147 from $97, implying up to 53% upside based on Friday's closing price, and kept an "overweight" rating on the stock. In addition, Schimmer believes that Dravet syndrome is a stepping stone to other indications for epidiolex.

      Now what: Since receiving an orphan drug designation for epidiolex in late February shares of GW have been on fire. The early data that we've received has indeed been suggestive of a nice balance of safety and efficacy which could lead to an approval for the treatment of Dravet syndrome. I would, however, continue to caution that we're talking about a company that's years upon years away from profitability, that'll have countless social obstacles to overcome with physicians for its use of cannabinoids from cannabis plants, and which is not guaranteed any additional indications for epidiolex as of yet. GW's valuation, at least to me, is looking frothier than ever and is certainly going to continue to keep me on the sidelines.

      GW shares may be surging, but this darling stock of Warren Buffett's might leave it in the dust over the long run!
      Imagine a company that rents a very specific and valuable piece of machinery for $41,000 per hour (That's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new free Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

      Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

      The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
      Avatar
      schrieb am 01.07.14 09:54:37
      Beitrag Nr. 241 ()
      Die Anlegerschaft feiert sowohl die positiven Aussichten und Phantasie und der damit einhergehendenPhantasie als auch die positiven Alystenkommentare. Charttechnisch sind kurzfristig alle Zielmarken (100-105$) abgearbeitet, ja sogar überfüllt. Der Schlusskurs notiert abermals ausserhalb der Bollinger Bänder, was einerseits für Stärke spricht, auf der anderen Seite jedoch zur Vorsicht mahnt. Ein scharfer Rücksetzer bis zum Mindestkorrekturniveau, dem 38er Fibo (aktuell bei etwa 93$) wäre eigentlich gesund. Das Momentum ist momentan jedoch so positiv, dass Shortüberlegungen definitiv hinten anstehen sollten (es sei denn im ultrakurzfristigen Bereich):



      Quelle:
      http://www.marihuana-aktien.de/news/cannaindex-im-hohenglug-…
      Avatar
      schrieb am 04.07.14 15:24:30
      Beitrag Nr. 242 ()
      Weiteres interessantes Infomaterial zur Cannabisbranche allgemein und Chartanalyse zu GWPH im Speziellen..gar nicht mal soo schlecht die Analysen des Typen

      http://www.marihuana-aktien.de/news/cannaindex-kw-27-10-64-/
      Avatar
      schrieb am 08.07.14 00:35:00
      Beitrag Nr. 243 ()
      http://clinicaltrials.gov/ct2/show/NCT01562314

      A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis

      Estimated Enrollment: 62
      Study Start Date: February 2012
      Estimated Study Completion Date: December 2014
      Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
      Avatar
      schrieb am 08.07.14 00:43:04
      Beitrag Nr. 244 ()
      Avatar
      schrieb am 08.07.14 11:54:13
      Beitrag Nr. 245 ()
      Capital Research and Management Company hat sich noch ein paar ADR`s einverleibt.

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/ho…

      Avatar
      schrieb am 08.07.14 21:43:07
      Beitrag Nr. 246 ()
      Erwartete GW-Pharmaceuticals-Korrektur am Kursziel
      http://www.marihuana-aktien.de/news/erwartete-gw-pharmaceuti…
      Avatar
      schrieb am 09.07.14 13:10:36
      Beitrag Nr. 247 ()
      CannaIndex büßt an 2 Handelstagen 1/5 seines Wertes ein
      siehe http://www.marihuana-aktien.de/blog-2/
      Avatar
      schrieb am 09.07.14 16:04:46
      Beitrag Nr. 248 ()
      Das ding läuft einfach so schön momentan. :)
      Avatar
      schrieb am 09.07.14 19:51:08
      Beitrag Nr. 249 ()
      Avatar
      schrieb am 11.07.14 00:39:05
      Beitrag Nr. 250 ()
      http://www.carlow-nationalist.ie/2014/07/10/cannabis-based-m…

      CANNABIS-BASED MEDICINES WILL BE LEGAL BY NEXT WEEK, SAYS MINISTER

      New laws allowing cannabis-based medicines to be prescribed in Ireland for the first time could be in place as early as tomorrow.

      Junior Health Minister Alex White says the laws will be signed early next week, if not before then.

      The change will allow doctors to prescribe drugs like Sativex to patients to relieve the pain from conditions like multiple sclerosis.

      The drug has already been approved by the Health Products Regulatory Authority and Minister White says it will be legal very soon.

      "If it doesn't happen by the end of this week, and I'm going to endeavour to do everything in my power to ensure that it could be done this week, there are one or two issues that just needed to be ironed out of a legal nature, I'm hopeful we can do it this week, if not I expect early next week and that's how imminent it is," he said.
      Avatar
      schrieb am 26.07.14 01:55:50
      Beitrag Nr. 251 ()
      Irland


      New Year wait for cannabis
      Published 21/07/2014|00:00

      People with multiple sclerosis are expected to wait until early next year before the cannabis-based medicine, which can relieve symptoms, becomes available.


      Regulations have been signed to pave the way to enable authorised cannabis-based medicinal products, including Sativex, to be legally prescribed to patients. However, it will have to go through assessment at the National Centre for Pharmcoeconomics to determine if it will be available on State drugs schemes. No cost for the medication is available here yet.

      There are around 8,000 people in Ireland with multiple sclerosis and Sativex could bring relief to a significant number of them. Beaumont Hospital neurologist, Dr Orla Hardiman, said the assessment could take several months and it is likely to be next year before it is finalised.

      The drug can ease symptoms of spasticity, where muscles become stiff and resistant to movement. It may be prescribed where other treatments have failed.

      Only doctors specialising in multiple sclerosis, such as neurologists or pain consultants, are expected to be allowed to prescribe the drug, which is an oral spray. It can only be prescribed to those who have found that other drugs did not bring relief, or who experienced side effects when taking them.

      Sativex is already available in several other European countries. MS Ireland, which campaigned for its availability, said that, in 2010, an Irish study carried out by the University of Limerick found that 68pc of people with the disease reported some degree of spasticity.

      If left untreated, spasticity can lead to pressure sores, falls and serious fatigue.

      Health & Living
      - See more at: http://www.independent.ie/life/health-wellbeing/new-year-wai…
      Avatar
      schrieb am 31.07.14 15:08:42
      Beitrag Nr. 252 ()
      GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 6 August, 2014 its third quarter financial results for the period ending 30 June, 2014. GW will also host a conference call the same day at 1:00 p.m. BST (8:00 a.m. EDT).
      Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

      http://de.advfn.com/p.php?pid=nmona&article=63075290
      Avatar
      schrieb am 31.07.14 22:29:48
      Beitrag Nr. 253 ()
      Avatar
      schrieb am 05.08.14 23:20:46
      !
      Dieser Beitrag wurde von CloudMOD moderiert. Grund: Spam, Werbung
      Avatar
      schrieb am 06.08.14 08:48:37
      Beitrag Nr. 255 ()
      FINANCIAL HIGHLIGHTS

      · Revenue for the three months ended 30 June 2014 of £7.6 million ($13.0 million) compared to £7.3 million for the three months ended 30 June 2013

      · Loss for the three months ended 30 June 2014 of £6.9 million ($11.9 million) compared to a loss of £2.0 million for the three months ended 30 June 2013. The increased loss primarily reflects the planned increase in GW funded R&D in order to fund the development of Epidiolex and other pipeline candidates

      · Cash and cash equivalents at 30 June 2014 of £168.3 million ($287.8 million) compared to £38.1 million as at 30 September 2013

      "During the third quarter GW announced important initial data on Epidiolex which provides promising signals of efficacy in children with treatment-resistant epilepsy, including patients with Dravet syndrome. Our preparations for Phase 3 clinical trials in both Dravet and Lennox-Gastaut syndromes are advancing rapidly and we look forward to the start of the first pivotal placebo-controlled trial in the second half of this year. The funds raised this quarter in the follow-on offering will not only allow GW to complete these development programs but also to commence pre-launch activities in the United States and build-up of inventory in readiness for future launch," stated Justin Gover, GW's Chief Executive Officer. "In parallel with GW's Epidiolex program, we are also progressing towards the conclusion of our U.S. Phase 3 cancer pain trials for Sativex and look forward to reporting initial top-line data from the first trial around the end of 2014. Finally, we continue to make strong progress across our cannabinoid pipeline, which continues to yield interesting new product candidates in a wide variety of therapeutic areas."

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/th…
      Avatar
      schrieb am 11.08.14 21:16:51
      Beitrag Nr. 256 ()
      den besten beitrag zu gw, den ich je gelesen habe..gefunden auf seekingalpha.com
      Der Artikel ist sehr kritisch gegenüber GW
      http://seekingalpha.com/article/2409465-the-long-and-short-o…
      Avatar
      schrieb am 11.08.14 22:07:03
      Beitrag Nr. 257 ()
      Zitat von cannatrader: den besten beitrag zu gw, den ich je gelesen habe..gefunden auf seekingalpha.com
      Der Artikel ist sehr kritisch gegenüber GW
      http://seekingalpha.com/article/2409465-the-long-and-short-o…


      Hi cannatrader,
      Gilt dies nicht mehr für dich?

      cannatrader
      Beitrag Nr. 225 (47.168.088)
      So langsam krisallisieren sich wenige Substanztitel heraus, hier ist mein persönlicher Favorit:GW Pharmaceuticals PLC



      Bei seekingalpha kann jeder seine Meinung (negativ wie positiv) zu Unternehmen schreiben, ob es alles der Wahrheit entspricht muß jeder selbst recherchieren.
      Bestimmt kommt bald eine Gegendarstellung eines anderen Schreibers auf seekingalpha. War bisher immer so.

      Ich persönlich halte nicht viel von dem "Blättchen", egal ob pro oder contra geschrieben wird.

      Gruß binda
      Avatar
      schrieb am 12.08.14 14:30:22
      Beitrag Nr. 258 ()
      http://www.benzinga.com/news/earnings/14/08/4771754/insys-gw…
      A well-known short-seller accused GW Pharmaceuticals (NASDAQ: GWPH) of making misleading statements about progress with its cannabis-based development drug for childhood epilepsy.


      Avatar
      schrieb am 12.08.14 21:05:54
      Beitrag Nr. 259 ()
      Avatar
      schrieb am 13.08.14 19:51:03
      Beitrag Nr. 260 ()
      Zitat von cannatrader: den besten beitrag zu gw, den ich je gelesen habe..gefunden auf seekingalpha.com
      Der Artikel ist sehr kritisch gegenüber GW
      http://seekingalpha.com/article/2409465-the-long-and-short-o…



      Hi cannatrader, hast Du umgeschichtet, so wie es in diesem Kommentar empfohlen wurde?

      Gruß binda
      Avatar
      schrieb am 14.08.14 10:32:09
      Beitrag Nr. 261 ()
      Also ich muss dir zustimmen Binda,
      bei Seekingalpha kann jeder seine Meinung schreiben. Es heisst ja nicht das es nicht stimmt, aber ich finde die sprechen ziemlich negativ über GW.. Ich bin auch schon länger drinn. Bei 1,97 eingestiegen. Mann sollte auch im Gedanke haben das GW mehrere Produkte in deren Pipline hat, die positiv laufen zb Sativex. Das Artikel bezieht sich mehr auf Dravet und nicht auf das gesamte Bild von GW, obwohl die sagen, dass GW noch keine Genähmigung für deren Produkte in den USA hat. Soweit ich weiss wurde Sativex in einigen plätze schon genämigt. Wenn ich mich irre bitte korrekiere mich. Hab mir den Forum durchgelesen und finde du hast schon eine feste Meinung zu GW da du ziemlich aktiv in dem Papier drin bist. Ich habe noch keine richtige meinung über Insys.. was meinst du?

      Gruss Jay-c
      Avatar
      schrieb am 14.08.14 16:30:54
      Beitrag Nr. 262 ()
      Avatar
      schrieb am 14.08.14 17:15:03
      Beitrag Nr. 263 ()
      Zitat von Jay-c: Also ich muss dir zustimmen Binda,
      Ich habe noch keine richtige meinung über Insys.. was meinst du?

      Gruss Jay-c



      Insys ist sehr interessant, doch was man nicht vergessen darf.

      Insys aktueller Kurs ca $34/a share
      GWPH aktueller Kurs ca $91/ 12 shares (ADR)

      Somit ist die einzelne Aktie von GW noch ziemlich niedrig bewertet und hat noch viel Luft nach oben, im Gegensatz zu Insys

      Hier eine persönliche Meinung/Vergleich zu den Beiden, geschrieben am 15.Juni von Todd Campbell
      Better Marijuana Stock: GW Pharma vs Insys
      http://www.fool.com/investing/general/2014/06/15/better-mari…
      Avatar
      schrieb am 14.08.14 17:25:37
      Beitrag Nr. 264 ()
      gravierender Unterschied

      Insys has developed its own cannabidiol which, unlike GW's plant-based product, is wholly synthetic

      http://news.investors.com/technology/080814-712488-gwph-insy…
      "You can get orphan status applied to different investigational drugs that are targeting the same indication," said Lala Gregorek, an analyst with Edison Investment Research who covers GW but not Insys. "But it's quite often the case that the one that gets to market first is the one that blocks the entry of the second. ... Insys is behind GW with respect to (clinical trials)."

      When asked about this, Insys CEO Michael Babich emphasized that his company has options.

      "With Lennox-Gastault and Dravet, I believe it's a race," he acknowledged. "Insys, in particular, works toward other indications in cannabidiol as well. That wouldn't prohibit us from getting approval in a different indication."

      Babich says Insys is investigating uses for adult epilepsy, cancer-related pain, glioblastoma (a type of brain tumor) and addiction to heroin and other opiates.

      GW, too, is investigating the cancer-pain indication for its older product, Sativex, a different kind of cannabinoid that is sold in Europe as a treatment for spasticity related to multiple sclerosis. It also has other cannabinoids in testing for brain tumors, diabetes, ulcerative colitis, schizophrenia and an orphan indication called neonatal hypoxic-ischemic encephalopathy.

      All these treatments, however, are still far in the future.
      Avatar
      schrieb am 14.08.14 20:40:16
      Beitrag Nr. 265 ()
      Hier mal die Tages-Charts der Beiden

      InsysGWPH
      Avatar
      schrieb am 15.08.14 12:07:23
      Beitrag Nr. 266 ()
      Danke!

      Alles gelesen... finde den Bericht von Todd Campbell ziemlich gut.

      Insys hat den Vorteil das die schon Geld machen. Doch GW hat mehr als das dreifache an verfügbares Geld, was zur weiter Entwicklung hilft...

      Was mich etwas beschäftigt ist, dass in der Pipeline von Insys nur 3 Produkten (2 approved) sich befinden.
      Bei GW gibt es 9 (1 approved: Sativex)! Soweit deren Homepages.. GW hat da mehr Spielraum...??

      Beide Unternehmen fokussieren sich auf die Zukunft (2017-2020) und nicht auf das jetzt. mal gucken...

      Jay-c
      Avatar
      schrieb am 17.08.14 20:49:13
      !
      Dieser Beitrag wurde von CloudMOD moderiert. Grund: Spam, Werbung
      Avatar
      schrieb am 19.08.14 09:16:03
      Beitrag Nr. 268 ()
      Avatar
      schrieb am 20.08.14 14:28:49
      Beitrag Nr. 269 ()
      Wenn jemand sich mit anderen Cannabis Werten auskennt bitte Link folgen und meine Frage beantworten.

      http://www.wallstreet-online.de/diskussion/1197844-1-10/cann…

      Wäre sehr dankbar!

      Jay-c
      Avatar
      schrieb am 08.09.14 21:48:31
      Beitrag Nr. 270 ()
      Presentation von Heute, zu hören auf der Webseite von GW
      08/09/2014
      12:50 PM ET Morgan Stanley Global Healthcare Conference
      http://ir.gwpharm.com/events.cfm
      Avatar
      schrieb am 19.09.14 10:29:25
      Beitrag Nr. 271 ()
      Sativex Spray Effectively Reduces Spasticity in Patients with MS
      By Kari Oakes, PA-C | September 14, 2014


      Spasticity for individuals with multiple sclerosis (MS) can be a difficult-to-treat, painful, and debilitating symptom that interferes significantly with mobility, sleep, and daily functioning. Sativex is a cannabinoid compound approved to treat moderate to severe spasticity for MS patients in the UK and several European countries.

      New results of a small study show that add-on Sativex therapy can help significantly with spasticity symptom severity, according to Letizia Leocani, MD, of Milan’s San Raffaele Hospital (Milan, Italy). She presented the findings of a study of individuals with progressive MS and spasticity at a late breaking session on the last day of the 2014 Joint ACTRIMS-ECTRIMS Meeting, held in Boston, MA.

      Sativex is delivered as an oromucosal spray; it is a balanced 1:1 combination of delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD), targeting the human cannabinoid (CB) receptors. According to Leocani, the CBD component of Sativex can help counteract some of THC’s psychoactive properties within the central nervous system’s CB1 receptors; CBD also has known analgesic and anti-inflammatory properties.

      To examine effects of Sativex on spasticity symptoms, Leocani and colleagues enrolled 43 subjects (20 female) with progressive MS and clinically evident spasticity, and with an Expanded Disability Status Scale (EDSS) of 3.5-6. A double-blind crossover study design had subjects randomized to a treatment arm (Sativex dose to a patient-controlled maximum of 12 puffs per day) versus placebo spray, with same dosing instructions. After a two-week washout, patients were crossed over to the opposite study arm. Baseline testing as well as crossover and endpoint testing was performed for each arm, and patient-rated scales were collected throughout. Patients with positive urine THC were excluded at enrollment and at any point during the study if not on the treatment arm (four subjects were discontinued for positive urine THC after washout).

      Discussing the pathophysiology of spasticity, Leocani noted that the stretch-reflex arc is implicated in MS spasticity, and that damage to the descending pathways can lead to disinhibition of the stretch-reflex arc. For the study, a variety of clinical and electrophysiologic tests were used to assess spasticity. Clinically, spasticity was evaluated by the modified Ashworth scale (MAS), with moderate to severe spasticity assessed as resistance to movement when the rater moves the limb through the full range of motion. Additionally, patient-scored numeric rating scales for pain and spasticity and a fatigue severity rating contributed to data collection. Other assessments used for this study included a 10-minute walk test and a motor evoked potential to assess corticospinal tracts, as well as the bilateral soleus H/M ratio, which measures a monosynaptic reflex response to electrical muscle stimulation.

      Results showed that while subjects were in the active arm, they had a significant improvement in spasticity as measured by lower limb MAS, with significantly higher improvement versus placebo (MAS change -1.51 vs+0.16, p=0.009). Self-report of spasticity also improved while receiving the real treatment, and correlated with MAS. Patients in the treatment arm self-administered significantly fewer puffs of the medication than they did while in the placebo arm, and averaged just over half (6.97) of the maximum 12 puffs allowed per day. No significant difference between the two arms was seen in neurophysiologic measures, though there was a trend toward correlation between MAS and H/M ratio.

      Side effects included some dizziness and subjective weakness, though differences between groups at either stage of the crossover study were not significant.

      Leocani addressed the lack of effect of Sativex on neurophysiologic measures in the present study. The physiopathology of spasticity is complicated, she noted, and there are probably both spinal and supraspinal mechanisms involved in MS spasticity that are not captured in testing only corticospinal and monosynaptic pathways. After the presentation, a question arose whether the study could have been partially unblinded because of the potential psychoactive activity of Sativex. In response, Leocani pointed to the lack of significant difference in reported side effects of fatigue, somnolence, or somatic symptoms between the two arms, making it unlikely that subjects were aware of their treatment arm.
      - See more at: http://www.hcplive.com/conferences/2014-ectrims/Sativex-Spra…
      Avatar
      schrieb am 03.10.14 01:13:07
      Beitrag Nr. 272 ()
      Könnte interessant werden:


      LONDON, Sept. 29, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (GWPH) (GWP.L) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, provided the following details regarding its upcoming Research and Development Day scheduled for 14 October, 2014:

      Location: New York City

      Date: 14 October, 2014

      Time: Registration begins at 9:30 a.m. ET, program from 10:00 a.m. ET -- 1:00 p.m. ET

      Agenda: The program will provide an update on GW's product pipeline and is expected to include presentations on the science and application of cannabinoids, updated data from the Epidiolex(R) epilepsy expanded access program, and a review of current pipeline programs including initial data from GW's ulcerative colitis Phase 2a clinical trial.

      In addition to GW presenters, guest speakers will include:

      Dr. Vincenzo Di Marzo, Director of the Institute of Biomolecular Chemistry of the National Research Council (ICB-CNR) in Naples, Italy and one of the world's leading cannabinoid scientists

      Dr. Elizabeth Thiele, Director of the Pediatric Epilepsy Program at Massachusetts General Hospital and Harvard Professor of Neurology

      Dr. Orrin Devinsky, Director the NYU Comprehensive Epilepsy Center and Professor of Neurology, Neurosurgery and Psychiatry at the NYU School of Medicine

      Attendees are requested to RSVP to Stephen Schultz, Vice President of Investor Relations. A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

      http://finance.yahoo.com/news/gw-pharmaceuticals-research-de…
      Avatar
      schrieb am 08.10.14 22:51:27
      Beitrag Nr. 273 ()
      http://www.telegraph.co.uk/finance/newsbysector/pharmaceutic…

      Drug spending authorities in England and Wales have clashed over whether a cannabis-based drug for treating pain in multiple sclerosis (MS) should be reimbursed by the NHS.
      Sativex, a spray which treats painful spasms in the neurological disease, has been given the green light in Wales but not in England.
      The National Institute for Health and Clinical Excellence (Nice) on Wednesday issued its final updated guidelines for MS in which it ruled that Sativex and another drug, Fampridine, should not be used as they are not cost-effective.
      Avatar
      schrieb am 02.12.14 15:28:06
      Beitrag Nr. 274 ()
      Jahres-und Quartalsbericht sind raus.
      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/fi…
      :)
      Ausblick:
      2015 Guidance:

      GW expects continued in-market sales volume growth by commercial partners to result in steady growth in Sativex sales revenues in 2015.

      Consistent with the use of proceeds commitments made at the time of our 2014 equity offerings, GW expects cash expenditure to increase significantly in 2015. There are a number of drivers for this:

      - The Company expects to complete recruitment into the Epidiolex Phase 3 clinical trials in Dravet and Lennox Gastuat syndromes by the end of 2015.

      - The Company expects to increase the scale of growing and manufacturing activities in preparation for the future anticipated launch of Epidiolex.

      - The Company expects to increase spend on U.S. commercial operations in preparation for future commercialization of Epidiolex.

      As a result, GW expects net cash outflow from operating activities to increase to approximately £50 million. Capital expenditure is expected to increase to approximately £22 million in order to complete construction of the Sativex manufacturing facility in preparation for anticipated U.S. launch, as well as to expand Epidiolex growing and manufacturing facilities. Total cash outflow for the 2015 financial year is therefore expected to be approximately £72 million. It should be noted that, in the event that the four Epidiolex clinical trials recruit as anticipated in 2015, Epidiolex-related clinical trial expenditure would be expected to decrease in 2016.
      Avatar
      schrieb am 02.12.14 15:37:48
      Beitrag Nr. 275 ()
      GW Pharmaceuticals PLC- (GWPH) Announces Quarterly Earnings, Beats Expectations By $0.71 EPS
      http://tickerreport.com/banking-finance/360278/gw-pharmaceut…
      2 Antworten
      Avatar
      schrieb am 25.03.15 18:34:19
      Beitrag Nr. 276 ()
      Antwort auf Beitrag Nr.: 48.474.038 von binda am 02.12.14 15:37:48Weiß jemnand warum die gerade so einbricht???
      Ist hier überhaupt noch jemand?
      1 Antwort
      Avatar
      schrieb am 26.03.15 11:15:20
      Beitrag Nr. 277 ()
      Antwort auf Beitrag Nr.: 49.421.705 von Zonk5050 am 25.03.15 18:34:19:rolleyes: denke, hier ist die Luft nach oben zu dünn und viele gehen zu Naturally...
      Avatar
      schrieb am 01.04.15 10:45:21
      Beitrag Nr. 278 ()
      http://www.smarteranalyst.com/2015/03/31/stock-update-nasdaq…

      Stock Update (NASDAQ:GWPH): GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
      March 31, 2015 7:09 AM EDT by Corey Williams in Healthcare • Stock News
      GW Pharmaceuticals PLC- ADR (Nasdaq:GWPH) (AIM:GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces it has initiated the Phase 3 part of a Phase 2/3 clinical trial of Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW anticipates that top-line data from this trial will be available around the end of 2015.

      "Dravet syndrome is a rare and catastrophic form of pediatric epilepsy in which there is a substantial unmet need and for which there are no specifically approved medicines in the United States," stated Orrin Devinsky MD, Professor of Neurology, Neurosurgery, and Psychiatry at NYU School of Medicine, and Principal Investigator of the trial. "This Phase 3 clinical trial of Epidiolex in Dravet syndrome is the first ever rigorous placebo-controlled trial of pure pharmaceutical cannabidiol (CBD) in the field of epilepsy and, as such, a trial of significant interest for the entire epilepsy physician and patient communities."

      "GW is dedicated to developing Epidiolex for Dravet syndrome as rapidly as possible. As such, the start of the first Dravet syndrome Phase 3 trial is a significant milestone for our Company and we are on track to start the second Phase 3 trial very shortly," stated Justin Gover, GW's Chief Executive Officer. "We look forward to working with epilepsy physicians across the United States to execute this program with the objective of submitting a New Drug Application for Epidiolex to the FDA in mid-2016."

      The Phase 3 trial is the second part of a two-part randomized double-blind, placebo-controlled parallel group safety, tolerability, pharmacokinetic and efficacy trial of Epidiolex to treat Dravet syndrome in children who are being treated with other anti-epileptic drugs. Part one completed in February 2015 and comprised the pharmacokinetic and dose-finding elements of the trial in a total of 34 patients over a three week treatment period. The dose for part two has been determined as 20mg/kg by a Data Safety Monitoring Committee (DSMC) after assessment of the part one safety and pharmacokinetic data.

      Part two is a 14-week comparison of Epidiolex versus placebo in a total of 100 patients to assess the safety and efficacy as an adjunctive antiepileptic treatment. The primary measure of this trial will be the percentage change from baseline in convulsive seizure frequency during the maintenance period of the study in patients taking Epidiolex versus placebo. Several additional efficacy and safety secondary outcome measures will be analysed. Part two will recruit an entirely new group of patients who did not participate in part one. Following their participation in the study, all patients are eligible to receive Epidiolex under a long term open label extension study.

      GW anticipates commencing the second pivotal Phase 3 trial in Dravet syndrome soon after this first trial, which will run in parallel with this Phase 2/3 trial. The Company also expects to commence two Phase 3 clinical trials in Lennox-Gastaut syndrome early in the second quarter of 2015. These additional pivotal trials are all expected to complete recruitment in 2015. (Original Source)

      Shares of GW Pharmaceuticals closed yesterday at $88.4. GWPH has a 1-year high of $111.46 and a 1-year low of $41.86. The stock's 50-day moving average is $85.28 and it's 200-day moving average is $77.81.

      On the ratings front, GWPH has been the subject of a number of recent research reports. In a report issued on February 4, Piper Jaffray analyst Joshua Schimmer maintained a Buy rating on GWPH, with a price target of $147, which represents a potential upside of 66.3% from where the stock is currently trading. Separately, on January 8, Cowen's Phil Nadeau reiterated a Buy rating on the stock and has a price target of $110.

      According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joshua Schimmer and Phil Nadeau have a total average return of 15.8% and 28.2% respectively. Schimmer has a success rate of 65.9% and is ranked #247 out of 3560 analysts, while Nadeau has a success rate of 68.9% and is ranked #160.
      Avatar
      schrieb am 01.04.15 15:14:57
      Beitrag Nr. 279 ()
      NOTIFICATION OF MAJOR INTEREST IN SHARES

      http://www.investegate.co.uk/gw-pharmaceuticals--gwp-/rns/ho…
      Avatar
      schrieb am 14.04.15 01:47:46
      Beitrag Nr. 280 ()
      http://www.bloomberg.com/news/articles/2015-04-13/marijuana-…

      Marijuana Plant Extract Reduces Epileptic Seizures by Half
      Avatar
      schrieb am 14.04.15 01:52:53
      Beitrag Nr. 281 ()
      http://www.smarteranalyst.com/2015/04/13/stock-update-nasdaq…

      “We are pleased that the American Academy of Neurology has chosen to highlight the importance of the Epidiolex expanded access data and look forward to more detailed information at the forthcoming AAN Annual Meeting being made available by the physicians leading this program,” stated Justin Gover, GW’s Chief Executive Officer.

      Shares of GW Pharmaceuticals closed today at $96.41, up $5.09 or 5.57%. GWPH has a 1-year high of $111.46 and a 1-year low of $41.86. The stock’s 50-day moving average is $88.24 and it’s 200-day moving average is $77.94.

      On the ratings front, GW Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on April 8, Piper Jaffray analyst Joshua Schimmer reiterated a Buy rating on GWPH, with a price target of $147, which implies an upside of 60.3% from current levels. Separately, on January 8, Cowen’s Phil Nadeau reiterated a Buy rating on the stock and has a price target of $110.
      Avatar
      schrieb am 14.04.15 10:04:13
      Beitrag Nr. 282 ()
      GW said safety and efficacy data on the drug will be presented as the academy's annual meeting on April 22, after which GW will make an additional disclosure.
      http://www.lse.co.uk/AllNews.asp?code=22hnbycw" target="_blank" rel="nofollow ugc noopener">http://www.lse.co.uk/AllNews.asp?code=22hnbycw
      Avatar
      schrieb am 23.04.15 00:30:35
      Beitrag Nr. 283 ()
      GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatme...
      GW PHARMACEUTICALS PLC (NASDAQ:GWPH)

      Today : Donnerstag 23 April 2015


      Conference Call Today at 6:30 p.m. ET

      New data issued in a poster presentation at the American Academy of Neurology annual meeting on 137 patients, representing increased patient numbers over previous disclosures
      Promising signals of efficacy with median 54% reduction in seizures after 12 weeks treatment and maintenance of clinical effect at 24 weeks
      Epidiolex was well tolerated and 90% of patients remained on treatment
      Data on Lennox-Gastaut syndrome (LGS) patients presented for first time
      Additional body of data in patients with diagnoses other than Dravet syndrome
      GW advancing plans to commence clinical development of Epidiolex in additional pediatric epilepsy target indication of Tuberous Sclerosis Complex

      GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced new physician reports of clinical effect and safety associated with the Epidiolex® expanded access program. These data were presented today by study authors at the American Academy of Neurology annual meeting in Washington DC1.

      "We are pleased to report that this promising data on significant numbers of additional children treated with Epidiolex further reinforces and supports the signals of efficacy seen in previous data disclosures. Epidiolex treatment was associated with meaningful reductions in seizures across a range of childhood epilepsies as well as a sustained response over a 6 month period and a 90% retention rate," stated Justin Gover, GW's Chief Executive Officer. "We believe that these findings fully support our decision to advance Epidiolex into Phase 3 placebo-controlled, double-blind trials in Dravet syndrome and Lennox-Gastaut syndrome and we look forward to advancing these trials rapidly during 2015."

      Physician reports of clinical effect and safety data have been presented on 137 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol (CBD) product candidate, Epidiolex, for a period of at least 12 weeks. These data are from eleven hospital sites in the United States and were generated under expanded access Investigational New Drug applications (INDs) authorized by the U.S. Food and Drug Administration (FDA). In addition, physician reports of safety data were presented on 213 patients (137 patients with 12 weeks treatment effect data plus additional patients still in their first 12 weeks of treatment or who withdrew from treatment). The expanded access program is comprised of clinical studies performed by individual physicians.

      FDA authorized expanded access programs facilitate access to investigational drugs for treatment use for patients with a serious or immediately life-threatening diseases or conditions who lack therapeutic alternatives. The patients included in the Epidiolex program had Dravet syndrome (18% of the total) and Lennox-Gastaut syndrome (LGS) (16% of the total), epilepsy types that can lead to intellectual disability and lifelong seizures, as well as 10 other types of severe epilepsy. Many of the 10 other types of epilepsy are extreme and rare, and several patients with these epilepsies have major congenital structural brain abnormalities.

      The 137 patients were predominately children with an average age of 11 years. In all cases, Epidiolex was added to current anti-epileptic drug (AED) treatment regimes. On average, patients were taking approximately 3 other AEDs.

      At the request of the study authors, the data disclosed in this press release is limited to the data presented at the AAN meeting.

      Clinical Effect Data – All Patients

      Data were presented on all 137 patients who had at least 12 weeks treatment. Treatment was open label. Of these 137 patients, 48 patients had also reached 24 weeks treatment at the time of data analysis. Information collected on all seizures (convulsive and non-convulsive) is reported for each patient. Data are presented showing the median reduction in seizure frequency and the proportion of patients achieving a response of 50% or greater compared to a 4-week baseline period....

      Conference Call and Presentation Information

      GW Pharmaceuticals will host a conference call and broadcast a slide show to discuss these data today at 6:30 p.m. EDT. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada) or 201-689-8040 (international). To view the slide show while using the audio dial-in, please go to the investor relations (presentation and events) section of GW's website at http://www.gwpharm.com. Investors may also access a live audio webcast of the call via the Company's website. A replay of the call will also be available through the GW website shortly after the call.
      Avatar
      schrieb am 23.04.15 00:31:16
      Beitrag Nr. 284 ()
      Avatar
      schrieb am 23.04.15 22:45:55
      Beitrag Nr. 285 ()
      GWPH ,die ADR`s ,(1 = 12 Einzelaktien)wurden hochgestuft:

      GW Pharmaceuticals PLC- Price Target Raised to $155.00 at Bank of America (GWPH)

      http://tickerreport.com/banking-finance/469085/gw-pharmaceut…
      Avatar
      schrieb am 24.04.15 10:07:46
      Beitrag Nr. 286 ()
      Piper Jaffray Reiterates Overweight on GW Pharmaceuticals; Here’s Why
      April 23, 2015 5:02 PM EDT by Jason Cohen, Editor in Exclusively Published • Healthcare • Insights
      In a research report published today, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) with a price target of $147, after the company hosted a call to review summary data from investigator sponsored trials of Epidiolex for refractory seizures which were presented at the AAN conference.

      Schimmer noted, “The results remain robust and consistent with the strong, differentiated profile which has been described previously for both Epidiolex and dispensary-procured CBD. GWPH is also moving to add Tuberous Sclerosis Complex on the development path for Epidiolex. We continue to believe investors underestimate both the probability of success for Epidiolex in seizures and beyond (autism?) as well as the market opportunity which lay ahead, as well as the ability to lifecycle manage by introducing new cannabinoid combinations.”

      http://www.smarteranalyst.com/2015/04/23/piper-jaffray-reite…
      Avatar
      schrieb am 24.04.15 16:03:58
      Beitrag Nr. 287 ()
      http://www.rttnews.com/2487268/gw-pharma-receives-orphan-dru…

      GW Pharma Receives Orphan Drug Status For Cannabidiol In NHIE; Stock UP
      4/24/2015 8:23 AM ET
      GW Pharmaceuticals Plc. (GWPH: Quote, GW.L) Friday said the U.S. Food and Drug Administration has granted orphan drug designation for Cannabidiol for use in treating newborn children with neonatal hypoxic-ischemic encephalopathy or NHIE, an acute or sub-acute brain injury due to asphyxia caused during the birth process as a result of deprivation of oxygen during birth.

      The incidence of NHIE is 1.5 to 2.8 per 1,000 births in the U.S., or, 6,500 to 12,000 cases per year. Of these, 35 percent are expected to die in early life and 30 percent may suffer from permanent disability. There are currently no FDA-approved medicines specifically indicated for NHIE. GW has developed an intravenous Cannabidiol formulation for use in this patient population. GW held a pre-IND meeting with the FDA and expects to submit an Investigational New Drug Application in the middle of 2015 and to commence a Phase 1 trial in the second half of 2015.
      Avatar
      schrieb am 30.04.15 21:35:22
      Beitrag Nr. 288 ()
      :eek:

      Avatar
      schrieb am 09.05.15 12:44:26
      Beitrag Nr. 289 ()
      GW Pharmaceuticals PLC- (NASDAQ:GWPH) is scheduled to post its Q215 quarterly earnings results on Monday, May 11th. Analysts expect GW Pharmaceuticals PLC- to post earnings of ($1.12) per share and revenue of $11.38 million for the quarter.
      Avatar
      schrieb am 20.11.15 02:59:14
      Beitrag Nr. 290 ()
      GW Pharmaceuticals (GWPH) Downward Abstract-Reaction
      Time to look at GW Pharmaceuticals (GWPH)

      http://galaxystocks.com/2015/11/19/intuit-intu-momentum-prof…


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      +0,76
      -4,37
      +1,26
      +0,43
      +4,85
      -2,18
      -0,26
      0,00
      -9,12
      -2,53

      Meistdiskutiert

      WertpapierBeiträge
      106
      80
      51
      48
      47
      34
      33
      28
      26
      26
      GW Pharmaceuticals - Erfolg auf Cannabis-Basis